
<html lang="en"     class="pb-page"  data-request-id="c4457ea8-2a83-47c4-b7a0-c386f14692e7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2004.47.issue-8;article:article:10.1021/jm030354b;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists†" /></meta><meta name="dc.Creator" content="Mukund M.  Mehrotra,*" /></meta><meta name="dc.Creator" content="Julie A.  Heath,§" /></meta><meta name="dc.Creator" content="Mark S.  Smyth," /></meta><meta name="dc.Creator" content="Anjali  Pandey,§" /></meta><meta name="dc.Creator" content="Jack W.  Rose,§" /></meta><meta name="dc.Creator" content="Joseph M.  Seroogy," /></meta><meta name="dc.Creator" content="Deborah L.  Volkots,§" /></meta><meta name="dc.Creator" content="Lisa  Nannizzi-Alaimo,§" /></meta><meta name="dc.Creator" content="Gary L.  Park," /></meta><meta name="dc.Creator" content="Joseph L.  Lambing,§" /></meta><meta name="dc.Creator" content="Stanley J.  Hollenbach,§ and" /></meta><meta name="dc.Creator" content="Robert M.  Scarborough*,§" /></meta><meta name="dc.Description" content="In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here o..." /></meta><meta name="Description" content="In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here o..." /></meta><meta name="dc.Publisher" content=" American Chemical Society " /></meta><meta name="dc.Date" scheme="WTN8601" content="March 11, 2004" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm030354b" /></meta><meta name="dc.Identifier" scheme="crossover-key" content="JMCMAr-47-8-2037" /></meta><meta name="dc.Identifier" scheme="pii" content="S0022-2623(03)00354-6" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2004 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm030354b" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm030354b" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm030354b" /></link>
        
    
    

<title>Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm030354b" /></meta><meta property="og:title" content="Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists†" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bn00001.jpeg" /></meta><meta property="og:description" content=" In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here our investigation of a variety of templates including spiropiperidinyl-γ-lactams, spiropiperidinylimide, spiropiperidinylureas, and spiropiperidinylhydantoins. With the appropriate acidic and basic pharmacophores in place, each template yielded analogues with potent GPIIb-IIIa inhibitory activity. One of the compounds, 59 (CT50787), was also used to demonstrate for the first time the use of a pharmacological agent which is αIIbβ3 specific to display biological activity in a lower species such as mouse and to extend bleeding times. Evaluation of the pharmacokinetic properties of selected compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of 22 (CT51464), a double prodrug, with excellent pharmacokinetic properties. It exhibited good pharmacokinetic profile across species (F% = 33 (Cyno), 73 (dog), 22 (rat); t1/2β = 14.2 h (Cyno), 8.97 h (dog), 1.81 h (rat)). The biologically active form, 23 (CT50728), displayed inhibition of platelet aggregation in platelet rich plasma (PRP) with an IC50 value of 53 nM in citrate buffer, 110 nM in PPACK anticoagulated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA). Both 23 and 22 were stable in human liver microsomes, did not inhibit the P450 3A4 isozyme, and had low protein binding (18.22% for 23) and a desirable log P (0.45 ± 0.06 for 22, and −0.91 ± 0.32 for 23). It is predicted that the high oral bioavailability for these compounds in multiple species should translate into lower intra- and intersubject variability in man. The long plasma half-life of the lead is consistent with once or twice daily administration for chronic therapy. Analogue 22 (CT51464) thus appears to be a promising oral GPIIb-IIIa inhibitor with significantly improved pharmacokinetic properties over the previously described clinical candidates and may be found useful in the treatment of arterial occlusive disorders.  " /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm030354b"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm030354b">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm030354b&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm030354b&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm030354b&amp;href=/doi/10.1021/jm030354b" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2004</span><span class="cit-fg-volume">, 47</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 2037-2061</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/47/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm031105q" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm030448l" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists<a class="ref internalNav" href="#jm030354bAF2" aria-label="†">†</a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mukund+M.++Mehrotra">Mukund M. Mehrotra</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julie+A.++Heath">Julie A. Heath</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+S.++Smyth">Mark S. Smyth</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anjali++Pandey">Anjali Pandey</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jack+W.++Rose">Jack W. Rose</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+M.++Seroogy">Joseph M. Seroogy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah+L.++Volkots">Deborah L. Volkots</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Nannizzi-Alaimo">Lisa Nannizzi-Alaimo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary+L.++Park">Gary L. Park</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+L.++Lambing">Joseph L. Lambing</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stanley+J.++Hollenbach">Stanley J. Hollenbach</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+M.++Scarborough">Robert M. Scarborough</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="JMCMAr" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm030354b&amp;href=/doi/10.1021%2Fjm030354b" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2004</span></span><span class="cit-volume">, 47</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 2037–2061</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 11, 2004</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 July 2003</li><li><span class="item_label"><b>Published</b> online</span>11 March 2004</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 1 April 2004</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm030354b" title="DOI URL">https://doi.org/10.1021/jm030354b</a></div><div class="article_header-article-copyright"><strong>Copyright © 2004 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2037%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMukund%2BM.%2BMehrotra%252C%2BJulie%2BA.%2BHeath%252C%2BMark%2BS.%2BSmyth%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D47%26issueNum%3D8%26contentID%3Djm030354b%26title%3DDiscovery%2Bof%2BNovel%2B2%252C8-Diazaspiro%255B4.5%255Ddecanes%2Bas%2BOrally%2BActive%2BGlycoprotein%2BIIb-IIIa%2BAntagonists%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2061%26publicationDate%3DApril%2B2004">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm030354b"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2019</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm030354b" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mukund&quot;,&quot;last_name&quot;:&quot;M. Mehrotra&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;A. Heath&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;S. Smyth&quot;},{&quot;first_name&quot;:&quot;Anjali&quot;,&quot;last_name&quot;:&quot;Pandey&quot;},{&quot;first_name&quot;:&quot;Jack&quot;,&quot;last_name&quot;:&quot;W. Rose&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;M. Seroogy&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;L. Volkots&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Nannizzi-Alaimo&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;L. Park&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;L. Lambing&quot;},{&quot;first_name&quot;:&quot;Stanley&quot;,&quot;last_name&quot;:&quot;J. Hollenbach&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;M. Scarborough&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2004&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;47&quot;,&quot;pages&quot;:&quot;2037-2061&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm030354b&quot;},&quot;abstract&quot;:&quot;In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here our investigation of a variety of templates including spiropiperidinyl-γ-lactams, spiropiperidinylimide, spiropiperidinylureas, and spiropiperidinylhydantoins. With the appropriate acidic and basic pharmacophores in place, each template yielded analogues with potent GPIIb-IIIa inhibitory activity. One of the compounds, 59 (CT50787), was also used to demonstrate for the first time the use of a pharmacological agent which is αIIbβ3 specific to display biological activity in a lower species such as mouse and to extend bleeding times. Evaluation of the pharmacokinetic properties of selected compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of 22 (CT51464), a double prodrug, with excellent pharmacokinetic properties. It exhibited good pharmacokinetic profile across species (F% = 3&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm030354b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm030354b" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm030354b&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm030354b" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm030354b&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm030354b" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm030354b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm030354b&amp;href=/doi/10.1021/jm030354b" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm030354b" /></input><a href="/doi/pdf/10.1021/jm030354b" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (474 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm030354b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm030354b%26sid%3Dliteratum%253Aachs%26pmid%3D15056002%26genre%3Darticle%26aulast%3DMehrotra%26date%3D2004%26atitle%3DDiscovery%2Bof%2BNovel%2B2%252C8-Diazaspiro%255B4.5%255Ddecanes%2Bas%2BOrally%2BActive%2BGlycoprotein%2BIIb-IIIa%2BAntagonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D47%26issue%3D8%26spage%3D2037%26epage%3D2061%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291411" title="Pharmacokinetics">Pharmacokinetics</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/47/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bn00001.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bn00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here our investigation of a variety of templates including spiropiperidinyl-γ-lactams, spiropiperidinylimide, spiropiperidinylureas, and spiropiperidinylhydantoins. With the appropriate acidic and basic pharmacophores in place, each template yielded analogues with potent GPIIb-IIIa inhibitory activity. One of the compounds, <b>59</b> (CT50787), was also used to demonstrate for the first time the use of a pharmacological agent which is αIIbβ3 specific to display biological activity in a lower species such as mouse and to extend bleeding times. Evaluation of the pharmacokinetic properties of selected compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of <b>22</b> (CT51464), a double prodrug, with excellent pharmacokinetic properties. It exhibited good pharmacokinetic profile across species (F% = 33 (Cyno), 73 (dog), 22 (rat); <i>t</i><sub>1/2</sub><i><sub>β</sub></i> = 14.2 h (Cyno), 8.97 h (dog), 1.81 h (rat)). The biologically active form, <b>23</b> (CT50728), displayed inhibition of platelet aggregation in platelet rich plasma (PRP) with an IC<sub>50</sub> value of 53 nM in citrate buffer, 110 nM in PPACK anticoagulated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA). Both <b>23 </b>and <b>22</b> were stable in human liver microsomes, did not inhibit the P450 3A4 isozyme, and had low protein binding (18.22% for <b>23</b>) and a desirable log <i>P</i> (0.45 ± 0.06 for <b>22</b>, and −0.91 ± 0.32 for <b>23</b>). It is predicted that the high oral bioavailability for these compounds in multiple species should translate into lower intra- and intersubject variability in man. The long plasma half-life of the lead is consistent with once or twice daily administration for chronic therapy. Analogue <b>22</b> (CT51464) thus appears to be a promising oral GPIIb-IIIa inhibitor with significantly improved pharmacokinetic properties over the previously described clinical candidates and may be found useful in the treatment of arterial occlusive disorders. </p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec fnGroup"><div class="fnGroupItem" id="jm030354bAF2"><span><h4><span class="NLM_fn-symbol">†</span></h4></span><span><p class="last">  Dedicated to Professor E. J. Corey on the occasion of his 75th birthday.</p></span></div><div class="fnGroupItem" id="jm030354bAF1"><span><h4><span class="NLM_fn-symbol">*</span></h4></span><span><p class="last">  To whom correspondence should be addressed. M.M.:  Tel:  650-866-4847. E-mail:  <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8de0f8e6f8e3e9d2e0e8e5ffe2f9ffeccde5e2f9e0ece4e1a3eee2e0a3">[email protected]</a> R.S.:  Tel:  650-246-7444. Fax:  650-615-9023. E-mail:  <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="80f2f3e3e1f2e2eff2eff5e7e8c0f0eff2f4efece1aee3efedae">[email protected]</a> </p></span></div><div class="fnGroupItem" id="jm030354bAF4"><span><h4><span class="NLM_fn-symbol">§</span></h4></span><span><p class="last">  Current address:  Portola Pharmaceuticals, Inc., 270 E. Grand Ave, Suite 22, South San Francisco, CA, 94080.</p></span></div></div><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Platelet rich clot formation is important in many vasooclusive disorders such as unstable angina, acute myocardial infarction, reocclusion after percutaneous interventions, and stroke.<sup><a onclick="showRef(event, 'jm030354bb00001'); return false;" href="javascript:void(0);" class="ref jm030354bb00001">1</a></sup> Platelet activation is produced by a wide variety of stimuli, but the final common event leading to platelet rich thrombus formation is the binding of the activated platelet integrin GPIIb-IIIa<sup><a onclick="showRef(event, 'jm030354bb00002'); return false;" href="javascript:void(0);" class="ref jm030354bb00002">2</a></sup> to the soluble plasma adhesive proteins fibrinogen (Fg) and von Willebrand factor (vWf).<sup><a onclick="showRef(event, 'jm030354bb00003'); return false;" href="javascript:void(0);" class="ref jm030354bb00003">3</a></sup> Fibrinogen and von Willebrand factor are multivalent and participate in the aggregation of platelets to form thrombi at the site of atherosclerotic plaque rupture. If GPIIb-IIIa is blocked from binding to adhesive proteins, then it should prevent formation and/or propagation of a platelet thrombus, no matter what the physiological stimuli was that initiated GPIIb-IIIa activation.<sup><a onclick="showRef(event, 'jm030354bb00004'); return false;" href="javascript:void(0);" class="ref jm030354bb00004">4</a></sup> The use of intravenous GPIIb-IIIa inhibitors (eptifibatide, tirofiban, abciximab) in preventing vessel closure after percutaneous coronary angioplasty (PTCA) is now well established,<sup><a onclick="showRef(event, 'jm030354bb00005'); return false;" href="javascript:void(0);" class="ref jm030354bb00005">5</a></sup> and GPIIb-IIIa receptor antagonists are considered to be the most potent antiplatelet drugs available to the clinician. </div><div class="NLM_p">Since chronic oral administration of GPIIb-IIIa antagonists could potentially address the additional indications of myocardial infarction and stroke, two of the most deadly cardiovascular diseases in the Western World, intense efforts have been devoted to the discovery of orally active GPIIb-IIIa antagonists.<sup><a onclick="showRef(event, 'jm030354bb00006 jm030354bb00007 jm030354bb00008 jm030354bb00009'); return false;" href="javascript:void(0);" class="ref jm030354bb00006 jm030354bb00007 jm030354bb00008 jm030354bb00009">6-9</a></sup> Unfortunately, despite the success of intravenous anti-platelet GPIIb-IIIa antagonists (ReoPro, Integrilin, and Aggrastat)<sup><a onclick="showRef(event, 'jm030354bb00010'); return false;" href="javascript:void(0);" class="ref jm030354bb00010">5,10</a></sup> in preventing cardiac events in the hospital, several clinical trials involving oral formulations of “super-aspirins” have failed to show prophylactic benefit in patients with recurrent vascular events in a long term dosing environment. Efficacy analysis of the oral agents orbofiban, xemilofiban, sibrafiban, and lotrafiban (Figure 1<a data-tab="pane-pcw-Figures" href="#jm030354bf00001" id="" class=" internalNav"></a>)<sup>8,9,11</sup><a onclick="showRef(event, 'jm030354bb00011'); return false;" href="javascript:void(0);" class="ref jm030354bb00011"></a> in the presence or absence of background aspirin showed no benefit to the composite endpoint of death, recurrent myocardial infarction, and other recurrent ischemic events<i>.</i> Overall, the results have been quite disappointing. Long-term oral GPIIb-IIIa inhibition has uniformly failed to provide protection from ischemic events and was associated with a paradoxical increase in adverse events. Mortality increased in each of the five trials (EXCITE, OPUS-TIMI 16, BRAVO, <a name="jm004700802038" id="jm004700802038"></a> SYMPHONY, 2nd SYMPHONY). A combined analysis reveals a highly significant 35% relative (or 0.7% absolute) increase in the risk of death in the 45 523 patients studied, with a 2-fold increase in the risk of bleeding.<sup>9b</sup><div id="_i4"><figure id="jm030354bf00001" data-index="1" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00001.jpeg" id="_i5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 1 Oral GPIIb/IIIa antagonists that have been studied in advanced stage clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00001"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Many reasons for the failure of orally administered GPIIb-IIIa inhibitors to prevent recurrent cardiac events have been proposed.<sup>4,12,13</sup><a onclick="showRef(event, 'jm030354bb00012'); return false;" href="javascript:void(0);" class="ref jm030354bb00012"></a><a onclick="showRef(event, 'jm030354bb00013'); return false;" href="javascript:void(0);" class="ref jm030354bb00013"></a> One leading explanation is that the pharmacokinetic properties of the agents tested so far were suboptimal. Short half-lives of these agents can result in large peak-to-trough ratios and poor oral bioavailability can result in significant intra- and interindividual variability of drug in the blood stream of individual patients. Either excess or insufficient drug in the bloodstream at any given time point may lead to undesirable consequences. Excessive drug levels may prevent the blood from clotting when necessary, such that bleeding events result. Too little drug may be ineffective in preventing the platelet aggregation that leads to cardiac events. It has also been suggested that GPIIb-IIIa inhibitors may lead to platelet activation and/or to the release of inflammatory mediators, at least under certain conditions or at specific drug concentrations.<sup>13b</sup> The proinflammatory trigger of subthreshold receptor blockade, particularly in the setting of high arterial shear stress, could be quite eventful. It is possible that improved pharmacokinetic properties would therefore lead to a successful oral GPIIb-IIIa inhibitor drug. Other potential mechanisms by which these drugs may cause the undesired side effects are also under investigation. While an in-depth biological examination of this class of antiplatelet drugs is needed, studies until recently have continued on two oral GPIIb-IIIa inhibitors, roxifiban and cromafiban, which have different properties from the earlier oral agents.<sup>9a,12,14</sup></div><div class="NLM_p last">The key aim of our investigation has been to identify active and selective GPIIb-IIIa inhibitors with improved pharmacokinetic properties. Most synthetic efforts in <a name="jm004700802039" id="jm004700802039"></a> the GPIIb-IIIa inhibitor class have focused on developing novel templates upon which an acidic and a basic pharmacophore are appended. Many classes of GPIIb-IIIa antagonists have been reported which contain constrained templates consisting of monocyclic and/or fused bicyclic scaffolds.<sup>11</sup> We have previously reported the use of spirocyclic scaffolds for designing potent GPIIb-IIIa antagonists.<sup>15</sup> Herein, we describe the optimization of the novel 2,8-diazaspiro[4.5]decane scaffold for obtaining orally active and selective inhibitors. Within this spirocyclic framework, highly potent compounds were obtained with favorable pharmacokinetics in the spirolactam, spirohydantoin, and spirourea templates. The spirolactam series which has a carbonyl group adjacent to the spiro ring junction (1-oxo) exhibits the most favorable pharmacokinetic profiles. Optimized compounds were evaluated for efficacy and pharmacokinetics in rat, dog, and cynomologous monkey. Synthesis, SAR, and pharmacokinetics of these compounds are described leading to the identification of the optimized prodrug analogue <b>22</b> (CT51464). </div></div><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For the synthesis of the proposed compounds, we first prepared the diazaspiro benzonitrile scaffolds (<b>11</b>, <b>12</b>, <b>18a</b>,<b> 18b</b>, <b>19a</b>,<b> 19b</b>, and <b>76</b>), followed by elaboration into the final targets. The spiropiperidines were first coupled with various carboxy-containing appendages, followed by transformation of the benzonitrile functionality into the corresponding benzamidines.<sup>16</sup></div><div class="NLM_p">The synthesis of the γ-spirolactams, 4-(1-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile <b>11</b>, 4-(3-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile <b>12</b>, and spiroimide, 4-(1,3-dioxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile <b>76</b>, are described in Scheme 1<a data-tab="pane-pcw-Figures" href="#jm030354bh00001" id="" class=" internalNav"></a>. Starting from the commercially available 1-benzyl-4-piperidone, the two γ-lactam scaffolds were synthesized in 10 steps in an overall yield of 22%. 1-Benzyl-4-piperidone was first subjected to Knoevenagel condensation with ethyl cyanoacetate, followed by reaction of the α,β-unsaturated ester with KCN to give the dinitrile <b>1</b>. This was hydrolyzed with concentrated HCl to yield the diacid <b>2</b>, which was subsequently dehydrated with DCC to furnish the anhydride <b>3</b>. The anhydride was reacted with 4-cyanoaniline to yield the mixture of amide-carboxylic acids, which were cyclized with NaOAc/Ac<sub>2</sub>O to give the imide <b>4</b>. The imide was reduced nonselectively with NaBH<sub>4</sub> in methanol to give a mixture of hydroxy-spirolactams <b>5</b> and <b>6</b>, which were reduced with NaBH<sub>4</sub>/TFA to give a mixture of the spirolactams <b>7</b> and <b>8</b> (ca. 1:2 by NMR, and analytical HPLC, vide infra). This mixture of isomeric lactams proved difficult to separate by flash chromatography on large scale, and so it was used in the next step without purification. The <i>N</i>-benzyl group was then conveniently deprotected in two steps as follows. Reaction with 2,2,2-trichloroethyl chloroformate (TrOCOCl) brought about the protective group exchange to yield trichloroethyl-carbamates <b>9</b> and <b>10.</b><sup>17</sup> This mixture of Troc-lactams was more easily separable by silica gel chromatography, and at this step both the lactams were fully characterized (<sup>1</sup>H NMR). The carbamates <b>9</b> and <b>10</b> were then individually treated with 10% Cd−Pb couple to effect reductive cleavage<sup>18</sup> of the Troc group to give the key γ-spirolactam intermediates <b>11</b> and <b>12</b>, respectively. This high yielding N-debenzylation route was also used for the conversion of <b>4</b> to afford the spiroimide <b>76</b>. <div id="_i7"><figure id="jm030354bh00001" data-index="2" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00001.jpeg" id="_i8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 1 <i><sup>a</sup></i><sup></sup> Synthesis of the γ-Spirolactam Scaffolds:  4-(1-Oxo-2,8-Diazaspiro [4.5]dec-2-yl)benzonitrile <b>11</b>, 4-(3-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile <b>12</b>, and Spiroimide Scaffold<b> 76</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) ethyl cyanoacetate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å sieves; (b) KCN, EtOH/H<sub>2</sub>O, Δ; (c) concd HCl, Δ; (d) DCC, DMF; (e) 4-cyanoaniline, TEA, DMF, rt; (f) Ac<sub>2</sub>O, NaOAc, Δ; (g) NaBH<sub>4</sub>, MeOH; (h) NaBH<sub>4</sub>, TFA; (i) 2,2,2-trichloroethyl chloroformate, CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>; separate isomers by flash chromatography; (j) 10% Cd−Pb, THF/NH<sub>4</sub>OAc, pH = 5.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00001"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">The synthesis of spirohydantoins, 4-(1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (and its 1-H analogue) <b>19b</b>,<b>a</b>, and of the spiroureas, 4-(1-methyl-2-oxo-1,3,8-triaza-spiro[4.5]dec-3-yl)benzonitrile (and its 1-H analogue) <b>18b</b>,<b>a</b>, are described in Scheme 2<a data-tab="pane-pcw-Figures" href="#jm030354bh00002" id="" class=" internalNav"></a>.<sup>19</sup> 1-Benzyl-4-piperidone was subjected to Strecker conditions by reaction with KCN and either ammonium chloride or methylamine hydrochloride to give α-amino-nitriles <b>13a</b> and<b> 13b</b>, respectively. These were then coupled with 4-cyanophenyl isocyanate to yield α-ureanitriles <b>14</b>. Cyclization to hydantoins <b>15 </b>was effected by treatment with 1 N HCl at reflux. The <i>N</i>-benzyl group was then removed as described before to afford the spirohydantoin scaffolds <b>19a</b>,<b>b</b>. For the synthesis of the spirourea template, the hydantoins <b>15</b> were first reduced with NaBH<sub>4</sub>/MeOH to give the hydroxy-urea intermediates <b>16</b>, followed by treatment with NaBH<sub>4</sub>/TFA as described previously to yield <b>17</b>. N-Debenzylation provided the key intermediates <b>18a</b>,<b>b</b>. <div id="_i9"><figure id="jm030354bh00002" data-index="3" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00002.jpeg" id="_i10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 2 <i><sup>a</sup></i><sup></sup> Synthesis of the Hydantoin and the Urea Scaffolds:  4-(1-Methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (and its 1-H analog) <b>19b</b>,<b>a</b> and 4-(1-Methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (and its 1-H analog) <b>18b</b>,<b>a</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) KCN, RNH<sub>2</sub>.HCl, EtOH/H<sub>2</sub>O; (b) 4-cyanophenyl isocyanate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (c) 1 N HCl, Δ; (d) NaBH<sub>4</sub>, MeOH; (e) NaBH<sub>4</sub>, TFA; (f) 2,2,2-trichloroethyl chloroformate, CH<sub>3</sub>CN/CHCl<sub>3</sub>; (g) 10% Cd−Pb, THF/NH<sub>4</sub>OAc, pH = 5.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00002"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">The spiropiperidines (<b>11</b>, <b>12</b>, <b>18a</b>,<b>b</b>, <b>19a</b>,<b>b, </b>and<b> 76)</b> were coupled with the carboxy-containing appendages by standard methods (Schemes 3−15). The required carboxylic acids, acid chlorides, and isocyanates were either commercially available or were synthesized as shown (Schemes 5, 7−13, and 15). </div><div class="NLM_p"><a name="jm004700802040" id="jm004700802040"></a>The general synthesis of the compounds with 3-urea-propionic acid tails (e.g., <b>23</b>) and their double prodrugs (e.g., <b>22</b>) is described in Scheme 3<a data-tab="pane-pcw-Figures" href="#jm030354bh00003" id="" class=" internalNav"></a>. The spiropiperidines were reacted with ethyl 3-isocyanatopropionate to give rise to the coupled urea compounds. The benzonitrile functionality was then converted into amidine either via thio-Pinner reaction<sup>16a</sup> or via amidoximes.<sup>16b</sup> Reaction of the benzonitriles with hydroxylamine hydrochloride/Et<sub>3</sub>N yielded the amidoxime ethyl ester double prodrugs. An analogous scheme for the synthesis of the corresponding amide-linked compounds, 5-oxo-5-azaspiro-1-yl-pentanoic acids (e.g., <b>28</b>), is described in Scheme 4<a data-tab="pane-pcw-Figures" href="#jm030354bh00004" id="" class=" internalNav"></a>. The spiropiperidines were first reacted with ethyl succinyl chloride, followed by transformation of the benzonitriles into benzamidines. <div id="_i11"><figure id="jm030354bh00003" data-index="4" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00003.jpeg" id="_i12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 3 <i><sup>a</sup></i><sup></sup> Synthesis of <b>23</b> (CT50728) and Its Double Prodrug <b>22</b> (CT51464) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt.; (b) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (c) 1 M LiOH, THF, rt; or 3 N HCl, rt; (d) NH<sub>2</sub>OH.HCl, Et<sub>3</sub>N, EtOH, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00003"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="jm030354bh00004" data-index="5" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00004.jpeg" id="_i13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 4 <i><sup>a</sup></i><sup></sup> Synthesis of <b>28</b> (CT50614) and Its Double Prodrug <b>27</b> (CT51269) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DMF, DIEA, rt.;(b) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (c) 3 N HCl, rt.; (d) NH<sub>2</sub>OH.HCl, Et<sub>3</sub>N, EtOH, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00004"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 5<a data-tab="pane-pcw-Figures" href="#jm030354bh00005" id="" class=" internalNav"></a> depicts the synthesis of the oxy-acetic acid analogue <b>33</b> and its amidoxime ethyl ester double prodrug <b>36</b>. Benzyl glycolate was subjected to a carbene insertion reaction with <i>tert</i>-butyl diazoacetate under rhodium(II) acetate dimer catalysis to yield <b>30a</b>. The benzyl group was then hydrogenolyzed to yield acid <b>31</b>, which was subsequently coupled with spirolactam <b>11</b> to afford <b>32</b>. The benzonitrile function was then transformed into <b>33</b> and <b>36</b> as described before. <div id="_i14"><figure id="jm030354bh00005" data-index="6" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00005.jpeg" id="_i15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 5 <i><sup>a</sup></i><sup></sup> Synthesis of <b>33</b> (CT51907) and Its Double Prodrug <b>36</b> (CT52108) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) CH<sub>2</sub>Cl<sub>2</sub>, rt.; (b) Pearlman's catalyst, EtOAc, 40 psi H<sub>2</sub>; (c) <b>11</b>, HBTU, DIEA, DMF; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH;(e) TFA;(f) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (g) 3 N HCl.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00005"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 6<a data-tab="pane-pcw-Figures" href="#jm030354bh00006" id="" class=" internalNav"></a> depicts the synthesis of the substituted amidine analogues <b>39b</b> and <b>40b</b>. The benzonitrile <b>25</b> was converted to thiomethylimidate <b>38</b> by the thio-Pinner procedure. Thiomethylimidate <b>38</b> was then treated with a mixture of morpholine and acetic acid (ca. 1:2) in methanol to afford <b>39a</b>. When acetic acid was omitted a poor yield of <b>39a</b> was obtained and the major byproduct was the starting nitrile <b>25</b>, formed via the base-catalyzed elimination of CH<sub>3</sub>SH from <b>38</b>. The same protocol was used for the synthesis of the <i>N</i>-ethylamidine analogue <b>40a</b>. Treatment of <b>39a</b> and <b>40a</b> with 3 N HCl yielded <b>39b</b> and <b>40b</b>. <div id="_i16"><figure id="jm030354bh00006" data-index="7" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00006.jpeg" id="_i17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 6 <i><sup>a</sup></i><sup></sup> Synthesis of the Substituted Amidine Analogues <b>39b</b> and <b>40b</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (b) morpholine, AcOH, MeOH, rt.; (c) EtNH<sub>2</sub>, AcOH, MeOH, rt.; (d) 3 N HCl, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00006"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">The synthesis of <b>44</b> and <b>45</b>, the 3-(<i>S</i>)-methyl and 3-(<i>R)</i>-methyl analogues of <b>28</b>, were achieved by using the route described in Scheme 7<a data-tab="pane-pcw-Figures" href="#jm030354bh00007" id="" class=" internalNav"></a>. (<i>R</i>)-1-Ethyl hydrogen 3-methylglutarate was converted to its <i>tert</i>-butyl ester <a name="jm004700802041" id="jm004700802041"></a> derivative <b>41</b>. The ethyl ester was then saponified to give free acid <b>42</b>. This was coupled with spirolactam <b>11</b> to yield the benzonitrile intermediate <b>43</b>, which was then transformed to <b>44</b> as described previously. A similar sequence of reactions provided the (<i>R</i>)-isomer <b>45</b>. <div id="_i18"><figure id="jm030354bh00007" data-index="8" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00007.jpeg" id="_i19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 7 <i><sup>a</sup></i><sup></sup> Synthesis of <b>44</b> and <b>45</b>, the 3-(<i>S</i>)- and 3-(<i>R</i>)-Methyl Analogues of <b>28</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DCC, <i>t</i>-BuOH, CH<sub>2</sub>Cl<sub>2</sub>; (b) 1 M LiOH, THF; then AcOH; (c)<b> 11</b>, HBTU, DIEA, DMF → <b>43</b>; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (e) TFA; (f) <b>11</b>, EDC·HCl, HOBt, DMF.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00007"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 8<a data-tab="pane-pcw-Figures" href="#jm030354bh00008" id="" class=" internalNav"></a> describes the synthesis of <b>48</b>, which is the 3-phenyl-substituted analogue of <b>28</b>. 3-Phenylglutaric acid was converted to 3-phenylglutaric anhydride by refluxing in acetic anhydride. This was then reacted with EtOH/Et<sub>3</sub>N to yield <b>46</b>, which was carried forward to <b>48</b> by procedures described before. <div id="_i20"><figure id="jm030354bh00008" data-index="9" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00008.jpeg" id="_i21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 8 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-Phenylpentanedioic Acid Monoethyl Ester <b>46</b> and Its Use in the Synthesis of<b> 48</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) Ac<sub>2</sub>O, Δ; (b) EtOH, Et<sub>3</sub>N, Δ ; (c) <b>11</b>, EDC·HCl, HOBt, DMF; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (e) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00008"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">The synthesis of <b>53</b>, the 3-(<i>S</i>)-methyl analogue of <b>23</b>, is shown in Scheme 9<a data-tab="pane-pcw-Figures" href="#jm030354bh00009" id="" class=" internalNav"></a>. Cbz-<span class="smallcaps smallerCapital">d</span>-Alanine was subjected to Arndt−Eistert homologation conditions to yield <b>49</b>.<sup>23b</sup> This was debenzylated to give ethyl (<i>S</i>)-3-aminobutanoate <b>50</b>, which was then converted to its 4-nitrophenyl carbamate derivative <b>51</b>. The carbamate was reacted with the spirolactam <b>11</b> to yield <b>52</b>, which was then transformed to <b>53</b> as described previously. <div id="_i22"><figure id="jm030354bh00009" data-index="10" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00009.jpeg" id="_i23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 9 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-(4-Nitrophenoxycarbonyl-amino)butyric Acid Ethyl Ester<b> 51</b> and Its Use in the Synthesis of<b> 53</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a)20% Pd(OH)<sub>2</sub>/C, EtOAc, 50 psi H<sub>2</sub>; (b) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (c) <b>11</b>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone (iii) NH<sub>4</sub>OAc, MeOH; (e) 3 N HCl.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00009"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 10<a data-tab="pane-pcw-Figures" href="#jm030354bh00010" id="" class=" internalNav"></a> describes the synthesis of spirohydantoin analogue <b>56</b>. Ethyl 3-amino-3-phenylpropanoate was reacted with 4-nitrophenyl chloroformate to yield the 4-nitrophenyl carbamate derivative <b>54</b>. This was then reacted with <b>19b </b>to afford <b>55</b>, which was carried through to <b>56</b> as described previously. <div id="_i24"><figure id="jm030354bh00010" data-index="11" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00010.jpeg" id="_i25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 10 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-(4-Nitrophenoxycarbon-ylamino)-3-phenylpropionic Acid Ethyl Ester <b>54 </b>and Its Use in the Synthesis of<b> 56</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>19b</b>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (c) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (d) 1 N LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00010"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 11<a data-tab="pane-pcw-Figures" href="#jm030354bh00011" id="" class=" internalNav"></a> depicts the synthesis of <b>59</b>, the 2-<i>R</i>-(3,5-dimethylisoxazole-4-sulfonamide) analogue of <b>28</b>. H-Glu-O-<i>t</i>-Bu was reacted with 3,5-dimethylisoxazole-4-sulfonyl chloride under Schotten−Baumann conditions to afford the sulfonamide <b>57</b>. This was coupled with spirolactam <b>11</b> to yield <b>58</b>, which was converted to <b>59</b> as described before. <div id="_i26"><figure id="jm030354bh00011" data-index="12" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00011.jpeg" id="_i27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 11 <i><sup>a</sup></i><sup></sup> Synthesis of the 2-(2-Carboxyethyl)-2-(3,5-dimethylisoxazole-4-sulfonylamino)-3,3-dimethylbutyric Acid<b> 57 </b>and its Use in the Synthesis of <b>59 </b>(CT50787) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) (i) 1 N NaOH, Na<sub>2</sub>CO<sub>3</sub>, 0 °C; (ii) 2 N HCl to pH = 3; (b) <b>11</b>, EDC·HCl, DMF; (c) TFA; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00011"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 12<a data-tab="pane-pcw-Figures" href="#jm030354bh00012" id="" class=" internalNav"></a> describes the synthesis of <b>63</b>, the α-tosylamide analogue of <b>23</b>. Ethyl (<i>S</i>)-2-amino-3-(Boc-amino)propanoate was reacted with TsCl to yield tosylamide <b>60</b>. Treatment with TFA yielded amine <b>61</b>. This was <a name="jm004700802042" id="jm004700802042"></a> then reacted with triphosgene, followed by spirolactam <b>11</b> to give <b>62. </b>The benzonitrile functionality was converted to the amidine via the amidoxime route. <b>62</b> was reacted with hydroxylamine hydrochloride/Et<sub>3</sub>N to yield the amidoxime, which was O-acetylated with Ac<sub>2</sub>O/AcOH, and then hydrogenolyzed to yield benzamidine. Hydrolysis of the ethyl ester with 1 M LiOH then provided <b>63</b>. <div id="_i28"><figure id="jm030354bh00012" data-index="13" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00012.jpeg" id="_i29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 12 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-Amino-2-(toluene-4-sul-fonylamino)propionic Acid Ethyl Ester <b>61 </b>and its Use in the Synthesis of<b> 63</b></p><p class="last"><p class="last"><sup>a</sup> Reagents and conditions:  (a) DIEA, DCM; (b) TFA; (c) <b>11</b>, triphosgene, CH<sub>2</sub>Cl<sub>2</sub>; (d) (i) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (ii) Ac<sub>2</sub>O, AcOH; (iii) 10% Pd/C, H<sub>2</sub>, 40 psi; (e) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00012"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">The synthesis of <b>69</b>, the α-<i>n</i>-butyl carbamate analogue of <b>28</b>, was achieved by the route outlined in Scheme 13<a data-tab="pane-pcw-Figures" href="#jm030354bh00013" id="" class=" internalNav"></a>. Z-Glu(O-<i>t</i>-Bu)-OH was converted to its ethyl ester <b>64</b>, followed by deprotection of the Cbz-group to yield <b>65</b>. This was reacted with <i>n</i>-butyl chloroformate to yield the carbamate <b>66</b>. De-<i>tert</i>-butylation gave <b>67</b>. This was then coupled with the spirolactam <b>11</b> to yield <a name="jm004700802043" id="jm004700802043"></a><b>68</b> and converted to <b>69</b> using previously described procedures. <div id="_i30"><figure id="jm030354bh00013" data-index="14" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00013.jpeg" id="_i31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 13 <i><sup>a</sup></i><sup></sup> Synthesis of the 2-Butoxycarbonylaminopentanedioic Acid 1-Ethyl Ester<b> 67</b> and Its Use in the Synthesis of<b> 69</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) EDC·HCl, HOBt, EtOH, DMF; (b) 20% Pd(OH)<sub>2</sub>/C, 1 atm H<sub>2</sub>, EtOH; (c) <i>n</i>-butyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (d) TFA; (e) <b>11</b>, HBTU, DIEA, DMF; (f) (i) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (ii) Ac<sub>2</sub>O, AcOH; (iii) 10% Pd/C, 1 atm H<sub>2</sub>; (g) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00013"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">Scheme 14<a data-tab="pane-pcw-Figures" href="#jm030354bh00014" id="" class=" internalNav"></a> describes the synthesis of <b>72</b>, which is the amine analogue of amide <b>28</b>. The spirolactam <b>11</b> was alkylated with ethyl 5-bromovalerate to yield <b>70</b>. The benzonitrile functionality was converted to benzamidine via amidoxime <b>71</b>, and then the ester group was saponified to yield <b>72</b>. <div id="_i32"><figure id="jm030354bh00014" data-index="15" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00014.jpeg" id="_i33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 14 <i><sup>a</sup></i><sup></sup> Synthesis of the 5-Azaspiro-1-ylpentanoic Acid Analogue <b>72</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DIEA, DMF, rt.; (b) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (c) (i) Ac<sub>2</sub>O, AcOH; (ii) 10% Pd/C; H<sub>2</sub>, 40 psi; (d) 1 N LiOH, THF/H<sub>2</sub>O, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00014"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p">In Scheme 15<a data-tab="pane-pcw-Figures" href="#jm030354bh00015" id="" class=" internalNav"></a> is outlined the synthesis of <b>75</b>. Methyl 2,2-dimethyl-3-hydroxypropionate was reacted with 4-nitrophenyl chloroformate to yield <b>73</b>. This was coupled with spirolactam <b>12</b> to give <b>74</b>, which was converted to <b>75</b> by previously described procedures. <div id="_i34"><figure id="jm030354bh00015" data-index="16" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00015.jpeg" id="_i35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 15 <i><sup>a</sup></i><sup></sup> Synthesis of the 2,2-Dimethylpropionic Acid Analogue<b> 75</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>12</b>, DIEA, DMF; (c) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (d) 1 N LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00015"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div class="NLM_p last">All the final compounds were purified by RP-HPLC and isolated either as their trifluoroacetate or HCl salts. </div></div><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><b>In Vitro SAR.</b> On the basis of our previous studies with other spirocyclic scaffolds,<sup>15</sup> initially the SAR investigation focused on optimizing the distance between the basic amidine functionality and the carboxylic acid group. This bond distance has been hypothesized to mimic the spacing between the basic guanidine and the acidic carboxylate of the RGD sequence of fibrinogen, which has been approximated to be 10−20 Å.<sup>20</sup> To explore this, we synthesized amides with C<sub>2</sub> to C<sub>5</sub> linkers (Table 1<a class="ref showTableEvent internalNav" data-ID="jm030354bt00001" href="#jm030354bt00001"></a>; <b>77</b>, <b>78</b>, <b>28</b>, <b>79</b>). The C<sub>4</sub>-linker was found to be optimum (<b>28</b>). By comparison, the compound with C<sub>3</sub>-linker (<b>78</b>) was found to be 9 times less potent, and the longer version with a C<sub>5</sub>-linker (<b>79</b>) was about 42 times less potent. This four-atom spacing between piperidine and carboxylate was found to be optimal in all the spiro-templates reported herein. <div class="NLM_table-wrap" id="jm030354bt00001"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 1.  In Vitro Activity and Pharmacokinetic Parameters for the 1-Oxospirolactam Scaffold-Based Analogues:  4-(1-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzamidines</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00001a.gif" alt="" id="_i37" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a</sup></i><sup></sup> Inhibition of platelet aggregation induced by 20 μM adenosine 5‘-diphosphate (ADP) in citrated human platelet rich plasma (<i>h</i>-PRP).<i><sup>b</sup></i><sup></sup> Inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay).<i><sup>c</sup></i><sup></sup> Inhibition of platelet aggregation induced by 20 μM ADP in <i>h</i>-PRP with PPACK (see Experimental Section for details).</p></div></div></div><div class="NLM_p">The potent activity of compound <b>28</b> confirmed to us that this novel series merited further investigation. The compounds of Table 1 were prepared to explore the SAR of this 1-oxo-γ-spirolactam series. In essence, having worked out the crucial spacing between the essential acidic and basic pharmacophores, we undertook the synthesis of numerous analogues of compound <b>28</b> to optimize its potency and improve in vivo properties. </div><div class="NLM_p">On the basis of our previous observations<sup>20,21</sup> as well as those reported in the literature for other series of integrin inhibitors, we targeted two regions of the lead molecule <b>28 </b>for modification:  the central rigid [4.5]-spirocyclic nucleus and the carboxyl linker unit. In the spirocyclic nucleus, we investigated the isomeric 3-oxo-γ-spirolactam, spiropiperidinylimide, spiropiperidinylureas, and spiropiperidinylhydantoins. On the linker unit, we compared urea with amide linkages to the piperidine of the scaffold and we made substitutions α or β to the carboxylate terminus. </div><div class="NLM_p">Most of the compounds in which the carboxylic acid appendage is attached to the piperidine via a urea linkage are generally slightly more potent than the corresponding amides (<b>28</b> versus <b>23 </b>(Table 1);<b> 87 </b>versus <b>84 </b>(Table 2<a class="ref showTableEvent internalNav" data-ID="jm030354bt00002" href="#jm030354bt00002"></a>);<b> 94 </b>versus <b>89 </b>(Table 3);<b> 101</b> versus<b> 99 </b>(Table 4);<b> 105 </b>versus<b> 104</b> (Table 5)). In the literature, analogues containing substituted β-amino acid units appended to various scaffolds have been widely studied as GPIIb-IIIa antagonists, and the β-amino acid unit has been postulated to mimic the β-carboxyl group of the aspartic acid residue of the RGD sequence.<sup>6e,7,11</sup> Further lipophilic substitutions at both α- and β-positions of these units have generally enhanced potency and PK properties. However, in the 1-oxo-γ-spirolactam scaffold, a β-position methyl group (<b>53</b>, <b>81</b> versus <b>23</b> (Table 1)) did not improve potency. This may imply special conformational requirements for this rigid template. <div class="NLM_table-wrap" id="jm030354bt00002"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 2.  In Vitro Activity and Pharmacokinetic Parameters for the 3-Oxospirolactam Scaffold-Based Analogues:  4-(3-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzamidines</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00002a.gif" alt="" id="_i38" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a</sup></i><sup></sup><sup><sup>,</sup></sup><sup><i>b</i></sup> See Table 1.</p></div></div></div><div class="NLM_p"><a name="jm004700802044" id="jm004700802044"></a>Hartman et al., Egbertson et al., and Xue et al.<sup>22</sup> have reported that introduction of a sulfonamide or a carbamate substituent α to the carboxylate resulted in very potent and specific inhibitors of GPIIb-IIIa. These authors have suggested that this favorable effect is the result of an interaction with an exosite in the integrin. These α-substituents might also be functioning as a surrogate for the α-carboxylic acid of the Asp-residue. This modification has been applied in our various series and was not found to be uniformly successful in enhancing the GPIIb-IIIa inhibitory activity of compounds. In the 1-oxo-γ-spirolactam series, α-sulfonamides (Table 1; <b>59</b>, <b>63</b>) or α-carbamate (<b>69</b>) substituents were close to equipotent with the parent compounds lacking substituents (<b>23</b>,<b> 28</b>). The result is different from our observations in the hydantoin series (Table 3; <b>92</b>, <b>97</b>, <b>91</b>) and <a name="jm004700802045" id="jm004700802045"></a> imide series (Table 5; <b>106</b>) in which such α-substitution leads to a significant improvement over the unsubstituted analogue in <i>h</i>PRP.<a class="ref showTableEvent internalNav" data-ID="jm030354bt00003" href="#jm030354bt00003"></a><a class="ref showTableEvent internalNav" data-ID="jm030354bt00004" href="#jm030354bt00004"></a><a class="ref showTableEvent internalNav" data-ID="jm030354bt00005" href="#jm030354bt00005"></a><div class="NLM_table-wrap" id="jm030354bt00003"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 3.  In Vitro Activity and Pharmacokinetic Parameters for the Spirohydantoin Scaffold-Based Analogues:  4-(2,4-Dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzamidines</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00003a.gif" alt="" id="_i39" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a,b</sup></i><sup></sup> See Table 1.</p></div></div><div class="NLM_table-wrap" id="jm030354bt00004"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 4.  In Vitro Activity and Pharmacokinetic Parameters for the Spirourea Scaffold-Based Analogues:  4-(2-Oxo-1,3,8-triazaspiro[4.5]decan-2-one-3-yl)benzamidines</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00004a.gif" alt="" id="_i40" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a,b</sup></i><sup></sup> See Table 1.</p></div></div><div class="NLM_table-wrap" id="jm030354bt00005"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 5.  In Vitro Activity and Pharmacokinetic Parameters for the Spiroimide Scaffold-Based Analogues:  4-(1,3-Dioxo-2,8- diazaspiro[4.5]decane-1,3-dione-2-yl)-benzamidines</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00005a.gif" alt="" id="_i41" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a,b</sup></i><sup></sup> See Table 1.</p></div></div></div><div class="NLM_p">Numerous studies of GPIIb-IIIa inhibitors have suggested that residues at or very near the aspartic acid of the RGD sequence can also modulate the selectivity of ligand binding to integrins, and introduction of aromatic or other hydrophobic residues proximal to the RGD site can significantly enhance the inhibitory activity and specificity of the RGD analogues.<sup>23</sup> On the basis of an extensive SAR study at a position β-to the carboxylic acid terminus in a different series of GPIIb-IIIa inhibitors, Zablocki et al.<sup>24</sup> have reported the discovery of potent platelet aggregation inhibitor, xemilofiban (Figure 1). We have studied the effect of β-substitutions to the carboxylic acid in our spirocyclic series by incorporating methyl and phenyl substituents. In the 1-oxo-γ-spirolactam series, β-substituents were less active than the corresponding compounds lacking substituents (Table 1; <b>44</b>, <b>45</b>, <b>48</b>). Again, this result is opposite to what is observed in the hydantoin (<b>93</b>), urea (<b>103</b>), and 3-oxo-γ-spirolactam series (<b>86</b>). For these, β-substitution resulted in a <a name="jm004700802046" id="jm004700802046"></a> significant improvement over the unsubstituted analogue in <i>h</i>PRP (Tables 2−4). </div><div class="NLM_p">Interestingly, all the templates investigated within the[4.5]-spirocyclic framework have provided potent compounds. This is consistent with the hypothesis that GPIIb-IIIa does not require significant interaction with the central template of inhibitors. Its sole purpose appears to be providing the scaffold to deliver the acidic and basic pharmacophores in the correct geometry to mimic the RGD sequence of fibrinogen receptor, which is believed to represent the minimal sequence necessary for binding to GPIIb-IIIa. </div><div class="NLM_p">Of all the spirocyclic templates that we have investigated, the 1-oxo-γ-spirolactam template has provided the most potent GPIIb-IIIa antagonists. Optimum binding to the RGD binding motif of the fibrinogen binding site in the basic framework was depicted in the compounds <b>28</b> and <b>23 </b>(Table 1). Attempts to improve their activity by utilizing the SAR previously documented in the other GPIIb-IIIa antagonist templates proved fruitless. Interestingly, SAR in other spiro-scaffolds described here has led to the expected enhancements in activity when modifications were made to the compounds. </div><div class="NLM_p">Changing only the spirocyclic scaffold, a comparison of the inhibitory activities of compounds <b>23</b> (Table 1), <b>87</b> (Table 2), <b>94, 95</b> (Table 3), <b>101, 102</b> (Table 4), and <b>105</b> (Table 5) implies that the 1-oxo-γ-spirolactam scaffold is in the appropriate rigid conformation to display the acidic and basic pharmacophores for optimum binding. </div><div class="NLM_p"><b>In Vivo Results.</b> In general, GPIIb-IIIa antagonists containing both an amidine and a carboxylic acid group have very low oral bioavailability. This has been attributed both to the strongly basic nature of the amidine functionality and to the highly polar, acidic nature of the carboxylic acid. Analogues which display both groups are expected to behave as zwitterionic species. In particular, the strongly basic amidine group would be expected to exist in its ionic form both in the acidic conditions of the stomach and also in the weakly basic conditions of the intestine. This lasting ionic form could prevent the absorption through a passive transport from the intestine, which is greatly dependent on the lipophilicity of the molecule. In addition, the terminal carboxylic acid may also contribute to poor absorption. To circumvent these problems, various approaches have been aimed at both masking the basicity of the amidine group and enhancing the lipophilicity of the molecule. </div><div class="NLM_p">When selected compounds from each spirocyclic scaffold were evaluated as their ethyl ester prodrugs in rat, they exhibited bioavailability of ≤5%, although some displayed encouraging elimination half-lives (Tables 1−5). Again, the strongly basic nature of the amidine group was considered a likely cause of the poor bioavailability. </div><div class="NLM_p">In one approach aimed at finding a less basic substitute for the amidine group, GPIIb-IIIa antagonists where a pyridine or piperidine ring substitutes for the benzamidine have been explored (Figure 1, ZD-2486,<sup>25</sup> lotrafiban,<sup>26</sup> elarofiban,<sup>27</sup> UR-12947). However, when used in the spirocyclic scaffold series, the pyridine-<a name="jm004700802047" id="jm004700802047"></a> containing compounds did not show a favorable pharmacokinetic profile. This was despite retaining equivalent potency compared to the corresponding amidine analogues.<sup>15</sup></div><div class="NLM_p">In another approach aimed at enhancing the lipophilicity of the overall molecule and also partially masking the charge on the amidine group, mono- and dialkylated amidino analogues have been investigated (Figure 1, NSL-96184, PSA0613). The dialkylated analogues have been found to retain their activity and exhibit improved PK profiles.<sup>28</sup> However, in the 1-oxo-spirolactam series, both mono- and disubstituted amidino analogues showed greatly diminished activity (Table 1; <b>40b</b> and <b>39b</b> versus <b>28</b>). This anomaly may also be rationalized by invoking the spatial-constraints of the centrally rigid spirocyclic template. </div><div class="NLM_p">A double prodrug approach relies on the strategy of masking both polarizable pharmacophore groups in order to enhance oral bioavailability. Such an approach has been employed previously to obtain orally bioavailable GPIIb-IIIa antagonists, e.g. lefradafiban (BIBU-104) (methyl carbamate),<sup>29</sup> sibrafiban (Ro 48−3657) (amidoxime), <sup>30</sup> gantofiban<sup>31</sup> (EMD-122347) (methyl carbamate) (Figure 1). In the novel amidoxime prodrug approach, aimed at lowering the p<i>K</i><sub>a</sub> of the basic benzamidine, the liver- and/or gut-mediated reduction of the amidoxime generates the active metabolite. Novel GPIIb-IIIa double prodrug containing antagonists with amidoxime and ethyl ester functionalities have been described which exhibit PK profiles in rats, dogs, and rhesus monkeys which are independent of the species. On the basis of these observations, we investigated this double prodrug strategy for our most potent spirocyclic compounds. The amidoxime ethyl ester double prodrugs described here were synthesized using the reaction sequence shown in Schemes 3 and 4. The pharmacokinetic data on the amidoxime ethyl ester double prodrugs, representing each spirocyclic scaffold, is depicted in Table 6<a class="ref showTableEvent internalNav" data-ID="jm030354bt00006" href="#jm030354bt00006"></a>. The double prodrugs of the spirourea and spirohydantoin-containing scaffolds (<b>111</b>, <b>112</b>, and <b>113</b>) did not show a noticeable improvement in bioavailability over their nonprotected version. However, for the 1-oxo-spirolactam series, a dramatic improvement was observed by the double prodrug approach. Three of the best of these (<b>22</b>, <b>27</b>, and <b>36</b>; Table 6) were chosen for further study. <div class="NLM_table-wrap" id="jm030354bt00006"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 6.  PK Properties of Active Drugs after Oral Administration of Double Prodrugs in Rats (1.0 mg/kg)</p></div></div><div class="scrollable-table-wrap"><table class="table single-image " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bu00006a.gif" alt="" id="_i42" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a</sup></i><sup></sup> Calculated using ACD/LogP version 4.56 (Advanced Chemistry Development, Inc., 90 Adelaide St. West, Toronto, Canada M5H 3V9).<i><sup>b</sup></i><sup></sup> Calculated using MOE (Chemical Computing Group, Inc., 1010 Sherbrooke St. West, #910, Montreal, Canada H3A 2R7).<i><sup>c</sup></i><sup></sup> Calculated using the method of Ertl.<sup>34</sup></p></div></div></div><div class="NLM_p">The higher oral bioavailability observed for the 1-oxospirolactam series over other spirocyclic scaffolds may be attributed to its higher rigidity, optimal lipophilicity, and its lower polar surface area (Table 6). Reduced polar surface area has been suggested to correlate better with increased permeation rate than does lipophilicity (cLogP), and this should also help explain the difference in <i>F</i>% for the compounds within this lactam series which have similar cLogP values (Table 1).<sup>32</sup></div><div class="NLM_p">The differences in PK properties of compounds <b>22, 110, 111</b>, and <b>112</b> (Table 6) which differ only in the nature of the five-membered ring is noteworthy in this regard. Hydantoin- and urea-containing spiro templates have relatively more polar surface area and thus they would be expected to be less able to penetrate membranes. They indeed are less bioavailable. For the 1-oxo- and 3-oxospirolactams (<b>22</b> and <b>110)</b>, one would expect the 3-oxo-carbonyl group in <b>110</b> to be more exposed to solvation than the corresponding 1-oxo-carbonyl group in <b>22</b>, as is reflected in their polar surface areas, and this may help explain the distinct differences in their PK profiles. This is noteworthy because for these two compounds all other physicochemical parameters are the same, including the number of rotatable bonds and the hydrogen-bond donor/acceptor groups. </div><div class="NLM_p">The pharmacokinetic data, in rats, for the double prodrugs <b>22 </b>(CT51464), <b>27 </b>(CT51269), and <b>36 </b>(CT52108) are shown in Table 7<a class="ref showTableEvent internalNav" data-ID="jm030354bt00007" href="#jm030354bt00007"></a>. This PK data indicates that all the double prodrugs are rapidly (<i>T</i><sub>max</sub> = 1 h) and well absorbed. All the drugs exhibited similar PK profiles. For example, after oral administration of <b>22</b>, at a dose of 1 mg/kg to male rats (<i>n</i> = 6) and the active drug (<b>23)</b> as well as amidoxime acid (<b>24)</b> were detected in plasma (Figure 2<a data-tab="pane-pcw-Figures" href="#jm030354bf00002" id="" class=" internalNav"></a>).<a data-tab="pane-pcw-Figures" href="#jm030354bf00003" id="" class=" internalNav"></a> While <b>23</b> showed a relatively long elimination half-life (<i>t</i><sub>1/2</sub><sub>β</sub> = 1.81 h, mean), amidoxime <b>24</b> disappeared more rapidly (<i>t</i><sub>1/2</sub><i><sub>β</sub></i> = 0.6 h ± 0.03, mean ± SD). <div id="_i43"><figure id="jm030354bf00002" data-index="17" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00002.jpeg" id="_i44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 2 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.1 mg/kg) and po administration of <b>22</b> (1.0 mg/kg) versus time, as determined by LC/MS/MS in rats (<i>n</i> = 6). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00002"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="jm030354bf00003" data-index="18" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00003.jpeg" id="_i45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 3 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.1 mg/kg) and po administration of <b>22</b> (1.0 mg/kg) versus time, as determined by LC/MS/MS in dogs (<i>n</i> = 4). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00003"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div class="NLM_table-wrap" id="jm030354bt00007"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 7.  Pharmacokinetic Parameters of <b>23</b>, <b>28</b> and <b>33</b> after Oral Administration of <b>22</b>, <b>27</b>, and <b>36</b> in Rat (1.0 mg/kg)</p></div></div><div class="scrollable-table-wrap"><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2" colspan="2">iv</td><td class="colsep2 rowsep2" colspan="3">po</td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">compound</td><td class="colsep2 rowsep2">AUC, ng·h/mL</td><td class="colsep2 rowsep2"><i>t</i><sub>1/2 β</sub></td><td class="colsep2 rowsep2">AUC, ng·h/mL</td><td class="colsep2 rowsep2"><i>t</i><sub>1/2</sub></td><td class="colsep2 rowsep2"><i>F</i>, %</td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>28</b>, CT50614</td><td class="colsep2 rowsep2">500.6</td><td class="colsep2 rowsep2">1.8</td><td class="colsep2 rowsep2">181.9</td><td class="colsep2 rowsep2">1.14</td><td class="colsep2 rowsep2">36.3</td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>23</b>, CT50728</td><td class="colsep2 rowsep2">565.1</td><td class="colsep2 rowsep2">1.81</td><td class="colsep2 rowsep2">126.2</td><td class="colsep2 rowsep2">1.42</td><td class="colsep2 rowsep2">22.3</td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>33</b>, CT51907</td><td class="colsep2 rowsep2">651</td><td class="colsep2 rowsep2">1.94</td><td class="colsep2 rowsep2">366.6</td><td class="colsep2 rowsep2">1.57</td><td class="colsep2 rowsep2">35.9</td></tr></tbody></table></div></div></div><div class="NLM_p">The double prodrug <b>22</b> was absorbed and converted to an active compound in vivo, most probably <a name="jm004700802048" id="jm004700802048"></a> to the amidino acid <b>24</b>. The metabolic reduction of benzamidoxime derivatives to benzamidines, in vivo as well as in vitro, is well documented.<sup>33</sup> The clearance mechanism for <b>24</b> has not been determined. Despite the two metabolic steps involved, the interindividual variability of the plasma concentration of active compound <b>23</b> was low. In either case, the rapid appearance of <b>24</b> suggests rapid absorption of prodrug. <i>T</i><sub>max</sub> for <b>24</b> after oral administration of <b>22</b> was 0.25 h, and that for <b>29</b> and <b>37</b> after oral administration of <b>27</b> and <b>36</b>, repectively, was ≤0.5 h. In a separate experiment, the amidoxime acid <b>29</b> exhibited low bioavailability in rats (<i>F</i> = 3.7%). </div><div class="NLM_p">The oral absorption of <b>22</b> (CT51464) may be a complicated process involving multiple absorption sites in the digestive tract. Metabolism of the double prodrug in the intestinal tract may also play a role in the absorption process. The rapid appearance of <b>24</b> and the delayed absorption maxima of <b>23</b> (Figure 2) may indicate a two-step absorption process. A portion of the drug may be absorbed from the stomach and/or proximal sections of the intestines while the remaining drug is absorbed in distal portions of the intestine. A second possibility for the delayed appearance of <b>23</b> may be that rapid absorption of the prodrug occurs but the intermediate product <b>24 </b>or the active compound <b>23</b> forms a conjugate (glucuronic acid, sulfate, glycine, etc.) which is subsequently hydrolyzed to give <b>23</b>. </div><div class="NLM_p">Figures 4, 5, and 6 show the PK profiles of <b>23</b>,<b> 28</b>, and<b> 33</b> in cynomolgus monkeys after iv administration of the active drugs <b>23</b>,<b> 28</b>, and <b>33</b> and after oral administration of their respective double prodrugs (<b>22</b>,<b> 27</b>, and <b>36</b>). From the in vivo data, the conversion of the ester to the acid seems to be faster than the conversion of the N-hydroxyamidine to the amidine. The data may also suggest that the relative rates of absorption of the different structures may vary by species. </div><div class="NLM_p">For <b>28</b>/<b>27</b> (Figure 5<a data-tab="pane-pcw-Figures" href="#jm030354bf00004" id="" class=" internalNav"></a><a data-tab="pane-pcw-Figures" href="#jm030354bf00005" id="" class=" internalNav"></a>),<a data-tab="pane-pcw-Figures" href="#jm030354bf00006" id="" class=" internalNav"></a> pharmacokinetic patterns similar to those described above for rats were observed. The peak plasma level of amidoxime acid <b>29</b> was higher and was reached earlier (<i>T</i><sub>max</sub> ≤ 0.5 h) than that of <b>28</b> (<i>T</i><sub>max</sub> = 2 h). For <b>33/36</b> (Figure 6),<a class="ref showTableEvent internalNav" data-ID="jm030354bt00008" href="#jm030354bt00008"></a><a class="ref showTableEvent internalNav" data-ID="jm030354bt00009" href="#jm030354bt00009"></a> a similar PK profile was observed. However, for <b>23/22</b> (Figure 4), the peak plasma levels of amidoxime acid <b>24</b> were lower than that of <b>23</b>, even at 0.5 h when the first samples were drawn. <i>T</i><sub>max</sub> for <b>24</b> and <b>23</b> were the same (1.5−3.5 h). <div id="_i46"><figure id="jm030354bf00004" data-index="19" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00004.jpeg" id="_i47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 4 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.2 mg/kg) and po administration of <b>22</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00004"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="jm030354bf00005" data-index="20" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00005.jpeg" id="_i48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 5 Plasma levels of <b>28</b> after iv administration of <b>28</b> (0.2 mg/kg) and po administration of <b>27</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>29</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00005"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="jm030354bf00006" data-index="21" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00006.jpeg" id="_i49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 6 Plasma levels of <b>33</b> after iv administration of <b>33</b> (0.2 mg/kg) and po administration of <b>36</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>37</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00006"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div class="NLM_table-wrap" id="jm030354bt00008"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 8.  Summary of Pharmacokinetic Parameters of <b>23</b>, <b>28</b>, and <b>33</b> after iv (1 mg/kg) and Oral Administration of <b>22</b>, <b>27</b>, and <b>36</b> in Rat, Dog, and Cyno</p></div></div><div class="scrollable-table-wrap"><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2" colspan="2"><i>F</i>, %<i><sup>a,c</sup></i><sup></sup></td><td class="colsep2 rowsep2" colspan="2"><i>t</i><sub>1/2</sub><sub>β</sub>, h<i><sup>a,b</sup></i><sup></sup></td><td class="colsep2 rowsep2" colspan="2"><i>V</i><sub>z</sub>, L/kg<sup><i>d</i></sup></td><td class="colsep2 rowsep2" colspan="2">Cl, mL/min/kg</td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">prodrug/drug</td><td class="colsep2 rowsep2">species</td><td class="colsep2 rowsep2">oral dose, mg/kg</td><td class="colsep2 rowsep2">average</td><td class="colsep2 rowsep2">SD</td><td class="colsep2 rowsep2">average</td><td class="colsep2 rowsep2">SD</td><td class="colsep2 rowsep2">average</td><td class="colsep2 rowsep2">SD</td><td class="colsep2 rowsep2">average</td><td class="colsep2 rowsep2">SD </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>27</b>/<b>28</b></td><td class="colsep2 rowsep2">rat (6) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">36.3 </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">1.8 </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">dog (4) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">39 </td><td class="colsep2 rowsep2">16.3 </td><td class="colsep2 rowsep2">10.3 </td><td class="colsep2 rowsep2">3.5 </td><td class="colsep2 rowsep2">5.75 </td><td class="colsep2 rowsep2">1.04 </td><td class="colsep2 rowsep2">6.44 </td><td class="colsep2 rowsep2">1.16 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">cyno (4) </td><td class="colsep2 rowsep2">2 </td><td class="colsep2 rowsep2">18.77 </td><td class="colsep2 rowsep2">1.2 </td><td class="colsep2 rowsep2">8.9 </td><td class="colsep2 rowsep2">2.4 </td><td class="colsep2 rowsep2">5.02 </td><td class="colsep2 rowsep2">5.26 </td><td class="colsep2 rowsep2">6.51 </td><td class="colsep2 rowsep2">6.83 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>22</b>/<b>23</b></td><td class="colsep2 rowsep2">rat (6) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">22.3 </td><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">1.81 </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">dog (4) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">72.9 </td><td class="colsep2 rowsep2">26.1 </td><td class="colsep2 rowsep2">8.97 </td><td class="colsep2 rowsep2">1.89 </td><td class="colsep2 rowsep2">4.12 </td><td class="colsep2 rowsep2">1.46 </td><td class="colsep2 rowsep2">8.43 </td><td class="colsep2 rowsep2">2.98 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">cyno (4) </td><td class="colsep2 rowsep2">2 </td><td class="colsep2 rowsep2">32.4 </td><td class="colsep2 rowsep2">8.85 </td><td class="colsep2 rowsep2">14.2 </td><td class="colsep2 rowsep2">3.18 </td><td class="colsep2 rowsep2">6.30 </td><td class="colsep2 rowsep2">2.12 </td><td class="colsep2 rowsep2">5.12 </td><td class="colsep2 rowsep2">1.73 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"><b>36</b>/<b>33</b></td><td class="colsep2 rowsep2">rat (6) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">35.9 </td><td class="colsep2 rowsep2">10 </td><td class="colsep2 rowsep2">1.94 </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td><td class="colsep2 rowsep2">− </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">dog (4) </td><td class="colsep2 rowsep2">1 </td><td class="colsep2 rowsep2">23.3 </td><td class="colsep2 rowsep2">3.9 </td><td class="colsep2 rowsep2">10.3 </td><td class="colsep2 rowsep2">1.35 </td><td class="colsep2 rowsep2">2.93 </td><td class="colsep2 rowsep2">0.32 </td><td class="colsep2 rowsep2">3.28 </td><td class="colsep2 rowsep2">0.36 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">cyno (4) </td><td class="colsep2 rowsep2">2 </td><td class="colsep2 rowsep2">30.6 </td><td class="colsep2 rowsep2">3.41 </td><td class="colsep2 rowsep2">7.51 </td><td class="colsep2 rowsep2">2.16 </td><td class="colsep2 rowsep2">1.75 </td><td class="colsep2 rowsep2">0.22 </td><td class="colsep2 rowsep2">2.70 </td><td class="colsep2 rowsep2">0.34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last"><i><sup>a</sup></i><sup></sup> Data are mean ± SD.<i><sup>b</sup></i><sup></sup> The apparent elimination half-life (<i>t</i><sub>1/2</sub><i><sub>β</sub></i>) was determined from the linear portion of the log plasma concentration−time profile.<i><sup>c</sup></i><sup></sup> The bioavailability (<i>F</i>) of <b>23</b>, <b>28</b> and <b>33</b> after po administration of <b>22</b>, <b>27</b>, and <b>36</b> was calculated accounting for the differences in molecular weights and doses.<sup><i>d</i></sup> The volume of distribution (<i>V</i><sub>Z</sub>) was calculated as dose/(AUCINF* λ<sub>z</sub>) where λ<sub>z</sub> is the terminal elimination rate constant. Lambda Z (λ<sub>z</sub>) is calculated as the slope of the terminal, linear portion of the log linear plot of plasma concentration versus time.</p></div></div><div class="NLM_table-wrap" id="jm030354bt00009"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 9.  Activity Summary for Leading Candidates:  Comparison to Sibrafiban and Orbofiban</p></div></div><div class="scrollable-table-wrap"><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2"><b>28</b> CT050614 (μM)</td><td class="colsep2 rowsep2"><b>23</b> CT050728 (μM)</td><td class="colsep2 rowsep2"><b>33</b> CT051907 (μM)</td><td class="colsep2 rowsep2">orbofiban (μM)</td><td class="colsep2 rowsep2">sibrafiban (μM)</td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">Aggregation Assays (in PRP) </td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">20 μM ADP−citrate </td><td class="colsep2 rowsep2">0.054 </td><td class="colsep2 rowsep2">0.053 </td><td class="colsep2 rowsep2">0.108 </td><td class="colsep2 rowsep2">0.068 </td><td class="colsep2 rowsep2">0.051 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.005) </td><td class="colsep2 rowsep2">(± 0.010) </td><td class="colsep2 rowsep2">(± 0.011) </td><td class="colsep2 rowsep2">(± 0.015) </td><td class="colsep2 rowsep2">(± 0.008) </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">20 μM ADP−PPACK </td><td class="colsep2 rowsep2">0.168 </td><td class="colsep2 rowsep2">0.110 </td><td class="colsep2 rowsep2">0.260 </td><td class="colsep2 rowsep2">0.137 </td><td class="colsep2 rowsep2">0.072 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.010) </td><td class="colsep2 rowsep2">(± 0.019) </td><td class="colsep2 rowsep2">(± 0.029) </td><td class="colsep2 rowsep2">(± 0.038) </td><td class="colsep2 rowsep2">(± 0.017) </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">5 μM TRAP6−citrate </td><td class="colsep2 rowsep2">0.123 </td><td class="colsep2 rowsep2">0.120 </td><td class="colsep2 rowsep2">0.273 </td><td class="colsep2 rowsep2">0.166* </td><td class="colsep2 rowsep2">0.147* </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.021) </td><td class="colsep2 rowsep2">(± 0.047) </td><td class="colsep2 rowsep2">(± 0.080) </td><td class="colsep2 rowsep2">(± 0.008) </td><td class="colsep2 rowsep2">(± 0.017) </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">5 μM TRAP6−PPACK </td><td class="colsep2 rowsep2">0.368 </td><td class="colsep2 rowsep2">0.365 </td><td class="colsep2 rowsep2">0.691 </td><td class="colsep2 rowsep2">0.362* </td><td class="colsep2 rowsep2">0.182* </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.009) </td><td class="colsep2 rowsep2">(± 0.092) </td><td class="colsep2 rowsep2">(± 0.034) </td><td class="colsep2 rowsep2">(± 0.013) </td><td class="colsep2 rowsep2">(± 0.011) </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">4 μg/mL collagen−citrate </td><td class="colsep2 rowsep2">0.175 </td><td class="colsep2 rowsep2">0.140 </td><td class="colsep2 rowsep2">0.393 </td><td class="colsep2 rowsep2">n.d. </td><td class="colsep2 rowsep2">n.d. </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.009) </td><td class="colsep2 rowsep2">(± 0.045) </td><td class="colsep2 rowsep2">(± 0.049) </td><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2"> </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">4 μg/mL collagen-PPACK </td><td class="colsep2 rowsep2">0.464 </td><td class="colsep2 rowsep2">0.450 </td><td class="colsep2 rowsep2">0.812 </td><td class="colsep2 rowsep2">n.d. </td><td class="colsep2 rowsep2">n.d. </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.073) </td><td class="colsep2 rowsep2">(± 0.072) </td><td class="colsep2 rowsep2">(± 0.187) </td><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2"> </td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">Solid-Phase Assays </td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">fibrinogen binding to GPIIb-IIIa </td><td class="colsep2 rowsep2">0.00367 </td><td class="colsep2 rowsep2">0.00390 </td><td class="colsep2 rowsep2">0.00976 </td><td class="colsep2 rowsep2">0.00238 </td><td class="colsep2 rowsep2">0.00114 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2"> </td><td class="colsep2 rowsep2">(± 0.00104) </td><td class="colsep2 rowsep2">(± 0.00128) </td><td class="colsep2 rowsep2">(± 0.0021) </td><td class="colsep2 rowsep2">(± 0.0032) </td><td class="colsep2 rowsep2">(± 0.0002) </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">vitronectin binding to α<sub>v</sub>β<sub>3</sub></td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">n.d. </td><td class="colsep2 rowsep2">>50</td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">Cell Adhesion Assays </td></tr></tbody></table><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">HUVEC adhesion to vitronectin </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">n.d. </td><td class="colsep2 rowsep2">>50 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">HUVEC adhesion to fibronectin </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">>50 </td><td class="colsep2 rowsep2">n.d. </td><td class="colsep2 rowsep2">>50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-"><p class="first last">*211-47 TRAP was used for these determinations.</p></div></div></div><div class="NLM_p">The half-life of <b>28</b> in cynomolgus monkeys (8.9 h) is longer than that observed in rats (1.8 h). The affinity of <b>28</b> for the cynomolgus monkey GPIIb-IIIa receptor is stronger than that for rat (IC<sub>50</sub> = 0.128 ± 0.031 μM versus 0.60 ± 0.013 μM), and we and others hypothesize <a name="jm004700802049" id="jm004700802049"></a> that the terminal half-life of the drug may be controlled to a large extent by its binding affinity to platelets.<sup>11</sup> Although this platelet binding hypothesis is in agreement with the half-life data obtained for <b>28</b>, no direct evidence exists to prove the hypothesis in this series. </div><div class="NLM_p">When compound <b>22</b> was given orally to fasted male beagle dogs at 1 mg/kg (<i>n</i> = 4), a pharmacokinetic pattern similar to that described above for cynomolgus monkey was observed (Figure 3). The peak plasma levels of amidoxime acid <b>24</b> were lower than that of <b>23</b> even at 0.5 h. For both <b>23</b> and <b>24</b>, the <i>T</i><sub>max</sub> was about 5 h. The <i>t</i><sub>1/2</sub><i><sub>β</sub></i> for <b>23</b> was 8.97 h. Compared to the experiment in monkeys, the half-life was longer and bioavailability was higher. The affinity of <b>23</b> for the dog GPIIb-IIIa receptor may be stronger than that for cyno (IC<sub>50</sub> = 0.239 ± 0.39 μM versus 0.410 ± 0.152 μM). </div><div class="NLM_p">The pharmacokinetic data for <b>22</b>, <b>27</b>, and <b>36</b> is summarized in Table 8, and the comprehensive in vitro data in Table 9 along with data for orbofiban and sibrafiban. The three selected double prodrug analogues all exhibit good activity in human plasma, have low protein binding, and are stable in gastric juice, phosphate-buffered saline (PBS), and water. They also exhibit superior stability in human hepatic microsomes and do not inhibit the P450 3A4 isozyme (data not shown). All the final candidates were also found to be negative in preliminary AMES tests. Virtually all the active compounds in this series demonstrated a selectivity of >5000-fold for GPIIb-IIIa versus the most closely related integrin, the vitronectin receptor α<sub>v</sub>β<sub>3</sub>. <b>22</b> (CT51464) was eventually chosen for further development due to its superior bioavailability and half-life. </div><div class="NLM_p">The relatively high oral bioavailability of <b>22</b> may obviate the problem of large plasma level variability from patient to patient, which has been postulated to be a drawback with previous oral GPIIb-IIIa antagonists that demonstrated no clear therapeutic benefits in Phase III clinical evaluation. The high bioavailability of <b>22</b> coupled with its long elimination half-life may also address the problem of a narrow therapeutic index leading to a narrow window of safety. </div><div class="NLM_p"><b>In Vivo Demonstration of GPIIb-IIIa Dependence of Mouse Bleeding Time.</b> A platelet-dependent mouse tail bleeding time model was used to demonstrate the in vivo antithrombotic capacity of these potent GPIIb-IIIa antagonists. In this model, <b>59</b> (CT50787), a specific αIIbβ3 (GPIIb-IIIa) antagonist, was administered to prevent platelets from aggregating and forming the platelet plug necessary to promote hemostasis. GPIIb-IIIa antagonists are generally very species selective, and of the many spirocyclic analogues that were tested, <b>59</b> was determined to have the highest affinity <a name="jm004700802050" id="jm004700802050"></a> for the mouse GPIIb-IIIa receptor with an in vitro IC<sub>50</sub> value of 48 nM. </div><div class="NLM_p">To test the effects of <b>59</b> on mouse bleeding times, it was administered iv to female C57/bl mice in 10% DMSO in water at 10−100 mg/kg via a tail vein. Bleeding was initiated by transection of the tip of the tail, which was then immersed in a 37 °C normal saline bath. The bleeding time was recorded until cessation of blood flow by visual inspection or up to 15 min (900 s). </div><div class="NLM_p">Because of the rapid clearance and a short half-life of <b>59</b> in rodents, maintaining an in vivo exposure level necessary to inhibit platelet aggregation and extend bleeding times was achieved by administering high doses via intravenous bolus injection. Table 10<a class="ref showTableEvent internalNav" data-ID="jm030354bt00010" href="#jm030354bt00010"></a> shows the bleeding times in the presence and absence of <b>59</b>. A dose-dependent extension of bleeding time was demonstrated with iv administration of <b>59</b> with no effect at the lowest dose of 10 mg/kg and a near maximal effect, up to 668% of baseline, at the highest dose examined. Ex vivo aggregation measurements were not accomplished at the end of the bleeding time procedure due to the low level of drug in the plasma at the end of the 15 min time period. <div class="NLM_table-wrap" id="jm030354bt00010"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><p class="first last"> Table 10.  Dose-Dependent Effect of <b>59</b> (CT50787) vs DMSO (Vehicle) on Bleeding Time in Mice</p></div></div><div class="scrollable-table-wrap"><table class="table " width="100%"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><tbody><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">treatment regimen, mg/kg</td><td class="colsep2 rowsep2"><i>n</i></td><td class="colsep2 rowsep2">mean BT (s)</td><td class="colsep2 rowsep2">SD</td><td class="colsep2 rowsep2">% of average vehicle control </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">vehicle control </td><td class="colsep2 rowsep2">15 </td><td class="colsep2 rowsep2">116.0 </td><td class="colsep2 rowsep2">30.4 </td><td class="colsep2 rowsep2"> </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">10 </td><td class="colsep2 rowsep2">3 </td><td class="colsep2 rowsep2">96.7 </td><td class="colsep2 rowsep2">22.1 </td><td class="colsep2 rowsep2">−17 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">40 </td><td class="colsep2 rowsep2">4 </td><td class="colsep2 rowsep2">196.5 </td><td class="colsep2 rowsep2">81.4 </td><td class="colsep2 rowsep2">69 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">50 </td><td class="colsep2 rowsep2">4 </td><td class="colsep2 rowsep2">562.5 </td><td class="colsep2 rowsep2">161.4 </td><td class="colsep2 rowsep2">385 </td></tr><tr valign="top" class="colsep2"><td class="colsep2 rowsep2">100 </td><td class="colsep2 rowsep2">8 </td><td class="colsep2 rowsep2">890.6 </td><td class="colsep2 rowsep2">26.5 </td><td class="colsep2 rowsep2">668</td></tr></tbody></table></div></div></div><div class="NLM_p last">Despite the limitation of not directly correlating the in vivo extension of bleeding time to ex vivo platelet aggregation inhibition, this experiment shows for the first time the use of a pharmacological agent which is αIIbβ3 specific to show extension of bleeding times in mice.<sup>35</sup> In addition, the dose dependent extensions of bleeding time shown in this study validates the platelet dependence of the mouse bleeding time model. </div></div><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have described the novel 2,8-diazaspiro[4.5]decane spirocyclic template for the disposition of pharmacophores to achieve potent and selective GPIIb-IIIa inhibition. Structural optimization within this scaffold has led to the characterization of a 1-oxo-spirolactam <b>23</b> (CT50728) as a novel, low molecular weight, selective, and reversible GPIIb-IIIa antagonist, with an IC<sub>50</sub> of 0.110 μM for the inhibition of ADP-induced human platelet aggregation in vitro. While the parent active compound <b>23</b> has negligible oral bioavailability, its double prodrug <b>22 </b><b>(</b>CT51464) exhibits good oral bioavailability across species (rat, dog, monkey) and is rapidly metabolized to the active compound in vivo. We ascribe the excellent bioavailability of <b>22</b> to its molecular rigidity, low polar surface area, remarkably good water solubility as a crystalline hydrochloride salt (>10 mg/mL), and its lipophilicity (log <i>P</i> = 0.45 ± 0.06). Its p<i>K</i><sub>a</sub> values (p<i>K</i><sub>a</sub><sub>1</sub> = 11.28, and p<i>K</i><sub>a</sub><sub>2</sub> = 4.74) indicate that the drug remains uncharged over a wide range, and this could enhance oral absorption. </div><div class="NLM_p last">Other potent inhibitors in this series also exhibited the required PK profile, including bioavailability, long elimination half-life, and metabolic stability. A favorable biological profile of these compounds as platelet aggregation inhibitors clearly demonstrates the utility of the spirocyclic structures as central templates for nonpeptide RGD mimics. The easy synthesis of these templates and the useful oral pharmacokinetic profile of novel compounds containing these templates may facilitate their utilization in other drug targets. </div></div><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. All reactions involving oxygen or moisture-sensitive compounds were performed under a dry argon atmosphere. All reaction mixtures and chromatography fractions were analyzed by thin-layer chromatography on 250 mm silica gel plates and visualized with UV light and I<sub>2</sub> stain. Flash column chromatography was carried out using Merck silica gel 60 (230−400 mesh). <sup>1</sup>H NMR spectra were recorded on a Varian Unity+400 instrument. Chemical shifts are expressed in ppm downfield from internal tetramethylsilane. Apparent multiplicities are designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad. Low-resolution mass spectra were recorded with a HP 1100-MSD LC-MS spectrometer. High-resolution mass spectra (HRMS) were recorded with a Sciex Qstar time-of-flight high-resolution mass spectrometer coupled with an Agilent HPLC. All mass spectra were taken in the positive ion mode under electrospray ionization (ESI). Final compounds were purified by reverse-phase high-performance liquid chromatography (RP-HPLC) using a Waters 4000Prep, Waters 490E multiwavelength detector, and Vydac 218TP1022 column (10 μm, C<sub>18</sub>, 22 mm × 250 mm). The new compounds synthesized were characterized by mass spectrometry (MS) and NMR, and purity was determined by HRMS and two RP-HPLC systems. We did not obtain melting points and elemental analyses of these compounds, as most of the derivatives were amorphous, hygroscopic, and prepared in small quantities. Purity of the compounds was confirmed by two diverse RP-HPLC systems using Waters 600 controller, Waters 996 photodiode array detector, and Keystone Beta Basic column (C18, 4.6 mm × 50 mm), analytical RP-HPLC run using 214 nm for detection. RP-HPLC (# 1):  Gradient method utilized 5−85% CH<sub>3</sub>CN/9 min in the H<sub>2</sub>O mixture with 0.1% trifluoroacetic acid (TFA). RP-HPLC (# 2):  Isocratic method using various % of CH<sub>3</sub>CN for 20 min in the H<sub>2</sub>O mixture with 0.1% trifluoroacetic acid (TFA) in order to have the compound elute at a reasonable time during the run. </div><div class="NLM_p">The typical experimental procedures, used in this study, for the conversion of benzonitriles to benzamidines are decribed below. </div><div class="NLM_p"><b>Typical Procedure A. Benzamidines from Benzonitriles via Thio-Pinner Synthesis.</b><sup>16a</sup> (a) H<sub>2</sub>S gas was bubbled into a solution of the benzonitrile (1.0 mmol) in 5.0 mL of the solvent mixture pyridine/Et<sub>3</sub>N (9:1) until a deep green color persisted. The reaction mixture was then stirred overnight at room temperature, concentrated, and partitioned between 5%MeOH/CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O (3 ×). The combined organic extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield the thioamide as a yellow/green solid. (b) The thioamide was then dissolved in acetone (2.50 mL) and treated with CH<sub>3</sub>I (5.0 mmol). The clear solution was stirred overnight at room temperature, and the resulting yellow suspension was concentrated to dryness to yield thiomethylimidate as a bright yellow solid. (c) The thiomethylimidate was mixed with NH<sub>4</sub>OAc (25.0 mmol), MeOH (5.0 mL) was added, and the reaction mixture was either stirred overnight at room temperature or refluxed for 2.0 h. After TLC/RP-HPLC showed the complete consumption of the thiomethylimidate, methanol was removed by rotary evaporation, and the benzamidine was purified by prep RP-HPLC as either TFA or HCl salt. </div><div class="NLM_p"><b>Typical Procedure B. Synthesis of the N-Substituted Benzamidines (39a, 40a) from </b><b>Benzonitriles </b><b>via</b><b> Thio-Pinner Route.</b> For the synthesis of the N-substituted <a name="jm004700802051" id="jm004700802051"></a> benzamidines (<b>39a</b> and <b>40a</b>), in step c of ‘Typical Procedure A,' appropriate amine (EtNH<sub>2</sub>, morpholine) was first treated with AcOH (2.0 equiv) in MeOH, and then this mixture was added to the thiomethylimidate. The resulting reaction mixture was stirred at room temperature, concentrated, and purified by prep RP-HPLC to afford the N-substituted-benzamidines. </div><div class="NLM_p"><b>Typical Procedure C. Benzamidines from Benzonitriles via Benzamidoximes.</b><sup>16b</sup> (a) To benzonitrile (10.0 mmol) in EtOH (50.0 mL) was added Et<sub>3</sub>N (50.0 mmol), followed by hydroxylamine hydrochloride (30.0 mmol), and the reaction mixture was either stirred overnight at room temperature or heated to 60 °C for 5.0 h until RP-HPLC indicated complete consumption of the benzonitrile. Then the reaction mixture was concentrated under reduced pressure and purified by prep RP-HPLC to afford pure benzamidoximes. (b) The benzamidoxime (5.0 mmol) was dissolved in glacial acetic acid (25.0 mL), and acetic anhydride (7.50 mmol) was added. After 0.5 h, RP-HPLC indicated complete consumption of the starting material. Then to it was added 10% Pd/C (15 wt %), and the mixture was shaken on a Parr hydrogenator at 40 psi H<sub>2</sub> for 5.0 h until RP-HPLC indicated no unreacted starting material. The reaction mixture was filtered through Celite and concentrated under reduced pressure to yield crude benzamidine, which was purified by prep RP-HPLC. </div><div class="NLM_p"><b>1-Benzyl-4-cyanomethylpiperidine-4-carbonitrile (1).</b> To a stirred solution of 1-benzyl-4-piperidone (50.0 g, 264.20 mmol) and ethyl cyanoacetate (39.0 g, 344.80 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) was added Et<sub>3</sub>N (75.0 mL, 538.10 mmol) dropwise. Then crushed 4 Å molecular sieves (25 g) were added, and the mixture was stirred at room temperature until TLC check showed complete consumption of 1-benzyl-4-piperidone. The reaction mixture was filtered through Celite, and the filtrate was concentrated to yield (1-benzylpiperidin-4-ylidine)cyanoacetic acid ethyl ester as a light yellow syrup. </div><div class="NLM_p">This was then dissolved in EtOH (500 mL) and treated with a solution of KCN (85.0 g, 1.30 mol) in H<sub>2</sub>O (200 mL). The brown solution was heated to reflux for 2.0 h, then concentrated to half its volume, and extracted with EtOAc (3 ×). The combined EtOAc extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield a brown solid. Flash chromatography using EtOAc/hexane furnished pure <b>1,</b> 55.10 g (87%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 7.26 (m, 5H), 3.43 (s, 2H), 3.04 (s, 2H), 2.80 (d, 2H), 2.04 (m, 2H), 1.86 (d, 2H), 1.61 (m, 2H). MS (ES):  240 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>1-Benzyl-4-carboxymethylpiperidine-4-carboxylic Acid Hydrochloride (2).</b> A suspension of dinitrile <b>1 </b>(50.0 g, 208.92 mmol) in concentrated HCl (750 mL) was refluxed for 3 days. Then the pale yellow solution was concentrated to dryness to afford the diacid <b>2</b> as an off-white solid, as its hydrochloride salt, 64.0 g (98%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 11.0 (m, 2H), 7.60 (s, 2H), 7.45 (s, 3H), 4.24 (dd, 2H), 3.11 (d, 1H), 3.05 (s, 2H), 2.90 (q, 1H), 2.40 (s, 2H), 2.08 (d, 2H), 1.88 (t, 2H). MS (ES):  278 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(8-Benzyl-1,3-dioxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (4). </b>To a stirred solution of the diacid hydrochloride <b>(2)</b> (4.70 g, 15.0 mmol) in DMF (50 mL) was added DCC (4.10 g, 19.87 mmol), and the slurry was stirred at room temperature for 2.0 h to furnish the anhydride (<b>3</b>). To it was added 4-aminobenzonitrile (2.20 g, 18.62 mmol) and Et<sub>3</sub>N (6.0 mL, 43.0 mmol). The suspension was stirred overnight at room temperature, filtered through Celite, and concentrated to yield 1-benzyl-4-[(4-cyano-phenylcarbamoyl)-methyl]-piperidine-4-carboxylic acid as a pale yellow syrup. This was then suspended in acetic anhydride (75 mL), mixed with anhyd NaOAc (4.50 g, 54.85 mmol), and refluxed for 2.0 h. The reaction mixture was filtered through Celite, concentrated to dryness, and partitioned between 5% MeOH−CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O (3 ×). The organic extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Flash chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH afforded pure <b>4</b>, as a colorless solid, 3.40 g (63%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 7.93 (d, 2H), 7.5 (d, 2H), 7.3 (m, 4H), 7.2 (m, 1H), 3.43 (s, 2H), 2.73 (m, 4H), 2.01 (t, 2H), 1.85 (t, 2H), 1.72 (d, 2H). MS (ES):  360 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(8-Benzyl-1-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (7) and </b><b>4-(8-Benzyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (8). </b>To a suspension of imide <b>4</b> (500 mg, 1.39 mmol) in MeOH (30 mL) at 0 °C was added NaBH<sub>4</sub> (275 mg, 7.27 mmol) in lots, and the mixture was stirred at room temperature until TLC showed complete consumption of the starting material. Then the reaction was quenched with AcOH and concentrated to dryness to yield a mixture of <b>5</b> and <b>6</b> (1:2 by NMR, and analytical RP-HPLC). </div><div class="NLM_p">The whole was then dissolved in TFA (25 mL) at 0 °C and treated with NaBH<sub>4</sub> (250 mg, 6.61 mmol) in lots (<i>caution:  reaction is extremely vigorous!</i>)<i>.</i> The reaction mixture was stirred at room temperature until TLC showed no starting material, concentrated to dryness, and partitioned between CH<sub>2</sub>Cl<sub>2</sub>/1 N NaOH (3 ×). The CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield a colorless solid. Purification by RP-HPLC yielded <b>7</b> (97 mg) and <b>8</b> (210 mg), in 64% overall yield. </div><div class="NLM_p"><b>4-(8-Benzyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (8). </b><sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.78 (d, 2H), 7.62 (d, 2H), 7.3 (m, 5H), 3.62 (s, 2H), 3.56 (s, 2H), 2.56 (m, 4H), 2.40 (m, 4H), 1.71 (m, 4H). MS (ES):  346 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid 2,2,2-Trichlor</b><b>o</b><b>ethyl </b><b>Ester (9), and 2-(4-Cyanophenyl)-3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid </b><b>2,2,2-trichlor</b><b>o</b><b>ethyl Ester (10). </b>The mixture of lactams <b>7</b> and <b>8</b> (2.30 g, 6.66 mmol) in CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub> (8:2) (40 mL) was treated with 2,2,2-trichloroethyl chloroformate (1.20 mL, 8.71 mmol), and the reaction mixture was stirred overnight at room temperature. Then all the solvents were evaporated, and the crude product was purified by flash chromatography (5% CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>9</b> (792 mg) and <b>10</b> (1.633 g); combined yield 85%. </div><div class="NLM_p"><b>2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid 2,2,2-trichlor</b><b>o</b><b>ethyl </b><b>Ester (9). </b><sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.79 (d, 2H), 7.61 (d, 2H), 4.73 (q, 2H), 4.05 (m, 2H), 3.81 (t, 2H), 3.30 (m, 2H), 2.12 (m, 2H), 1.96 (m, 2H), 1.56 (m, 2H). MS (ES):  430 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-(4-Cyanophenyl)-3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid 2,2,2-trichlor</b><b>o</b><b>ethyl </b><b>Ester (10). </b><sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.72 (d, 2H), 7.62 (d, 2H), 4.73 (q, 2H), 3.78 (m, 2H), 3.67 (s, 2H), 3.4 (m, 2H), 2.6 (s, 2H), 1.75 (m, 4H). MS (ES):  430 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(1-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (11). </b>To a solution of TCE-carbamate <b>9</b> (740 mg, 1.718 mmol) in THF (10 mL), under argon, was added 10 mL of a 1 M solution of NH<sub>4</sub>OAc in H<sub>2</sub>O (10 mmol), followed by 10% Cd−Pb couple<sup>18</sup> (1.20 g, 9.0 mmol of Cd). The cloudy suspension was stirred at room temperature until TLC showed disappearance of starting material. Then the reaction mixture was filtered through Celite, the aqueous layer was made basic with 1 N NaOH, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 ×). The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and chromatographed to yield <b>11</b>, 325 mg (74%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.8 (d, 2H), 7.63 (d, 2H), 3.78 (m, 2H), 3.1 (m, 2H), 2.72 (t, 2H), 2.13 (t, 2H), 1.88 (m, 2H), 1.48 (m, 2H). MS (ES):  256 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(3-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (12). </b>This compound was prepared from TCE-carbamate <b>10 </b>using the method described above for the synthesis of <b>11</b>. Colorless solid, yield 89%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 7.8 (q, 4H), 3.62 (s, 2H), 2.65 (m, 4H), 2.42 (s, 2H), 1.43 (m, 4H). MS (ES):  256 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>1-Benzyl-4-methylaminopiperidine-4-carbonitrile (13b). </b>To a mixture of 1-benzyl-4-piperidone (47.32 g, 0.25 mol) and methylamine hydrochloride (16.90 g, 0.25 mol) in 1:1 MeOH/H<sub>2</sub>O (100 mL), under stirring and at 0 °C, was added a solution of KCN (16.30 g, 0.25 mol) in H<sub>2</sub>O (40 mL) dropwise, and the mixture was stirred overnight at room temperature. It was then diluted with Et<sub>2</sub>O/H<sub>2</sub>O (150 mL/75 mL) and transferred to a separatory funnel. The aqueous layer was extracted with ether (2 ×), and the combined ether extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield <b>13b</b>, 53.90 g (94%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.29 (m, 5H), 3.53 (s, 2H), 2.80 <a name="jm004700802052" id="jm004700802052"></a> (d, 2H), 2.50 (s, 3H), 2.34 (d, 2H), 2.0 (d, 2H), 1.71 (m, 2H). MS (ES):  230 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>1-(1-Benzyl-4-cyanopiperidin-4-yl)-3-(4-cyanophenyl)-1-methylurea (14b). </b>To a solution of 4-cyanophenyl isocyanate (10.60 g, 73.54 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (75 mL) at 0 °C was added a solution of <b>13b</b> (17.0 g, 74.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (35 mL), followed by Et<sub>3</sub>N (14.0 mL, 100.44 mmol). After stirring overnight at room temperature, the reaction mixture was concentrated to dryness and recrystallized from CH<sub>2</sub>Cl<sub>2</sub>/MeOH/hexane (150/10/100 mL) to afford <b>14b</b> as a colorless solid, 25.20 g (92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.5 (t, 2H), 7.28 (m, 4H), 7.11 (m, 1H), 3.62 (s, 2H), 2.96 (m, 5H), 2.78 (m, 2H), 2.09 (m, 2H), 1.90 (d, 2H). MS (ES):  374 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>1-(1-Benzyl-4-cyanopiperidin-4-yl)-3-(4-cyanophenyl)urea (14a).</b> This compound was prepared starting from 1-benzyl-4-piperidone using the procedures described above for <b>14b</b> and substituting methylamine hydrochloride with NH<sub>4</sub>Cl in the first step (Scheme 2), in an overall yield of 74%, as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 9.25 (s, 1H), 8.81 (s, 1H), 7.86 (d, 2H), 7.70 (d, 2H), 7.2−7.35 (m, 5H), 3.49 (s, 2H), 2.72 (m, 2H), 2.30 (m, 2H), 2.01 (m, 2H), 1.52 (d, 2H). MS (ES):  360 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(8-Benzyl-1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (15b). 14b</b> (3.0 g, 8.033 mmol) was suspended in 1 N HCl (100 mL) and refluxed for 16 h. The clear reaction mixture was then concentrated to dryness, suspended in CH<sub>2</sub>Cl<sub>2</sub>, washed with 1 N NaOH and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was triturated with ether to afford <b>15b</b> as a colorless solid, 2.68 g (89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.74 (d, 2H), 7.64 (d, 2H), 7.28 (m, 5H), 3.62 (s, 2H), 2.96 (s, 3H), 2.82 (m, 4H), 2.14 (m, 2H), 1.76 (m, 2H). MS (ES):  375 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(8-Benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (15a). </b>This compound was prepared from <b>14a</b> using the method described above for <b>15b</b>, as a colorless solid (80%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>):  δ 9.14 (s, 1H), 7.91 (d, 2H), 7.62 (d, 2H), 7.28 (m, 4H), 7.22 (m, 1H), 3.48 (s, 2H), 2.71 (m, 2H), 2.13 (m, 2H), 1.92 (m, 2H), 1.71 (m, 2H). MS (ES):  361 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(1-Methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (19b).</b> This compound was synthesized from <b>15b</b>, using the procedure described above for the preparation of <b>11</b> from <b>7</b>. (a) To <b>15b</b> (1.70 g, 4.54 mmol) in CH<sub>3</sub>CN/CHCl<sub>3</sub> (20/10 mL) at room temperature was added 2,2,2-trichloroethyl chloroformate (1.0 mL, 7.264 mmol), and the mixture was stirred at room temperature for 6 h. Then it was concentrated to dryness and purified by flash chromatography to afford the TCE-carbamate intermediate, 3-(4-cyanophenyl)-1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid 2,2,2-trichloroethyl ester, 1.80 g (86%). (b) To a stirred solution of the TCE-carbamate (1.80 g, 3.91 mmol) in THF (20 mL), under argon, was added 20 mL of a 1 M solution of NH<sub>4</sub>OAc in H<sub>2</sub>O (20 mmol), followed by 10% Cd−Pb couple (2.70 g, 20.2 mmol of Cd). The suspension was stirred overnight at room temperature and then filtered through Celite, and the aqueous layer was made basic with 1 N NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 ×). The CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and chromatographed to yield <b>19b</b>, as a colorless solid, 880 mg (79%).<sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.80 (d, 2H), 7.63 (d, 2H), 3.27 (m, 2H), 2.99 (m, 2H), 2.91 (s, 3H), 1.97 (m, 2H), 1.80 (m, 2H). MS (ES):  285 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>4-(8-Benzyl-1-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (17b).</b> The urea <b>17b</b> was synthesized from the hydantoin <b>15b</b> using the previously described procedure for the synthesis of <b>7</b> and <b>8</b> from <b>4</b>. (a) To a suspension of the hydantoin <b>15b</b> (800 mg, 2.136 mmol) in MeOH (30 mL) at 0 °C was added NaBH<sub>4</sub> (400 mg, 10.57 mmol) in lots, and the mixture was stirred overnight at room temperature. Then the reaction was quenched with AcOH (1.0 mL) at 0 °C, and concentrated to dryness to afford crude 4-(8-benzyl-4-hydroxy-1-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile <b>16b</b>. (b) The crude <b>16b</b> was then dissolved in TFA (35 mL) at 0 °C and treated with NaBH<sub>4</sub> (400 mg, 10.57 mmol) in lots (<i>caution:  reaction is extremely vigorous!</i>)<i>.</i> The reaction mixture was stirred overnight at room temperature and then concentrated to dryness and partitioned between CH<sub>2</sub>Cl<sub>2</sub>/1 N NaOH (3 ×). The CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield a colorless solid, which was purified by RP-HPLC to yield <b>17b</b> as a colorless solid, 562 mg (73%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.65 (d, 2H), 7.55 (d, 2H), 7.28 (m, 5H), 3.60 (s, 2H), 3.55 (s, 2H), 2.96 (m, 2H), 2.79 (s, 3H), 2.08 (m, 4H), 1.48 (m, 2H). MS (ES):  361 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}propionic Acid </b><b>Ethyl Ester (20).</b> To a stirred solution of <b>11</b> (500 mg, 1.958 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) at 0 °C was added ethyl-3-isocyanatopropionate (300 mg, 2.10 mmol), followed by Et<sub>3</sub>N (320 μL, 2.30 mmol), and the mixture was stirred at room temperature for 9 h. The reaction was then quenched with H<sub>2</sub>O (200 μL), concentrated to dryness, and purified by flash chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>20</b>, 715 mg (92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.75 (d, 2H), 7.60 (d, 2H), 5.30 (m, 1H), 4.02 (q, 2H), 3.81 (t, 2H), 3.46 (m, 2H), 3.38 (m, 2H), 3.06 (m, 2H), 2.48 (m, 2H), 2.10 (t, 2H), 1.90 (m, 2H), 1.51 (m, 2H), 1.22 (t, 3H). MS (ES):  399 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}propio</b><b>nic Acid Ethyl Ester (21).</b> Compound <b>21</b> was synthesized from <b>20</b> using Typical Procedure A. (a). H<sub>2</sub>S gas was bubbled into a solution of <b>20</b> (125 mg, 0.313 mmol) in 5.0 mL of pyridine/Et<sub>3</sub>N (9:1) until a deep green color persisted. After stirring overnight at room temperature, the mixture was concentrated and partitioned between 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O (3 ×). The organic extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield 3-{[1-oxo-2-(4-thiocarbamoylphenyl)-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}propionic acid ethyl ester as a yellow/green solid. (b). This was then dissolved in acetone (5.0 mL), CH<sub>3</sub>I (195 μL, 3.13 mmol) was added, and the reaction mixture was stirred overnight at room temperature. The yellow suspension was concentrated to dryness to afford 3-{[2-(4-methylsulfanylcarbonimidoyl-phenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}propionic acid ethyl ester as a yellow solid. (c). This was then dissolved in MeOH (5.0 mL) and NH<sub>4</sub>OAc (600 mg, 7.78 mmol) was added. The reaction mixture was stirred overnight at room temperature, concentrated to dryness, and purified by RP-HPLC to afford <b>21</b> as its HCl salt, as a colorless solid, 98 mg (75% overall from <b>20</b>). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ. 9.11 (s, 1H), 8.68 (s, 2H), 7.98 (d, 2H), 7.83 (d, 2H), 4.13 (q, 2H), 3.94 (m, 2H), 3.45 (t, 2H), 3.11 (m, 2H), 2.54 (m, 2H), 2.22 (t, 2H), 1.83 (m, 2H), 1.61 (m, 2H), 1.24 (t, 3H). MS (ES):  416 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 416.2220; found, 416.2239. </div><div class="NLM_p"><b>3-{[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}propio</b><b>nic Acid (23) (CT50728).</b><b>21</b> (40 mg, 0.096 mmol) in THF (5.0 mL) was treated with 1 M LiOH (1.0 mL), and the reaction mixture was stirred at room temperature for 6 h. Then it was cooled in ice, acidified with 6 N HCl, concentrated to dryness, and purified by RP-HPLC to afford <b>23</b> as a colorless solid as its TFA salt, 43 mg (89%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.92 (d, 2H), 7.79 (d, 2H), 3.87 (m, 3H), 3.38 (t, 2H), 3.30 (m, 1H), 3.05 (t, 2H), 2.47 (m, 2H), 2.18 (t, 2H), 1.80 (m, 2H), 1.55 (d, 2H). MS (ES):  388 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 388.1979; found, 388.1944. </div><div class="NLM_p"><b>3-({2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl}a</b><b>mino)propionic Acid Ethyl Ester (22) (CT51464).</b> To <b>20</b> (1.13 g, 2.836 mmol) in EtOH (25 mL) was added Et<sub>3</sub>N (1.60 mL, 11.48 mmol), followed by hydroxylamine hydrochloride (590 mg, 8.49 mmol). The reaction mixture was then stirred overnight at room temperature, concentrated, and purified by RP-HPLC to afford <b>22</b> as its HCl salt, 1.052 g (79%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.93 (d, 2H), 7.70 (d, 2H), 4.12 (q, 2H), 3.91 (m, 4H), 3.40 (m, 2H), 3.06 (m, 2H), 2.51 (m, 2H), 2.20 (m, 2H), 1.81 (m, 2H), 1.56 (m, 2H), 1.23 (t, 3H). MS (ES):  432 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 432.2241; found, 432.2254. </div><div class="NLM_p"><b>3-({2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl}a</b><b>mino)propionic Acid (24).</b> The ethyl ester <b>22</b> (215 mg, 0.498 mmol) was treated with <a name="jm004700802053" id="jm004700802053"></a> 3 N HCl (5.0 mL) and the mixture was stirred at room temperature for 8 h. It was then concentrated, and purified by RP-HPLC to afford <b>24</b> as its HCl salt, 203 mg (92%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.88 (d, 2H), 7.67 (d, 2H), 3.88 (t, 4H), 3.38 (t, 2H), 3.05 (t, 2H), 2.48 (t, 2H), 2.18 (t, 2H), 1.80 (t, 2H), 1.53 (d, 2H). MS (ES):  404 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 404.1928; found, 404.1889. </div><div class="NLM_p"><b>5-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxopentanoic Acid Ethyl Ester </b><b>(25).</b> To <b>11</b> (150 mg, 0.587 mmol) in DMF (3.0 mL) at 0 °C was added DIEA (180 μL, 1.03 mmol), followed by ethyl glutaryl chloride (136 mg, 0.761 mmol), and the reaction mixture was stirred at room temperature for 4 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography to afford <b>25</b>, 214 mg (92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.78 (d, 2H), 7.62 (d, 2H), 4.25 (m, 1H), 4.07 (q, 2H), 3.87 (m, 1H), 3.80 (m, 2H), 3.25 (m, 1H), 3.12 (m, 1H), 2.36 (m, 4H), 2.10 (m, 2H), 1.92 (m, 4H), 1.54 (m, 2H), 1.21 (t, 3H). MS (ES):  398 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxopentanoic Acid </b><b>Ethyl Ester (26).</b> Compound <b>25</b> was converted to <b>26</b>, using Typical Procedure A, elaborated above for the synthesis of <b>21</b> from <b>20</b>. Overall yield, 68%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.92 (d, 2H), 7.80 (d, 2H), 4.28 (m, 1H), 4.07 (q, 2H), 3.93 (m, 3H), 3.32 (m, 1H), 3.05 (m, 1H), 2.44 (t, 2H), 2.35 (t, 2H), 2.21 (m, 2H), 1.85 (m, 2H), 1.76 (m, 2H), 1.61 (m, 2H), 1.20 (t, 3H). MS (ES):  415 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 415.2339; found, 415.2313. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxopentanoic Acid (28) </b><b>(CT50614).</b> The ethyl ester <b>26</b> (57 mg, 0.137 mmol) was suspended in 3 N HCl (2.0 mL) and the reaction mixture was stirred overnight at room temperature. Then it was concentrated, and purified by RP-HPLC to afford <b>28</b>, 49 mg (92%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.80 (d, 2H), 7.68 (d, 2H), 4.17 (m, 1H), 3.8 (m, 3H), 3.21 (m, 1H), 2.94 (m, 1H), 2.33 (t, 2H), 2.23 (t, 2H), 2.10 (m, 2H), 1.6−1.8 (m, 4H), 1.52 (m, 2H). MS (ES):  387 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 387.2026; found, 387.2017. </div><div class="NLM_p"><b>5-{2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-5-oxopentan</b><b>oic Acid Ethyl Ester (27) (CT51269).</b> To <b>25</b> (400 mg, 1.006 mmol) in EtOH (10 mL) was added Et<sub>3</sub>N (420 μL, 3.01 mmol), followed by hydroxylamine hydrochloride (174 mg, 2.50 mmol). The mixture was stirred overnight at room temperature, concentrated, and purified by RP-HPLC to afford <b>27</b> as its HCl salt, as a colorless solid, 390 mg (83%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.85 (d, 2H), 7.66 (d, 2H), 4.35 (m, 1H), 4.05 (q, 2H), 3.80 (m, 3H), 3.31 (t, 1H), 3.04 (t, 1H), 2.43 (t, 2H), 2.34 (m, 2H), 2.18 (t, 2H), 1.83 (m, 2H), 1.74 (m, 2H), 1.60 (m, 2H), 1.17 (t, 3H). MS (ES):  431 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 431.2288; found, 431.2294. </div><div class="NLM_p"><b>5-{2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-5-oxopentan</b><b>oic Acid (29).</b> The ethyl ester <b>27</b> (160 mg, 0.37 mmol) was treated with 3 N HCl (2.0 mL), and the reaction mixture was stirred at room temperature for 9 h. Then it was concentrated, and purified by RP-HPLC to afford <b>29</b> as its HCl salt, 155 mg (95%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.87 (d, 2H), 7.64 (d, 2H), 4.25 (m, 1H), 3.90 (m, 3H), 3.29 (m, 1H), 3.01 (m, 1H), 2.40 (t, 2H), 2.30 (t, 2H), 2.17 (m, 2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.57 (m, 2H). MS (ES):  403 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 403.1975; found, 403.2002. </div><div class="NLM_p"><b><i>tert</i></b><b>-Butoxycarbonylmethoxyacetic Acid Benzyl Ester (30a).</b> To a stirred solution of benzyl glycolate (2.34 g, 14.0 mmol) and rhodium acetate dimer (62 mg, 0.14 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added a solution of <i>tert</i>-butyl diazoacetate (2.01 g, 14.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20.0 mL), via a syringe pump over 2.0 h. The reaction mixture was stirred overnight at room temperature, filtered through Celite, concentrated, and purified by flash chromatography (20% EtOAc/hexane) to afford <b>30a</b>, 2.40 g (61%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.35 (m, 5H), 5.20 (s, 2H), 4.13 (s, 2H), 4.08 (s, 2H), 1.46 (s, 9H). MS (ES):  281 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b><i>tert</i></b><b>-Butoxycarbonylmethoxyacetic Acid (31).</b> The reaction mixture composed of <b>30a</b> (1.0 g, 3.56 mmol) and 150 mg of 20% Pd(OH)<sub>2</sub>/C (Pearlman's catalyst) in EtOAc (40 mL) was shaken on a Parr hydrogenator at 40 psi of H<sub>2</sub> for 8 h. It was then filtered through Celite and concentrated to yield <b>31</b>, 651 mg (96%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 4.11 (s, 2H), 4.04 (s, 2H), 1.43 (s, 9H). MS (ES):  191 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>{2-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-oxo-ethoxy}acetic Acid </b><b><i>tert</i></b><b>-Butyl Ester (32).</b> The reaction mixture composed of <b>11</b> (70 mg, 0.274 mmol), <b>31</b> (70 mg, 0.368 mmol), HBTU (230 mg, 0.606 mmol), and DIEA (150 μL, 0.86 mmol) in anhyd DMF (5.0 mL) was stirred at room temperature for 20 h. Then the reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography to yield <b>32</b>, 96 mg (82%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.78 (d, 2H), 7.63 (d, 2H), 4.15−4.35 (m, 5H), 4.0 (m, 1H), 3.82 (m, 2H), 3.2−3.4 (m, 2H), 2.13 (q, 2H), 1.95 (m, 2H), 1.59 (m, 2H), 1.46 (s, 9H). MS (ES):  428 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>{2-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-oxoethoxy}acetic Acid </b><b>(33) (CT51907).</b> The compound <b>33 </b>was synthesized from <b>32</b> by using Typical Procedure A, described previously for the synthesis of <b>21</b> from <b>20</b>, followed by deprotection of the <i>tert</i>-butyl ester functionality by treating with neat TFA, concentration, and RP-HPLC purification to yield as its HCl salt. Overall yield, 68%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.93 (d, 2H), 7.70 (d, 2H), 4.34 (m, 2H), 4.24 (m, 1H), 4.14 (m, 2H), 3.92 (m, 3H), 3.34 (m, 1H), 3.10 (m, 1H), 2.14 (m, 2H), 1.8 (m, 2H), 1.60 (m, 4H). MS (ES):  389 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 389.1819; found, 389.1731. </div><div class="NLM_p"><b>{2-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-oxoethoxy}acetic Acid Ethyl </b><b>Ester (35).</b> A mixture of <b>11</b> (225 mg, 0.881 mmol), <b>34</b> (172 mg, 1.061 mmol), HBTU (435 mg, 1.147 mmol), and DIEA (400 μL, 2.29 mmol) in DMF (5.0 mL) was stirred at room temperature for 6 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub> (3 ×). The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography to afford <b>35</b>, 306 mg (87%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.78 (d, 2H), 7.63 (d, 2H), 4.15−4.35 (m, 7H), 4.0 (m, 1H), 3.82 (m, 2H), 3.2−3.4 (m, 2H), 2.13 (q, 2H), 1.95 (m, 2H), 1.59 (m, 2H), 1.37 (t, 3H). MS (ES):  400 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>(2-{2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-2-oxoethoxy</b><b>)acetic Acid Ethyl Ester Hydrochloride (36) (CT052108).</b><b>35</b> (43 mg, 0.108 mmol) in EtOH (3.0 mL) at room temperature was treated with Et<sub>3</sub>N (125 μL, 0.896 mmol), followed by hydroxylamine hydrochloride (33.0 mg, 0.47 mmol), and the mixture was stirred overnight at room temperature. Then it was concentrated under reduced pressure and purified by RP-HPLC to afford <b>36</b> as its HCl salt, 42 mg (83%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.93 (d, 2H), 7.71 (d, 2H), 4.15−4.4 (m, 8H), 3.93 (q, 2H), 3.32 (m, 1H), 3.11 (m, 1H), 2.25 (m, 2H), 1.8 (m, 2H), 1.65 (m, 2H), 1.25 (t, 3H). MS (ES):  433 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 433.2081; found, 433.2086. </div><div class="NLM_p"><b>(2-{2-[4-(</b><b><i>N</i></b><b>-</b><b>Hydroxycarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-2-oxoethoxy</b><b>)acetic Acid (37).</b><b>36</b> (16.0 mg, 0.034 mmol) was treated with 3 N HCl (1.0 mL), and the mixture was stirred at room temperature for 3 h. Then it was purified by RP-HPLC to afford <b>37</b>, 13 mg(86%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.88 (d, 2H), 7.66 (d, 2H), 4.33 (d, 2H), 4.24 (m, 1H), 3.89 (q, 3H), 3.29 (m, 1H), 3.11 (m, 1H), 2.20 (m, 2H), 1.79−1.92 (m, 2H), 1.62 (m, 2H). MS (ES):  405 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 405.1768; found, 405.1775. </div><div class="NLM_p"><b>5-{2-[4-(</b><b><i>N</i></b><b>-Ethylcarbamimidoyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-5-oxopentanoic </b><b>Acid (40b).</b><b>40b</b> was synthesized using Typical Procedure B. (a). The benzonitrile <b>25</b> (36 mg, 0.090 mmol) was converted to thiomethylimidate <b>38</b> by Typical Procedure A, described previously for the synthesis of <b>21</b>. (b). EtNH<sub>2</sub> (2.0 M/THF) (1.0 mL, 2.0 mmol) in MeOH (2.0 mL) was treated with AcOH (230 μL, 4.0 mmol). Then this mixture was added to thiomethyl imidate <b>38</b> (0.090 <a name="jm004700802054" id="jm004700802054"></a> mmol). After a stirring of 15 h at room temperature, the reaction mixture was concentrated, and purified by RP-HPLC to afford <b>40a</b>, 5-{2-[4-(<i>N</i>-Ethylcarbamimidoyl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl}-5-oxopentanoic acid ethyl ester, TFA salt, 39 mg (77% overall). (c). <b>40a</b> (34 mg, 0.061 mmol) was treated with 3 N HCl (1.0 mL) and the reaction mixture was stirred at room temperature for 8h. Then it was concentrated, and purified by RP-HPLC to afford <b>40b</b>, 29 mg (90%), as a colorless solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.84 (d, 2H), 7.68 (d, 2H), 4.25 (m, 1H), 3.87 (m, 3H), 3.40 (m, 2H), 3.29 (m, 1H), 3.01 (m, 1H), 2.41 (m, 2H), 2.30 (m, 2H), 2.17 (m, 2H), 1.65−1.8 (m, 5H), 1.57 (m, 2H), 1.28 (t, 2H). MS (ES):  415 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 415.2267; found, 415.2285. </div><div class="NLM_p"><b>5-{2-[4-(Iminomorpholin-4-ylmethyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-5-oxopenta</b><b>noic Acid Ethyl Ester (39a).</b><b>39a</b> was synthesized from <b>38</b> using Typical Procedure B. Morpholine (35 μL, 0.40 mmol) in MeOH (1.0 mL) was treated with AcOH (50 μL, 0.87 mmol). This clear solution was then added to thiomethylimidate <b>38</b> (0.10 mmol, prepared from 0.10 mmol of <b>25</b>). The reaction mixture was stirred at room temperature for 20 h, concentrated, and purified by RP-HPLC to afford <b>39a, </b>as its TFA salt, 49 mg (82%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.93 (d, 2H), 7.60 (d, 2H), 4.30 (m, 1H), 4.09 (q, 2H), 3.93 (m, 3H), 3.89 (m, 2H), 3.78 (t, 2H), 3.72 (t, 2H), 3.49 (t, 2H), 3.35 (m, 1H), 3.07 (m, 1H), 2.46 (m, 2H), 2.39 (t, 2H), 2.24 (m, 2H), 1.89 (m, 2H), 1.78 (m, 2H), 1.63 (m, 2H), 1.21 (t, 3H). MS (ES):  485 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 485.2758; found, 485.2775. </div><div class="NLM_p"><b>5-{2-[4-(Iminomorpholin-4-ylmethyl)phenyl]-1-oxo-2,8-diazaspiro[4.5]dec-8-yl}-5-oxopenta</b><b>noic Acid (39b).</b><b>39b</b> was synthesized from <b>39a</b> by the procedure described above for the synthesis of <b>40b</b> from <b>40a,</b> to yield <b>39b</b> as its TFA salt, 40 mg (86%).<sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.86 (d, 2H), 7.52 (d, 2H), 4.23 (m, 1H), 3.85 (m, 3H), 3.71 (t, 2H), 3.66 (t, 2H), 3.30 (m, 1H), 3.01 (m, 1H), 2.41 (m, 2H), 2.32 (m, 2H), 2.19 (t, 2H), 1.80 (m, 2H), 1.73 (m, 2H), 1.59 (m, 2H). MS (ES):  457 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 457.2445; found, 457.2459. </div><div class="NLM_p"><b>3-(</b><b><i>R</i></b><b>)-Methylpentanedioic Acid </b><b><i>tert</i></b><b>-Butyl Ester Ethyl Ester (41).</b> The reaction mixture comprised of (<i>R</i>)-1-ethyl hydrogen-3-methylglutarate (1.0 g, 5.74 mmol), <i>tert</i>-butyl alcohol (4.30 g, 58.0 mmol), DMAP (250 mg, 2.046 mmol), and DCC (1.50 g, 7.27 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred at room temperature for 20 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to yield <b>41</b>, 1.10 g (83%). MS (ES):  231 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-(</b><b><i>S</i></b><b>)-Methylpentanedioic Acid Mono-</b><b><i>tert</i></b><b>-butyl Ester (42).</b> Compound <b>41</b> (1.20 g, 4.647 mmol) in THF (40 mL) was treated with 1 M LiOH (10 mL, 10.0 mmol), and the mixture was stirred at room temperature for 18 h. It was acidified at 0 °C with AcOH (2.0 mL), and partitioned between EtOAc/brine. The combined EtOAc extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to afford <b>42</b>, 854 mg (81%). MS (ES):  203 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-3-(S)-methyl-5-oxopentanoic Acid </b><b><i>tert</i></b><b>-Butyl Ester (43).</b> The reaction mixture comprised of <b>11</b> (70.0 mg, 0.274 mmol), <b>42</b> (80 mg, 0.395 mmol), HBTU (230 mg, 0.606 mmol), and DIEA (0.150 mL, 0.86 mmol) in DMF (2.0 mL) was stirred at room temperature for 17 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to yield <b>43</b>, 103 mg (86%). MS (ES):  440 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-3-(S)-methyl-5-oxopenta</b><b>noic Acid (44).</b> Compound <b>44</b> was synthesized from <b>43</b>, by Typical Procedure A, described previously for the synthesis of <b>21</b> from <b>20</b>, followed by deprotection of the <i>tert</i>-butyl ester functionality by treatment with neat TFA, in 67% overall yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.86 (d, 2H), 7.72 (d, 2H), 4.23 (m, 1H), 3.9 (m, 3H), 3.3 (m, 1H), 3.01 (m, 1H), 2.46 (m, 2H), 2.1−2.4 (m, 5H), 1.77 (m, 2H), 1.58 (m, 2H), 0.97 (d, 3H). MS (ES):  401 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 401.2183; found, 401.2142. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-3-(R)-methyl-5-oxopenta</b><b>noic Acid (45).</b> Compound <b>45</b> was synthesized starting from (R)-1-ethyl-hydrogen-3-methyl glutarate and <b>11</b> by the procedures described above for the synthesis of <b>44</b>, in 71% overall yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.86 (d, 2H), 7.72 (d, 2H), 4.18 (m, 1H), 3.9 (m, 3H), 3.3 (m, 1H), 3.01 (m, 2H), 2.54 (d, 1H), 2.40 (d, 1H), 2.21 (t, 2H), 1.83 (m, 2H), 1.56 (m, 2H), 1.2 (d, 3H). MS (ES):  401 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 401.2183; found, 401.2156. </div><div class="NLM_p"><b>3-Phenylpentanedioic Acid Monoethyl Ester (46).</b> 3-Phenylglutaric acid (1.0 g, 4.80 mmol) was suspended in Ac<sub>2</sub>O (20.0 mL), and the reaction mixture was refluxed for 15 h. Then it was concentrated under reduced pressure to afford 3-phenylglutaric anhydride. </div><div class="NLM_p">This was dissolved in EtOH (30.0 mL), Et<sub>3</sub>N (3.0 mL, 21.52 mmol) was added, and the mixture was stirred at room temperature for 20 h. Then it was concentrated and purified by flash chromatography (40% EtOAc/hexane) to afford <b>46</b>, 984 mg (87%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.24 (m, 5H), 3.96 (q, 2H), 3.53 (m, 1H), 2.5−2.8 (m, 4H), 1.08 (t, 3H). MS (ES):  237 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxo-3-phenylpentanoic Acid </b><b>Ethyl Ester (47).</b> The reaction mixture composed of <b>11</b> (90 mg, 0.352 mmol), <b>46</b> (110 mg, 0.465 mmol), EDC·HCl (160 mg, 0.834 mmol), and HOBt (95 mg, 0.70 mmol) in anhyd DMF (4.0 mL) was stirred at room temperature for 20 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to afford <b>47</b>, 149 mg (89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.76 (d, 2H), 7.60 (d, 2H), 7.18 (m, 5H), 4.05−4.25 (m, 2H), 3.98 (q, 2H), 3.79 (m, 3H), 3.68 (m, 1H), 3.16 (m, 2H), 2.81 (m, 1H), 2.64 (m, 4H), 2.05 (m, 2H), 1.8 (m, 2H), 1.09 (t, 3H). MS (ES):  474 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxo-3-phenylpentanoic </b><b>Acid (48).</b> Compound <b>48</b> was synthesized from <b>47</b> by using the procedures described previously for the synthesis of <b>23</b> from <b>20</b>, in overall yield of 64%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.92 (d, 2H), 7.8 (d, 2H), 7.2 (m, 5H), 4.2 (m, 1H), 3.92 (m, 3H), 3.58 (m, 1H), 2.9−3.25 (m, 2H), 2.6−2.8 (m, 4H), 2.10 (m, 2H), 1.2−1.8 (m, 4H). MS (ES):  463 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 463.2267; found, 463.2288. </div><div class="NLM_p"><b>3-(4-Nitro-phenoxycarbonylamino)-butyric Acid Ethyl Ester (51).</b> Ethyl 3-(<i>R</i>)-methyl-β-alanine <b>(50)</b> (1.0 g, 7.623 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20.0 mL) was treated with DIEA (3.0 mL, 17.22 mmol), followed by 4-nitrophenyl chloroformate (2.0 g, 9.922 mmol), and the mixture was stirred at room temperature for 9 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography to afford <b>51</b>, 1.96 g (87%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 8.22 (d, 2H), 7.30 (d, 2H), 5.84 (s, 1H), 4.16 (m, 3H), 2.60 (m, 2H), 1.33 (d, 3H), 1.26 (t, 3H). MS (ES):  297 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}-butyric Acid </b><b>Ethyl Ester (52).</b><b>11</b> (500 mg, 1.958 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10.0 mL) was treated with DIEA (0.700 mL, 4.02 mmol), followed by <b>51</b> (750 mg, 2.531 mmol), and the reaction mixture was stirred overnight at room temperature. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography to afford <b>52</b>, 687 mg (85%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.78 (d, 2H), 7.63 (d, 2H), 5.7 (s, 1H), 4.23 (m, 1H), 4.12 (m, 2H), 3.83 (m, 4H), 3.12 (m, 2H), 2.51 (m, 2H), 2.12 (m, 2H), 1.96 (m, 2H), 1.56 (m, 2H), 1.2 (m, 6H). MS (ES):  413 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}-butyri</b><b>c Acid (53)</b>. <a name="jm004700802055" id="jm004700802055"></a> Compound <b>53</b> was synthesized from <b>52</b> by using Typical Procedure A, described previously for the synthesis of <b>23</b> from <b>20</b>, in overall yield of 70%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.9 (d, 2H), 7.78 (d, 2H), 4.14 (m, 1H), 3.88 (m, 4H), 3.04 (m, 2H), 2.48 (m, 1H), 2.38 (m, 1H), 2.18 (d, 2H), 1.79 (m, 2H), 1.53 (d, 2H), 1.15 (m, 3H). MS (ES):  402 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 402.2135; found, 402.2160. </div><div class="NLM_p"><b>3-(4-Nitro-phenoxycarbonylamino)-3-phenylpropionic Acid Ethyl Ester (54).</b> 3-Amino-3-phenylpropionic acid ethyl ester (1.0 g, 5.175 mmol) was converted to its 4-nitrophenyl carbamate <b>54</b> by using the procedure described previously for the synthesis of <b>51 </b>from <b>50</b>. Yield, 1.54 g (83%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 8.21 (d, 2H), 7.3 (m, 7H), 6.31 (d, 1H), 5.22 (m, 1H), 4.1 (q, 2H), 2.93 (m, 2H), 1.18 (t, 3H). MS (ES):  359 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[3-(4-Cyanophenyl)-1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carbonyl]amino}-</b><b>3-phenylpropionic Acid Ethyl Ester (55). </b>Compound <b>55</b> was synthesized in 79% overall yield from <b>54</b> (160 mg, 0.446 mmol) and <b>19b</b> (100 mg, 0.351 mmol) by using the procedure described previously for the synthesis of <b>52</b>. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.8 (d, 2H), 7.62 (d, 2H), 7.35 (d, 2H), 7.3 (d, 2H), 7.2 (m, 1H), 5.3 (dd, 1H), 4.05 (m, 4H), 3.4−3.6 (m, 2H), 2.90 (s, 3H), 2.7−2.85 (m, 2H), 1.95−2.1 (m, 2H), 1.85 (d, 2H), 1.09 (t, 3H). MS (ES):  504 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[3-(4-Carbamimidoylphenyl)-1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carbony</b><b>l]amino}-3-phenylpropionic Acid (56).</b> Compound <b>56</b> was synthesized from <b>55</b> by using Typical Procedure A, described previously for the synthesis of <b>23</b> from <b>20</b>, in overall yield 69%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.9 (d, 2H), 7.7 (d, 2H), 7.35 (d, 2H), 7.3 (d, 2H), 7.2 (m, 1H), 5.3 (dd, 1H), 4.05 (t, 2H), 3.4−3.6 (m, 2H), 2.90 (s, 3H), 2.7−2.85 (m, 2H), 1.95−2.1 (m, 2H), 1.85 (d, 2H). MS (ES):  493 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 493.2121; found, 493.2146. </div><div class="NLM_p"><b>2-(3,5-Dimethylisoxazole-4-sulfonylamino)pentanedioic Acid 1-</b><b><i>tert</i></b><b>-Butyl Ester (57).</b> l-Glutamic acid α-<i>tert</i>-butyl ester (1.0 g, 4.92 mmol) was dissolved in 1 N NaOH (5.0 mL, 5.0 mmol), diluted with H<sub>2</sub>O (50 mL), and cooled to 0 °C. Then Na<sub>2</sub>CO<sub>3</sub> (583 mg, 5.50 mmol) was added, followed by 3,5-dimethylisoxazole-4-sulfonyl chloride (1.06 g, 5.418 mmol), and the mixture was stirred at room temperature for 20 h. Then it was acidified with 2 N HCl at 0 °C to pH 3 and extracted with EtOAc (3 ×). The combined EtOAc extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by RP-HPLC to afford <b>57</b>, 1.57 g (88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 3.75 (m, 1H), 2.60 (s, 3H), 2.54 (m, 1H), 2.39 (s, 3H), 2.08 (m, 1H), 1.84 (m, 1H), 1.32 (s, 9H). MS (ES):  363 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-(3,5-dimethylisoxazole-4-sulfony</b><b>lamino)-5-oxopentanoic Acid </b><b><i>tert</i></b><b>-Butyl Ester (58).</b> The reaction mixture composed of <b>11</b> (25.0 mg, 0.0979 mmol), <b>57</b> (42 mg, 0.116 mmol), and EDC·HCl (37.0 mg, 0.193 mmol) in DMF (2.0 mL) was stirred at room temperature for 18 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to afford <b>58</b>, 53 mg (90%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.95(d, 2H), 7.80 (d, 2H), 4.25 (m, 1H), 3.95 (m, 4H), 3.35 (m, 1H), 3.13 (q, 1H), 2.58 (m, 4H), 2.38 (s, 3H), 2.22 (t, 2H), 1.6−2.0 (m, 7H), 1.43 (s, 9H). MS (ES):  600 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-(3,5-dimethylisoxazole-</b><b>4-sulfonylamino)-5-oxopentanoic Acid (59) (CT50787). </b>Compound <b>59</b> was synthesized from <b>58</b> using Typical Procedure A, described previously for the synthesis of <b>21</b> from <b>20</b>. Overall yield, 66%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.95(d, 2H), 7.80 (d, 2H), 4.25 (m, 1H), 3.95 (m, 4H), 3.35 (m, 1H), 3.13 (q, 1H), 2.58 (m, 4H), 2.38 (s, 3H), 2.22 (t, 2H), 1.6−2.0 (m, 7H). MS (ES):  561 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 561.2125; found, 561.2120. </div><div class="NLM_p"><b>3-</b><b><i>tert</i></b><b>-Butoxycarbonylamino-2-(toluene-4-sulfonylamino)propionic Acid Ethyl Ester (60).</b> 2-<span class="smallcaps smallerCapital">l</span>-Amino-3-<i>tert</i>-butoxycarbonylaminopropionic acid ethyl ester (2.0 g, 8.61 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) at 0 °C was treated with DIEA (3.0 mL, 17.22 mmol), followed by tosyl chloride (1.64 g, 8.60 mmol), and stirred at room temperature for 2.0 h. Then the reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to yield <b>60</b>, 2.30 g (69%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.70 (d, 2H), 7.28 (d, 2H), 5.50 (d, 1H), 4.9 (m, 1H), 3.95 (m, 3H), 3.44 (m, 2H), 2.39 (s, 1H), 1.41 (s, 9H), 1.11 (t, 2H). MS (ES):  387 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-Amino-2-(toluene-4-sulfonylamino)propionic Acid Ethyl Ester (61).</b><b>60</b> (1.72 g, 4.45 mmol) was treated with anhyd TFA (15.0 mL) at room temperature. After 2.0 h the reaction mixture was concentrated to dryness, and partitioned between EtOAc/satd NaHCO<sub>3</sub>. The EtOAc extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield <b>61</b>, 1.02 g (90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.71 (d, 2H), 7.27 (d, 2H), 3.98 (q, 2H), 3.86 (m, 1H), 2.95−3.05 (m, 2H), 2.40 (s, 3H), 1.10 (t, 3H). MS (ES):  287 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}-2-(toluene-4-sul</b><b>fonylamino)propionic Acid Ethyl Ester (62).</b> A mixture of <b>11</b> (28.0 mg, 0.109 mmol) and DIEA (80 μL, 0.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) was added dropwise to a solution of triphosgene (12.0 mg, 0.0404 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. Then was added a solution of <b>61</b> (33.0 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL), and the mixture was stirred overnight at room temperature. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>, and CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by prep-TLC (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>62</b>, 40 mg (64%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.79 (d, 2H), 7.69 (d, 2H), 7.63 (d, 2H), 7.28 (d, 2H), 5.77 (d, 1H), 5.14 (t, 1H), 4.01 (q, 2H), 3.8−3.95 (m, 2H), 3.82 (t, 2H), 3.68−3.76 (m, 2H), 3.3−3.45 (m, 1H), 3.2−3.3 (m, 1H), 3.03 (m, 1H), 2.40 (s, 3H), 2.13 (t, 2H), 1.85−2.0 (m, 2H), 1.5−1.65 (m, 2H), 1.12 (t, 3H). MS (ES):  568 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>3-{[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}-2-(tolu</b><b>ene-4-sulfonylamino)propionic Acid (63).</b> Compound <b>63</b> was synthesized from <b>62</b> by using Typical Procedure C. (a) <b>62</b> (48.0 mg, 0.0845 mmol) in EtOH (2.0 mL) was treated with Et<sub>3</sub>N (60 μL, 0.430 mmol), followed by hydroxylamine hydrochloride (24.0 mg, 0.345 mmol). The reaction mixture was heated to 50 °C for 8.0 h and then partitioned between CH<sub>2</sub>Cl<sub>2</sub>/brine. The CH<sub>2</sub>Cl<sub>2</sub> extract was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford 3-({2-[4-(<i>N</i>-Hydroxycarbamimidoyl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carbonyl}amino)-2-(toluene-4-sulfonylamino)propionic acid ethyl ester, 35 mg (69%). (b) This was then dissolved in acetic acid (1.0 mL), treated with acetic anhydride (12.0 μL, 0.127 mmol), and stirred at room temperature for 0.5 h. Then 10% Pd/C (10.0 mg) was added, and the reaction mixture was stirred under 1 atm H<sub>2</sub> pressure (balloon) for 3.0 h. The mixture was filtered through Celite and concentrated to afford 3-{[2-(4-carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl]amino}-2-(toluene-4-sulfonylamino)propionic acid ethyl ester. (c) This was then dissolved in THF (5.0 mL), treated with 1 M LiOH (1.0 mL, 1.0 mmol), and the mixture was stirred at room temperature for 14 h. The reaction mixture was acidified with 6N HCl, concentrated to dryness, and purified by RP-HPLC to afford <b>63 </b>as a colorless solid as its TFA salt, 43 mg (76% overall). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.96 (d, 2H), 7.83 (d, 2H), 7.71 (d, 2H), 7.34 (d, 2H), 4.0 (dd, 1H), 3.93 (t, 2H), 3.84 (m, 2H), 3.51 (dd, 1H), 3.1 (t, 2H), 2.42 (s, 3H), 2.20 (t, 2H), 1.82 (m, 2H), 1.59 (d, 2H), 1.36 (dd, 1H). MS (ES):  557 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 557.2176; found, 557.2207. </div><div class="NLM_p"><b>2-Benzyloxycarbonylaminopentanedioic Acid 5-</b><b><i>tert</i></b><b>-Butyl Ester 1-Ethyl Ester (64).</b> The reaction mixture, consisting of Z-Glu (O-<i>t</i>-Bu)-OH (5.0 g, 14.82 mmol), EtOH (8.75 mL, 150 mmol), EDC·HCl (6.53 g, 34.06 mmol), and HOBt (4.53 g, 33.52 mmol) in DMF (50 mL) was stirred at room temperature for 16 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>, the CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash <a name="jm004700802056" id="jm004700802056"></a> chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to yield <b>64</b>, 4.47 g (83%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.3 (m, 5H), 5.42 (d, 1H), 5.06 (s, 2H), 4.34 (m, 1H), 4.15 (q, 2H), 2.27 (m, 2H), 2.11 (m, 1H), 1.90 (m, 1H), 1.4 (s, 9H), 1.23 (t, 3H). MS (ES):  366 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-Aminopentanedioic Acid 5-</b><b><i>tert</i></b><b>-Butyl Ester 1-Ethyl Ester (65).</b><b>64</b> (4.47 g, 12.23 mmol) in EtOH (60 mL) was mixed with 20% Pd(OH)<sub>2</sub>/C (250 mg), and the mixture was shaken on a Parr hydrogenator under 50 psi H<sub>2</sub> for 7 h. Then it was filtered through Celite and concentrated to yield <b>65</b>, 2.58 g (91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 4.05 (q, 2H), 3.60 (s, 1H), 3.32 (m, 1H), 2.23 (t, 2H), 1.91 (m, 1H), 1.58 (m, 1H), 1.33 (s, 9H), 1.15 (t, 3H). MS (ES):  232 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-Butoxycarbonylaminopentanedioic Acid 5-</b><b><i>tert</i></b><b>-Butyl Ester 1-Ethyl Ester (66).</b> To a solution of <b>65</b> (2.58 g, 11.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at 0 °C was added DIEA (3.90 mL, 22.39 mmol), followed by butyl chloroformate (1.87 mL, 14.70 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL). The reaction mixture was stirred at room temperature for 20 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to yield <b>66</b>, 3.18 g (86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 4.30 (m, 1H), 4.15 (q, 2H), 4.02 (t, 2H), 2.28 (m, 2H), 2.09 (m, 1H), 1.88 (m, 1H), 1.54 (m, 2H), 1.39 (s, 9H), 1.32 (m, 2H), 1.24 (t, 3H), 0.94 (t, 3H). MS (ES):  332 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-Butoxycarbonylaminopentanedioic Acid 1-Ethyl Ester (67).</b><b>66</b> (2.61 g, 7.875 mmol) was treated with TFA (20.0 mL), and the mixture was stirred at room temperature for 5.0 h, then concentrated to yield <b>67</b>, 2.08 g (96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 4.35 (m, 1H), 4.15 (q, 2H), 4.02 (t, 2H), 2.42 (m, 2H), 2.15 (m, 1H), 1.84 (m, 1H), 1.57 (m, 2H), 1.18−1.4 (m, 5H), 0.87 (t, 3H). MS (ES):  276 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-Butoxycarbonylamino-5-[2-(4-cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-5-oxopent</b><b>anoic Acid Ethyl Ester (68).</b> The reaction mixture consisting of <b>11</b> (98 mg, 0.383 mmol), <b>67</b> (127 mg, 0.46 mmol), HBTU (218 mg, 0.575 mmol), and DIEA (150 μL, 0.86 mmol) in DMF (3.0 mL) was stirred at room temperature for 17 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>, the CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to yield <b>68</b>, 167 mg (85%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.73(d, 2H), 7.56 (d, 2H), 4.3 (m, 1H), 4.2 (m, 3H), 4.04 (t, 2H), 3.84 (t, 1H), 3.1−3.4 (m, 3H), 2.55 (m, 2H), 2.25 (m, 2H), 1.85−2.05 (m, 2H), 1.75−1.85 (m, 2H), 1.6 (m, 2H), 1.4 (m, 2H), 1.28 (m, 2H), 0.93 (t, 3H). MS (ES):  513 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-Butoxycarbonylamino-5-[2-(4-carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-</b><b>5-oxopentanoic Acid (69).</b><b>69</b> was synthesized from <b>68</b> by Typical Procedure C, described previously for the synthesis of <b>63</b> from <b>62</b>. Overall yield, 68%. <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.95(d, 2H), 7.85 (d, 2H), 4.3 (m, 1H), 4.18 (m, 1H), 4.04 (t, 2H), 3.84 (t, 1H), 3.1−3.4 (m, 3H), 2.55 (m, 2H), 2.25 (m, 2H), 1.85−2.05 (m, 2H), 1.75−1.85 (m, 2H), 1.6 (m, 2H), 1.4 (m, 2H), 1.28 (m, 2H), 0.93 (t, 3H). MS (ES):  502 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 502.2660; found, 502.2701. </div><div class="NLM_p"><b>5-[2-(4-Cyanophenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]pentanoic Acid Ethyl Ester (70).</b> The reaction mixture consisting of <b>11</b> (160 mg, 0.626 mmol), ethyl 5-bromovalerate (130 μL, 0.821 mmol), and DIEA (0.400 mL, 2.29 mmol) in DMF (2.0 mL) was stirred overnight at room temperature. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to afford <b>70</b>, 174 mg (73%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.80 (d, 2H), 7.62 (d, 2H), 4.10 (q, 2H), 3.76 (t, 2H), 2.86 (m, 2H), 2.32 (m, 4H), 2.03 (m, 6H), 1.63 (m, 2H), 1.5 (m, 4H), 1.24 (t, 3H). MS (ES):  384 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>5-[2-(4-Carbamimidoylphenyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]pentanoic Acid (72).</b><b>72</b> was synthesized from <b>70</b> by using Typical Procedure C described for the synthesis of <b>63</b> from <b>62</b>. Yield, 66 mg (65%).<sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.98 (d, 2H), 7.82 (d, 2H), 3.96 (m, 1H), 3.63 (m, 1H), 3.45 (m, 1H), 3.10 (m, 4H), 2.4 (t, 2H), 2.3 (m, 2H), 2.13 (m, 2H), 1.9 (m, 3H), 1.80 (m, 2H), 1.66 (m, 2H). MS (ES):  373 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 373.2234; found, 373.2272. </div><div class="NLM_p"><b>2,2-Dimethyl-3-(4-nitrophenoxycarbonyloxy)propionic Acid Methyl Ester (73).</b> Methyl 2,2-dimethyl-3-hydroxypropionate (1.26 g, 9.53 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40.0 mL) at 0 °C was treated with Et<sub>3</sub>N (3.0 mL, 21.52 mmol), followed by 4-nitrophenyl chloroformate (2.50 g, 12.40 mmol). The reaction mixture was then stirred overnight at room temperature, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (20% CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>73</b>, 2.35 g (83%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 8.24 (d, 2H), 7.36 (d, 2H), 4.30 (s, 2H), 3.71 (s, 3H), 1.3 (s, 6H). MS (ES):  298 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-(4-Cyanophenyl)-3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid </b><b>2-Methoxycarbonyl-2-methylpropyl Ester (74).</b><b>12</b> (50 mg, 0.196 mmol) in DMF (2.0 mL) was treated with DIEA (70.0 μL, 0.40 mmol), followed by <b>73</b> (71 mg, 0.238 mmol), and the reaction mixture was stirred at room temperature for 18 h. Then it was partitioned between CH<sub>2</sub>Cl<sub>2</sub>/satd NaHCO<sub>3</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by flash chromatography (3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>74</b>, 68 mg (84%). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  δ 7.72 (d, 2H), 7.62 (d, 2H), 4.09 (s, 2H), 3.62 (m, 7H), 3.28 (m, 2H), 2.53 (s, 2H), 1.65 (m, 4H), 1.19 (s, 6H). MS (ES):  414 (M + H)<sup>+</sup>. </div><div class="NLM_p"><b>2-(4-Carbamimidoylphenyl)-3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylic Acid </b><b>2-Carboxy-2-methylpropyl Ester (75).</b><b>75</b> was synthesized from <b>74</b> (27.0 mg, 0.065 mmol) by using Typical Procedure A, described previously for the synthesis of <b>56</b> from <b>55</b>. Yield, 23 mg of TFA salt (66%). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  δ 7.78 (d, 2H), 7.67 (d, 2H), 3.90 (s, 2H), 3.64 (s, 2H), 3.42 (m, 2H), 3.23 (m, 2H), 2.43 (s, 2H), 1.45 (m, 4H), 1.03 (s, 6H). MS (ES):  417 (M + H)<sup>+</sup>. Exact mass (FAB, M + 1)<sup>+</sup> calcd, 417.2132; found, 417.2096. </div><div class="NLM_p"><b>Pharmacology. In Vitro Assay Systems. </b>All compounds were subjected to a series of functional in vitro assays to determine their relative activities. The following activities are expressed as the amount required to inhibit 50% of any given response (IC<sub>50</sub> values). Each compound was first tested for its ability to inhibit platelet aggregation induced by 20 μM ADP in citrated platelet rich plasma (PRP). If that IC<sub>50</sub> was <0.1 μM, the IC<sub>50</sub> was also obtained for most compounds with PPACK PRP using 20 μM ADP. If that criterion was met, then TRAP was tested as the agonist for comparison. In vitro fibrinogen binding to purified GPIIb-IIIa in a plate assay was also performed for the majority of the compounds and corresponding IC<sub>50</sub> values were obtained. Additionally, candidate compounds selected for further analysis were tested for their specificity for GPIIb-IIIa. This included analysis of inhibition of vitronectin (VN) binding to purified vitronectin receptor (VNR) in a plate assay and inhibition of cell adhesion mediated by various Integrins. </div><div class="NLM_p"><b>Materials and Methods (</b>Platelet aggregation in platelet rich plasma)<b>. </b>Materials: ADP diluted to 5 mL in PBS is 1 mM and prediluted Collagen are from Chrono-log Corp. TRAP6 (SFLLRN−NH2) was purchased from PenLabs, and TRAP 211−47 was synthesized in house at COR Therapeutics, Inc. 3.8% trisodium citrate (TSC) and PPACK (25 mg/mL in 0.01 N HCl, from CalBiochem) stock solutions were used. Fresh human blood was obtained from donors. Compounds were at a stock concentration of 40 mM in DMSO. Chrono-Log Whole Blood Aggregometer and Aggro-Link Software (Chrono-log corp., Havertown, PA) were used. </div><div class="NLM_p">Procedure:  Blood donors were selected who had not had any medications within the past 7 days and blood was drawn into 1/7 volume of TSC (8.6 mL TSC per 60 mL whole blood:  final concentration:  0.54%) or PPACK (final concentration 0.3 mM). Ten milliliters of blood was aliquoted into 15 mL polypropylene tubes and centrifuged at 900 rpm for 20 min (160<i>g</i>). The platelet rich plasma (PRP) was carefully removed and pooled in a new tube. Platelet poor plasma (PPP), for the blank sample in the aggregometer, was obtained by pelleting platelets by centrifuging 2 × 600 μL aliquots of PRP for 5 min on high in a microfuge (15 000<i>g</i>). </div><div class="NLM_p"><a name="jm004700802057" id="jm004700802057"></a>The platelet aggregation procedure was as follows:  500 μL of PRP was aliquoted into a cuvette with a stir bar, then 1 μL of either vehicle or compound in vehicle was added. The aggregometer was set to zero, and sample was allowed to incubate while stirring for approximately 1 min. To initiate platelet aggregation, 10 μL of 1 mM ADP was added to the cuvette for a final ADP concentration of 20 μM ADP (or TRAP for a final concentration of 5 μM). Aggregation proceeded for 5 min per sample. The amplitude value (height) of each aggregation curve, generated by the Aggro-Link Software, was used to generate inhibition curves for each compound. The IC<sub>50</sub> of each compound was calculated by linear regression using the two points that surround the 50% aggregation value. The average of at least three separate IC<sub>50</sub> determinations are reported here(± SD). </div><div class="NLM_p"><b>Fibrinogen Binding to Immobilized GPIIb-IIIa.</b> (Protocol also used for vitronectin binding to VNR− αvβ3). Materials:  Immulon-2 96-well microtiter plate. Biotinylated fibrinogen or vitronectin as per protocol (below). Buffer A:  0.15 M NaCl, 0.02 M Tris; pH 7.4, 0.001 M CaCl<sub>2</sub>, 0.02% NaN<sub>3</sub>. Buffer B:  0.1 M NaCl, 0.05 M Tris; pH 7.4, 0.002M CaCl<sub>2</sub>, 0.02% NaN<sub>3</sub>. Buffer C:  (blocking buffer):  Buffer B with 35 mg/mL BSA. Buffer D:  (Incubation Buffer):  Buffer B with 1 mg/ml BSA. 0.4 N NaOH. Bovine serum albumin (BSA) (Sigma, St. Louis, MO). </div><div class="NLM_p">Anti-biotin antibody−alkaline phosphatase conjugate (Sigma, St. Louis, MO. Product No. A-7064). Alkaline Phosphatase substrate kit (Biorad Laboratories, Hercules,CA. Cat No. 172-1063). V Max Plate Reader (Molecular Devices, Sunnyvale, CA). </div><div class="NLM_p">Procedure:  Purified GPIIb-IIIa complex or purified VNR was immobilized onto Immulon-2 96 well plates by diluting a 1 mg/ml stock 1:200 in buffer A and immediately adding 100 μL to each well (0.5 μg). The plates were incubated overnight at 4 °C. At the time of the experiment, the wells were washed twice with buffer B, by emptying then filling by aspiration. The wells were blocked with 0.1 mL of buffer C for 2 h at room temperature. The wells were washed with 250 μL of buffer D and then the samples were added as follows:  test compound and 10 nM biotinylated fibrinogen in buffer D were mixed together and 0.1 mL per well was added in triplicate. Following a 2 h incubation at room temperature, wells were washed once with 250 μL buffer D and then 0.1 mL anti-biotin antibody (1:20 000 dilution in buffer D) was added and incubated for 1 h at room temperature. Wells were again washed with 250 μL buffer D. Alkaline phosphatase substrate was diluted according to kit directions, and 0.1 mL/well was added and developed at room temp for 10 min. The reaction was stopped by adding 0.1 mL 0.4 N NaOH, and the endpoints were read at 405 nm on the V max plate reader. Percent specific binding was calculated by subtracting binding of fibrinogen to BSA-coated wells, and the IC<sub>50</sub> values from three replicate experiments were calculated as described above. Notes:  In preliminary experiments we determined that fibrinogen binding increased linearly up to 0.3 μg GP IIb-IIIa added to each well and the addition of higher amounts of GP IIb-IIIa to the wells did not further increase the amount of fibrinogen that bound. Plates coated with GPIIb-IIIa were stored up to 2 months at 4 °C. </div><div class="NLM_p">Biotinylation of Fibrinogen or Vitronectin. Materials:  Purified Fibrinogen (Haematologic Technologies, VT.). Purified Vitronectin 4. Dialysis Buffer:  0.1 M NaHCO<sub>3</sub> pH 8.3, 0.1 M NaCl. TS:  50 mM Tris, pH 7.4, 0.1 M NaCl, 0.05% NaN<sub>3</sub>. </div><div class="NLM_p">Procedure:  The ligand (fibrinogen or vitronectin) was dialyzed at 4°C into the dialysis buffer above. In the case of fibrinogen, it was centrifuged in the TL-100 tabletop ultracentrifuge (Beckman Instruments) at 100 000<i>g</i> for 20 min at 4 °C to remove any particulate matter. The ligand concentration was then adjusted to 1 mg/ml with dialysis buffer. Sulfo-<i>N</i>-hydroxysuccinomide-Biotin (Pierce, catalog # 21217) was added as a solid (0.2 mg of biotin ester/mL of ligand) and gently mixed on an end-over-end Nutator for 30 min at room temperature. Unreacted biotin reagent was removed by exhaustive dialysis with TS buffer at 4 °C. The final protein concentration was determined by O.D. 280 nm (fibrinogen:  EC = 1.51 vitronectin:  EC = 1.38) and single use aliquots were stored frozen at −80 °C. </div><div class="NLM_p">HUVEC Adhesion to Vitronectin or Fibronectin. Materials: Human umbilical vein endothelial cells (HUVEC)5. Vitronectin 4 and Fibronectin in PBS. Blocking media:  M199 media + 2.5 mg/mL BSA. Assay Media:  M199 media + 0.25 mg/mL BSA. 3% paraformaldehyde. 0.5% toluidine blue (dissolved in 3.7% formaldehyde). 2% SDS. Assay controls:  Abciximab, an inhibitor of GPIIb-IIIa and theVNR (αvβ3) was purchased from Centocor, Malvern PA; the function blocking fibronectin receptor antibody BIIG2, was a gift from Caroline Damsky6, UCSF; Echistatin, a disintegrin was purchased from Sigma; the cyclic-RGD peptide (C64-89, Mpr-RGDWPC-NH2) was synthesized in house (at COR Therapeutics, Inc.). </div><div class="NLM_p">Procedure:  1 μg/well of VN or FN was plated onto Immulon 2 96-well plates and incubated overnight at 4 °C. Before use the plates were washed 2× with PBS and blocked for 1−2 h at room temperature. Confluent HUVEC were lifted with trypsin and added to media with serum before pelleting cells. (HUVECs were used between 3rd and ∼8th passage). Cells were resuspended in assay media and counted on a hemocytometer. Assay media ± inhibitors were added to Eppendorf tubes and mixed. Then cells were added such that 100 μL added to each well yielded ∼50 000 cells. The quadruplicate samples were incubated at 37 °C in the 5% CO<sub>2</sub> incubator for 40 min. Nonadherent cells were removed by aspiration and washed 3× with 150 μL PBS. The cells were then fixed by the addition of 100 μL of 3% paraformaldehyde for 10 min at room temperature. This was aspirated and 90 μL of 0.5% toluidine blue stained the cells for 3 min. Wells were then washed 2× with 150 μL PBS and 100 μL 2% SDS was added for 5 min. After mixing well, the plate was read at 650 nM in the Molecular Devices plate reader. Specific adhesion from 2 to 3 separate experiments was determined by subtracting nonspecific HUVEC adhesion to BSA-coated wells from the total. </div><div class="NLM_p"><b>Assessment of Oral Bioavailability and Other PK Properties in Rats. </b>Sprague Dawley Rats were used for the first assessment of the oral activity of potent compounds. The compounds (double prodrugs, or mono-prodrugs) were solubilized in water and orally administered to six rats. The corresponding free acids were solubilized in 50% PEG-300 and administered intravenously to six rats. The administered doses were 1 mg/kg for all compounds. The animals were instrumented 2 days prior to the experiment and were fully conscious on the day of the experiment. Blood samples were collected on EDTA or sodium citrate and centrifuged to give PPP. </div><div class="NLM_p">Plasma samples were prepared and extracted using the following method:  An internal standard was added to test samples, which were then mixed with an equivalent volume of acetonitrile (ACN) to sediment proteins. The resulting serum was then filtered through a 1000 MW cutoff filter by centrifugation at 5 °C for 1−2 h. Standards were prepared in a plasma and extracted as described above. A 10 point standard curve was prepared for each compound over a concentration range of 5−5000 ng/mL. QC samples, prepared at concentrations of 10, 250, and 2500 ng/mL, were analyzed in triplicate at each concentration. Filtrates were, in some cases, evaporated to dryness, and the residue was dissolved in RP-HPLC mobile phase. In other cases, the UF filtrates were analyzed directly by LC/MS/MS. A variety of LC/MS conditions were used depending on the chromatographic and mass spectral properties of the compounds of interest. </div><div class="NLM_p">Samples were analyzed for free acids by LC/MS using protocols previously established for these compounds. Individual plasma samples obtained from each rat at each time point following PO dosing were analyzed. For iv administration, composites were prepared of the plasma obtained at each time point and the composites were analyzed (i.e. at each time point, 20 μL of plasma from each of the rats was mixed to form a composite sample. An aliquot of this composite was analyzed). </div><div class="NLM_p">Each compound was administered in either a cassette (multiple compounds) form or a single compound form. All drug <a name="jm004700802058" id="jm004700802058"></a> administration studies were performed utilizing a serial method of blood sampling. Plasma samples were collected at specific time points, analyzed for plasma concentration, and then reported as mean plasma concentration versus time. The pharmacokinetic profile generated from both treatment groups (orally and intravenously administered) of rats were used to obtain the percent oral bioavailability for each drug. Area under the curve (AUC) data were measured in both groups as well as <i>C</i><sub>max</sub> (maximum concentration) and <i>t</i><sub>1/2</sub><i><sub>β</sub></i> (half-life). Since the po and iv doses were the same, percent oral bioavailability was simply determined by dividing the AUC in the oral group that received the prodrug by the AUC in the iv group that received the drug (acid form of the compound). </div><div class="NLM_p">For the in vivo demonstration of GPIIb-IIIa dependence of mouse bleeding time experiment, the compound CT50787 was administered as an iv bolus injection (10% DMSO in water) via tail vein at 10, 40, 50 and 100 mg/kg in approximately 150 μL volume to anesthetized mice. To initiate bleeding, the tail was transected 2 mm proximal to its tip and immersed in 37 °C normal saline bath. The bleeding time was recorded as the time required until cessation of blood flow or up to 15 min (900 s). PRP of CT50787 in the mouse utilized citrated pooled (C57/Bl) mouse PRP and 20 μM ADP as the agonist in a standard aggregometry assay. </div><div class="NLM_p"><b>Pharmacokinetics in Cynomolgus Monkeys. </b>The general procedure for the determination of bioavailability and other pharmacokinetic properties is exemplified here for <b>27</b> (CT51269). </div><div class="NLM_p">The stability of the compounds in rat, cynomolgus monkey, and dog plasmas were evaluated to compare the cholinesterase activities in the various species against the prodrug. Compound stability was also evaluated in a solution containing a suspended section of rat ileum to determine the metabolic stability of the prodrug in the intestine. A standard was used as a control in these studies. </div><div class="NLM_p">In Vivo Bioavailability. Animals (<i>n</i> = 3, weight <b>= </b>7.1−7.5 kg) were fasted on the afternoon prior to dose administration but water was allowed ad libitum. On the day of the experiment, the monkeys were placed in chair restraints. Blood samples were obtained by percutaneous venipuncture via cepholic or saphenous veins. Blood samples were anticoagulated with EDTA, and the plasma obtained was frozen for later analysis. In the first week of the study, <b>28</b> (CT50614) was administered at 200 μg/kg as a 15 min infusion of the compound dissolved in 50% PEG-300 (2.0 mg/mL) and further diluted with plasmalyte. Each animal received a 3.5 mL infusion of the drug solution for each kg of body weight. In the second week of the study, <b>27</b> (CT51269) was dissolved in distilled water at 2.0 mg/mL and administered to the same animals at 2000 μg/kg via nasogastric feeding tube. An additional 10 mL of water was administered to ensure complete delivery. For intraveneously administered compound, blood samples (1.0 mL) were collected at 0 (predose), 5, 15, 30, and 45 min and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 28, 32, and 48 h after dose administration. For orally administered animals, blood samples were collected at 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 28, 32, and 48 h after dose administration. Blood samples were centrifuged at 1500 g for 10 min, and the resulting platelet poor plasma (PPP) was decanted into Eppendorf tubes and frozen at −15 °C. </div><div class="NLM_p">Sample Preparation for LC/MS/MS Analysis. A 200 μL aliquot of the plasma samples was mixed with an equal volume of acetonitrile (ACN), and an internal standard (LY314378) was added to a concentration of 500 ng/mL of plasma. The samples were then centrifuged and filtered through an ultrafiltration membrane (10,000 MW cutoff, Microcon 10, Amicon Inc.). A 60 μL aliquot of the filtrate was evaporated to dryness in a centrifugal evaporator, and the residue was dissolved in 120 μL of water containing 0.5% formic acid. </div><div class="NLM_p">LC/MS/MS Analysis. All separations were performed on a Keystone C18 column (2 × 10 mm, 5 μm) using a linear gradient from 5 to 95% ACN over 5 min at a flow rate of 200 μL/min. Formic acid (0.5%) was used in the mobile phase as an ion-transfer agent for MS detection. The column effluent was introduced to the MS/MS through a turbo-ion spray source (Temp = 450 °C, ion-spray voltage = 5200 V, turbo-gas flow = 7 L/min). Parent and daughter ions selected for specific MS/MS detection of each compound were used. Collision energies were optimized for maximum sensitivity for each compound, and the optimum settings were used during the scan periods for each compound. </div><div class="NLM_p">For quantitation, standards of each compound were prepared in cynomolgus monkey plasma and prepared as described above. For each compound, a blank extract was prepared as well as a 10-point standard curve over the concentration range of 1 to 1000 ng/mL. Ratios of peak area of each analyte to that of an internal standard were computed using MacQuan software. Calibration curves were constructed using a weighted (1/<i>x</i><sup>2</sup>) linear regression of the standard plasma concentrations to measured peak area ratios. Plasma concentrations of unknowns were determined by interpolation from the corresponding standard curve for each compound. </div><div class="NLM_p">Quality control samples (QCs) consisting of cynomolgus monkey plasma spiked with either 5, 50, or 500 ng/mL of each compound (three replicates at each concentration) were analyzed with every sample set as a measure of assay performance. Test acceptance criteria required that measured concentrations for QCs be within 20% of theoretical concentrations (accuracy) and that the coefficient of variance for replicate samples at each level be <20% (precision). </div><div class="NLM_p">In Vitro Determination of Compound Stability in Plasma. Fresh samples of PPP (EDTA anticoagulant) from rat and dog or frozen plasma samples from cynomolgus monkey were used in these experiments. In a typical experiment, compounds were added to plasma (1 mL) to give a final concentration of 2.5 μg/mL as a DMSO solution (10 μL of a 250 μg/mL stock solution). Samples (150 μL) were taken at 2, 5, 15, 30, 60, and 120 min, mixed with an equal volume of ACN containing an internal standard, centrifuged, and filtered as described above and analyzed by LC/MS/MS. Standards (six-point standard curve) were prepared in either rat or cynomolgus monkey plasma. </div><div class="NLM_p">In Vitro Metabolism of <b>27</b> (CT51269) by Rat Ileum. Freshly harvested intestinal tissue from a single rat was stripped of muscle tissue, blotted dry, cut into two sections (6 × 6 mm and 7 × 6 mm), and weighed (27.8 mg and 25.9 mg). The sections were suspended in 2 mL portions of phosphate buffer, and 5 μg of CT51269 was added to each tube as a DMSO solution (20 μL of a 250 μg/mL stock solution). Samples (150 μL) of the media were taken at 5, 15, 30, 60, and 120 min, mixed with an equal volume of ACN containing an internal standard, centrifuged, and filtered as described above, and analyzed by LC/MS/MS. Standards were prepared in phosphate buffer (six-point standard curve) and treated identically to the samples. </div><div class="NLM_p">After the 2 h incubation period, 1.25 mL of ACN/IS mixture was added to the sample (consisting of tissue suspended in 1.25 mL of buffer), the sample was homogenized using a sonic probe and mixed for 1 h. The homogenate was centrifuged and filtered using the procedure described above. Analyte concentrations in this sample were determined using a standard curve prepared in phosphate buffer. </div><div class="NLM_p">LC/MS/MS Determination of Glucuronides of <b>28</b> (CT50614) and <b>29</b> (CT51270). Two different procedures were used for the determination of glucuronides in the cynomolgus plasma samples. In the first procedure, β-glucuronidase was added to plasma samples obtained from one of the subjects to which <b>27</b> (CT51269) had been orally administered. Changes in the concentrations of <b>28</b> (CT50614) and <b>29</b> (CT51270) were measured by LC/MS/MS relative to similarly treated plasma not treated with glucuronidase. In the second procedure, RP-HPLC effluent was monitored by MS in a narrow mass range around the expected <i>m</i>/<i>z</i> value predicted for CT50614-glucuronide. LC/MS monitoring was also used to verify the extent of hydrolysis of CT50614-glucuronides by the β-glucuronidase treatment. </div><div class="NLM_p">β-Glucuronidase (100 μL of a 200 units/mL solution in 8 mM phosphate buffer, Sigma Chemical Co., Cat # G-5897) was <a name="jm004700802059" id="jm004700802059"></a> added to 100 μL of plasma. Control portions of plasma received 100 μL of phosphate buffer (no enzyme). Both portions were incubated at 37 °C for 2 h at which time ACN and an internal standard were added to the sample, and the samples were centrifuged and filtered as described above. Standards (10-point standard curve) and QCs were prepared in cynomolgus PPP and treated identically to the control samples. The concentrations of <b>27</b> (CT51269) and <b>29</b> (CT51270) were determined using LC/MS/MS as described above. </div><div class="NLM_p">For direct LC/MS detection of the glucuronide of <b>28</b> (CT50614), the control and treated samples were subjected to RP-HPLC as described above. The MS eluant was monitored by MS (Q1 scan) over a scan range of 560−570 amu with a step size of 0.5 amu and a dwell time of 50 ms (total scan time = 1 s). </div><div class="NLM_p"><b>Pharmacokinetics in Beagle Dogs. </b>The general procedure for the determination of bioavailability and other pharmacokinetic properties is exemplified here for <b>27</b> (CT51269). </div><div class="NLM_p">The pharmacokinetic parameters of <b>27</b> (CT51269) were investigated in beagle dogs in a crossover experiment. Plasma samples, collected on EDTA, were analyzed by LC/MS/MS for both the active metabolite of CT51269, <b>28</b> (CT50614), and for the inactive, mono-prodrug form of the compound, <b>29</b> (CT51270). </div><div class="NLM_p">Fasted, female beagle dogs (9−10 kg) were used in crossover design studies with a 1 week washout period between studies. In the first week, CT50614 was administered intravenously as an iv bolus in 50% PEG at a dose of 0.1 mg/kg. Blood samples of 1.0 mL were obtained, via percutaneous sampling of the cephalic veins, onto EDTA and centrifuged to give PPP. In the second week, <b>27</b> (CT51269) was administered orally, in water, to the same subjects via a 12F feeding tube at a dose of 1 mg/kg. </div><div class="NLM_p">Plasma samples were analyzed by LC/MS/MS using protocols described above. An internal standard, selected for its chemical similarity to the test compounds, was used in quantitation. The linear range for this assay has been determined to be 1−500 ng/mL with accuracy and precision throughout the range of 85−115% and ±10% respectively. </div><div class="NLM_p last">The data were analyzed for pharmacokinetic parameters using WinNonlin software with noncompartmental data treatment. </div></div><div class="NLM_back"><div class="article_supporting-info" id=""><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm030354b/suppl_file/jm030354b_s.pdf">jm030354b_s.pdf (966.56 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm030354b" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><ul></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mukund M. Mehrotra</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie A. Heath</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark S. Smyth</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjali Pandey</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jack W. Rose</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph M. Seroogy</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah L. Volkots</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Nannizzi-Alaimo</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary L. Park</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph L. Lambing</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanley J. Hollenbach</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert M. Scarborough</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 256 E. Grand Avenue, South San Francisco, California 94080 </span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge helpful discussions with Charles J. Homcy, David Phillips, and Daniel D. Gretler of Millennium Pharmaceuticals, Inc. </p></div><div class="refs-header-label"></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="jm030354bb00001"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00001'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="jm030354bb00001_1"><span><span class="NLM_string-ref">(a) Fuster, V.; Badimon, L.; Badimon, J. J.; Chesebro, J. H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes (Part I). <i>  N. Engl. J. </i><i>Med.</i><b>1992</b>, <i>326</i>, 242−250.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=250&author=V.+Fuster&author=L.+Badimon&author=J.+J.+Badimon&author=J.+H+Chesebro&title=The+Pathogenesis+of+Coronary+Artery+Disease+and+the+Acute+Coronary+Syndromes+%28Part+I%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuster%26aufirst%3DV.%26atitle%3DThe%2520Pathogenesis%2520of%2520Coronary%2520Artery%2520Disease%2520and%2520the%2520Acute%2520Coronary%2520Syndromes%2520%2528Part%2520I%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_2"><span><span class="NLM_string-ref">(b) Fuster, V.; Badiman, L.; Badimon, J. J.; Chesebro, J. H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes (Part II). <i>  N. Engl. J. Med.</i><b>1992</b>, <i>326</i>, 310−318.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=318&author=V.+Fuster&author=L.+Badiman&author=J.+J.+Badimon&author=J.+H+Chesebro&title=The+Pathogenesis+of+Coronary+Artery+Disease+and+the+Acute+Coronary+Syndromes+%28Part+II%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuster%26aufirst%3DV.%26atitle%3DThe%2520Pathogenesis%2520of%2520Coronary%2520Artery%2520Disease%2520and%2520the%2520Acute%2520Coronary%2520Syndromes%2520%2528Part%2520II%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_3"><span><span class="NLM_string-ref">(c) Hynes, R. O. Integrins:  Versatility, Modulation, and Signaling in Cell Adhesion. <i>  Cell</i><b>1992</b>, <i>69</i>, 11−25.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28c%29+Hynes%2C+R.+O.+Integrins%3A%E2%80%89+Versatility%2C+Modulation%2C+and+Signaling+in+Cell+Adhesion.+Cell+1992%2C+69%2C+11%E2%88%9225.+%28c%29+Hynes%2C+R.+O.+Integrins%3A%E2%80%89+Versatility%2C+Modulation%2C+and+Signaling+in+Cell+Adhesion.+Cell1992%2C+69%2C+11%E2%88%9225."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DR.%2BO.%26jtitle%3DCell%26date%3D1992%26volume%3D69%26spage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_4"><span><span class="NLM_string-ref">(d) Humphries, M. J. Integrin Cell Adhesion Receptors and the Concept of Agonism. <i>  Trends Pharmacol. Sci</i>. <b>2000</b>, <i>21</i>, 29−32.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=32&author=M.+J+Humphries&title=Integrin+Cell+Adhesion+Receptors+and+the+Concept+of+Agonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DM.%2BJ%26atitle%3DIntegrin%2520Cell%2520Adhesion%2520Receptors%2520and%2520the%2520Concept%2520of%2520Agonism%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_5"><span><span class="NLM_string-ref">(e) Aota, S.; Yamada, K. M. Integrin Functions and Signal Transduction. <i>  Adv. </i><i>Exp. Med. Biol.</i><b>1997</b>, <i>400B</i>, 669−682.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400B&publication_year=1997&pages=682&author=S.+Aota&author=K.+M+Yamada&title=Integrin+Functions+and+Signal+Transduction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DS.%26atitle%3DIntegrin%2520Functions%2520and%2520Signal%2520Transduction%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1997%26volume%3D400B%26spage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_6"><span><span class="NLM_string-ref">(f) Coller, B. S. Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy. <i>  Circulation</i><b>1995</b>, <i>92</i>, 2373−80.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=80&author=B.+S+Coller&title=Blockade+of+Platelet+GPIIb%2FIIIa+Receptors+as+an+Antithrombotic+Strategy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColler%26aufirst%3DB.%2BS%26atitle%3DBlockade%2520of%2520Platelet%2520GPIIb%252FIIIa%2520Receptors%2520as%2520an%2520Antithrombotic%2520Strategy%26jtitle%3DCirculation%26date%3D1995%26volume%3D92%26spage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00001_7"><span><span class="NLM_string-ref">(g) Ruef, J.; Katus, H. A. New Antithrombotic Drugs on the Horizon. <i>  Expert Opin. Invest. Drugs</i><b>2003</b>, <i>12(5)</i>, 781−797.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=797&issue=5&author=J.+Ruef&author=H.+A+Katus&title=New+Antithrombotic+Drugs+on+the+Horizon"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuef%26aufirst%3DJ.%26atitle%3DNew%2520Antithrombotic%2520Drugs%2520on%2520the%2520Horizon%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D12%26issue%3D5%26spage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00002"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00002'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="jm030354bb00002_1"><span><span class="NLM_string-ref">Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. <i>  Blood </i><b>1988</b><i>,</i><i>71</i>, 831−843.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1988&pages=843&author=D.+R.+Phillips&author=I.+F.+Charo&author=L.+V.+Parise&author=L.+A+Fitzgerald&title=The+Platelet+Membrane+Glycoprotein+IIb-IIIa+Complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00002_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26atitle%3DThe%2520Platelet%2520Membrane%2520Glycoprotein%2520IIb-IIIa%2520Complex%26jtitle%3DBlood%26date%3D1988%26volume%3D71%26spage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00003"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00003'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="jm030354bb00003_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Design of Potent and Specific Integrin Antagonists. <i>  J. Biol. Chem.</i><b>1993</b>, <i>268</i>, 1066−1073.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=1073&author=R.+M.+Scarborough&author=M.+A.+Naughton&author=W.+Teng&author=J.+W.+Rose&author=D.+R.+Phillips&author=L.+Nannizzi&author=A.+Arfsten&author=A.+M.+Campbell&author=I.+F+Charo&title=Design+of+Potent+and+Specific+Integrin+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Specific%2520Integrin%2520Antagonists%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00003_2"><span><span class="NLM_string-ref">(b) Charo, I. F.; Nannizzi, L.; Phillips, D. R.; Hsu, M. A.; Scarborough, R. M. Inhibition of Fibrinogen Binding to GP IIb-IIIa by a GP IIIa Peptide. <i>  J. </i><i>Biol. Chem.</i><b>1991</b>, <i>266</i>, 1415−1421.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1991&pages=1421&author=I.+F.+Charo&author=L.+Nannizzi&author=D.+R.+Phillips&author=M.+A.+Hsu&author=R.+M+Scarborough&title=Inhibition+of+Fibrinogen+Binding+to+GP+IIb-IIIa+by+a+GP+IIIa+Peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DInhibition%2520of%2520Fibrinogen%2520Binding%2520to%2520GP%2520IIb-IIIa%2520by%2520a%2520GP%2520IIIa%2520Peptide%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1991%26volume%3D266%26spage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00003_3"><span><span class="NLM_string-ref">(c) Alig, L.; Edenhofer, A.; Hadvary, P.; Hurzeler, M.; Knopp, D.; Muller, M.; Steiner, B.; Trzeciak, A.; Weller, T. Low Molecular Weight, Non-Peptide Fibrinogen Receptor Antagonists. <i>  J. Med. Chem.</i><b>1992</b>, <i>35</i>, 4393−4407.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4407&author=L.+Alig&author=A.+Edenhofer&author=P.+Hadvary&author=M.+Hurzeler&author=D.+Knopp&author=M.+Muller&author=B.+Steiner&author=A.+Trzeciak&author=T+Weller&title=Low+Molecular+Weight%2C+Non-Peptide+Fibrinogen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlig%26aufirst%3DL.%26atitle%3DLow%2520Molecular%2520Weight%252C%2520Non-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00003_4"><span><span class="NLM_string-ref">(d) Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzman, L. A.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen:  A Proposal on the Nature of the Binding Interaction between the Arg-guanidine of RGDX Mimetics and the Platelet GP IIb-IIIa Receptor. <i>  J. Med. Chem.</i><b>1993</b>, <i>36</i>, 1811−1819.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1819&author=J.+A.+Zablocki&author=M.+Miyano&author=R.+B.+Garland&author=D.+Pireh&author=L.+A.+Schretzman&author=S.+N.+Rao&author=R.+J.+Lindmark&author=S.+G.+Panzer-Knodle&author=N.+S.+Nicholson&author=B.+B.+Taite&author=A.+K.+Salyers&author=L.+W.+King&author=J.+G.+Campion&author=L.+P+Feigen&title=Potent+in+Vitro+and+in+Vivo+Inhibitors+of+Platelet+Aggregation+Based+upon+the+Arg-Gly-Asp-Phe+Sequence+of+Fibrinogen%3A%E2%80%89+A+Proposal+on+the+Nature+of+the+Binding+Interaction+between+the+Arg-guanidine+of+RGDX+Mimetics+and+the+Platelet+GP+IIb-IIIa+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZablocki%26aufirst%3DJ.%2BA.%26atitle%3DPotent%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Inhibitors%2520of%2520Platelet%2520Aggregation%2520Based%2520upon%2520the%2520Arg-Gly-Asp-Phe%2520Sequence%2520of%2520Fibrinogen%253A%25E2%2580%2589%2520A%2520Proposal%2520on%2520the%2520Nature%2520of%2520the%2520Binding%2520Interaction%2520between%2520the%2520Arg-guanidine%2520of%2520RGDX%2520Mimetics%2520and%2520the%2520Platelet%2520GP%2520IIb-IIIa%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00004"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00004'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="jm030354bb00004_1"><span><span class="NLM_string-ref">(a) Lincoff, A. M.; Topol, E. J. Overview of the Glycoprotein IIb/IIIa Interventional Trials. In <i>Platelet Glycoprotein IIb/IIIa Inhibitors in </i><i>Cardiovascular Disease, </i>2nd ed.; Lincoff, A., Michael, Eds.; Humana Press Inc.:  Totowa, N. J., 2003; pp 167−199.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=199&author=A.+M.+Lincoff&author=E.+J.+Topol&title=Platelet+Glycoprotein+IIb%2FIIIa+Inhibitors+in+Cardiovascular+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00004_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26atitle%3DOverview%2520of%2520the%2520Glycoprotein%2520IIb%252FIIIa%2520Interventional%2520Trials%26btitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%2520in%2520Cardiovascular%2520Disease%26pub%3DHumana%2520Press%2520Inc%26date%3D2003%26spage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00004_2"><span><span class="NLM_string-ref">(b) Agah, R.; Plow, E. F.; Topol, E. J. GPIIb-IIIa Antagonists. In <i>Platelets</i>; Michelson, A. D., Eds.; Academic Press:  California, 2002; pp 769−785.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=785&author=R.+Agah&author=E.+F.+Plow&author=E.+J.+Topol&title=Platelets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00004_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAgah%26aufirst%3DR.%26atitle%3DGPIIb-IIIa%2520Antagonists%26btitle%3DPlatelets%26pub%3DAcademic%2520Press%26date%3D2002%26spage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00005"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00005'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="jm030354bb00005_1"><span><span class="NLM_string-ref">Lincoff, A. M.; Califf, R. M.; Topol, E. J. Platelet Glycoprotein IIb-IIIa, Receptor Blocade in Coronary Artery Disease. <i>  J. Am. Coll. Cardiol.</i><b>2000</b>, <i>35</i>, 1103−1115.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=1115&author=A.+M.+Lincoff&author=R.+M.+Califf&author=E.+J+Topol&title=Platelet+Glycoprotein+IIb-IIIa%2C+Receptor+Blocade+in+Coronary+Artery+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00005_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb-IIIa%252C%2520Receptor%2520Blocade%2520in%2520Coronary%2520Artery%2520Disease%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2000%26volume%3D35%26spage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00006"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00006'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="jm030354bb00006_1"><span><span class="NLM_string-ref">(a) Coller, B. S. Anti-GPIIb/IIIa Drugs:  Current Strategies and Future Directions. <i>  Thromb. Haemost.</i><b>2001</b>, <i>86</i>, 427−443.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28a%29+Coller%2C+B.+S.+Anti-GPIIb%2FIIIa+Drugs%3A%E2%80%89+Current+Strategies+and+Future+Directions.+Thromb.+Haemost.+2001%2C+86%2C+427%E2%88%92443.+%28a%29+Coller%2C+B.+S.+Anti-GPIIb%2FIIIa+Drugs%3A%E2%80%89+Current+Strategies+and+Future+Directions.+Thromb.+Haemost.2001%2C+86%2C+427%E2%88%92443."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColler%26aufirst%3DB.%2BS.%26jtitle%3DThromb.%2520Haemost.%26date%3D2001%26volume%3D86%26spage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00006_2"><span><span class="NLM_string-ref">(b) Konstantopoulos, K.; Mousa, S. A. Antiplatelet Therapies:  Platelet GPIIb/IIIa Antagonists and Beyond. <i>  Curr. Opin. Invest. Drugs</i><b>2001</b>, <i>2</i>, 1086−1092.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Konstantopoulos%2C+K.%3B+Mousa%2C+S.+A.+Antiplatelet+Therapies%3A%E2%80%89+Platelet+GPIIb%2FIIIa+Antagonists+and+Beyond.+Curr.+Opin.+Invest.+Drugs+2001%2C+2%2C+1086%E2%88%921092.+%28b%29+Konstantopoulos%2C+K.%3B+Mousa%2C+S.+A.+Antiplatelet+Therapies%3A%E2%80%89+Platelet+GPIIb%2FIIIa+Antagonists+and+Beyond.+Curr.+Opin.+Invest.+Drugs2001%2C+2%2C+1086%E2%88%921092."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantopoulos%26aufirst%3DK.%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00006_3"><span><span class="NLM_string-ref">(c) Dogne, J.; De Leval, X.; Benoit, P.; Delarge, J.; Masereel, B.; David, J. Recent advances in antiplatelet agents. <i>  Curr. Med. Chem.</i><b>2002</b>, <i>9</i>, 577−589.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=589&author=J.+Dogne&author=X.+De+Leval&author=P.+Benoit&author=J.+Delarge&author=B.+Masereel&author=J+David&title=Recent+advances+in+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDogne%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520antiplatelet%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00006_4"><span><span class="NLM_string-ref">(d) Ojima, I.; Chakravarty, S.; Dong, Q. Antithrombotic Agents:  From RGD to Peptide Mimetics. <i>  Bioorg. Med. Chem.</i><b>1995</b>, <i>3</i>, 337−360.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28d%29+Ojima%2C+I.%3B+Chakravarty%2C+S.%3B+Dong%2C+Q.+Antithrombotic+Agents%3A%E2%80%89+From+RGD+to+Peptide+Mimetics.+Bioorg.+Med.+Chem.+1995%2C+3%2C+337%E2%88%92360.+%28d%29+Ojima%2C+I.%3B+Chakravarty%2C+S.%3B+Dong%2C+Q.+Antithrombotic+Agents%3A%E2%80%89+From+RGD+to+Peptide+Mimetics.+Bioorg.+Med.+Chem.1995%2C+3%2C+337%E2%88%92360."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1995%26volume%3D3%26spage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00006_5"><span><span class="NLM_string-ref">(e) Scarborough, R. M. Structure−Activity Relationships of β-Amino Acid-Containing Integrin Anagonists. <i>  Curr. Med. Chem.</i><b>1999</b>, <i>6</i>, 971−981.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=981&author=R.+M+Scarborough&title=Structure%E2%88%92Activity+Relationships+of+%CE%B2-Amino+Acid-Containing+Integrin+Anagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM%26atitle%3DStructure%25E2%2588%2592Activity%2520Relationships%2520of%2520%25CE%25B2-Amino%2520Acid-Containing%2520Integrin%2520Anagonists%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D1999%26volume%3D6%26spage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00007"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00007'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="jm030354bb00007_1"><span><span class="NLM_string-ref">Mousa, S. A.; Iqbal, O.; Fareed, J. Antithrombotics and Thrombolytics in Stroke. <i>  Curr. Opin. Invest. Drugs</i><b>2002</b>,<i> 3</i>, 878−885.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=885&author=S.+A.+Mousa&author=O.+Iqbal&author=J+Fareed&title=Antithrombotics+and+Thrombolytics+in+Stroke"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00007_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DAntithrombotics%2520and%2520Thrombolytics%2520in%2520Stroke%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00008"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00008'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="jm030354bb00008_1"><span><span class="NLM_string-ref">Wang, W.; Borchardt, R. T.; Wang, B. Orally Active Peptidomimetic RGD Analogues that are Glycoprotein IIb/IIIa Antagonists. <i>  Curr. Med. Chem.</i><b>2000</b>, <i>7</i>, 437−453.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=453&author=W.+Wang&author=R.+T.+Borchardt&author=B+Wang&title=Orally+Active+Peptidomimetic+RGD+Analogues+that+are+Glycoprotein+IIb%2FIIIa+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00008_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26atitle%3DOrally%2520Active%2520Peptidomimetic%2520RGD%2520Analogues%2520that%2520are%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2000%26volume%3D7%26spage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00009"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00009'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="jm030354bb00009_1"><span><span class="NLM_string-ref">(a) Cannon, C. P. The Evolving Story of Oral Platelet Glycoprotein IIb-IIIa Receptor Inhibitors. <i>  Curr. Opin. Cardiovascular, Pulmonary & Renal </i><i>Invest. Drugs </i><b>2000</b>, <i>2</i>, 114−123.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=123&author=C.+P+Cannon&title=The+Evolving+Story+of+Oral+Platelet+Glycoprotein+IIb-IIIa+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00009_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP%26atitle%3DThe%2520Evolving%2520Story%2520of%2520Oral%2520Platelet%2520Glycoprotein%2520IIb-IIIa%2520Receptor%2520Inhibitors%26jtitle%3DCurr.%2520Opin.%2520Cardiovascular%252C%2520Pulmonary%2520%2526%2520Renal%2520Invest.%2520Drugs%26date%3D2000%26volume%3D2%26spage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00009_2"><span><span class="NLM_string-ref">(b) Quinn, M. J.; Plow, E. F.; Topol, E. J. Platelet Glycoprotein IIb/IIIa Inhibitors:  Recognition of a Two-Edged Sword? <i>Circulation</i><b>2002</b>, <i>106</i>, 379−385.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=385&author=M.+J.+Quinn&author=E.+F.+Plow&author=E.+J+Topol&title=Platelet+Glycoprotein+IIb%2FIIIa+Inhibitors%3A%E2%80%89+Recognition+of+a+Two-Edged+Sword"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00009_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DM.%2BJ.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%253A%25E2%2580%2589%2520Recognition%2520of%2520a%2520Two-Edged%2520Sword%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00010"><div class="reference"><div class="NLM_citation" id="jm030354bb00010_1"><span><span class="NLM_string-ref">Scarborough, R. M. Eptifibatide. <i>  Drugs Future</i><b>1998</b>, <i>23(6)</i>, 585−590.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scarborough%2C+R.+M.+Eptifibatide.+Drugs+Future+1998%2C+23%286%29%2C+585%E2%88%92590.+Scarborough%2C+R.+M.+Eptifibatide.+Drugs+Future1998%2C+23%286%29%2C+585%E2%88%92590."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00010_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26jtitle%3DDrugs%2520Future%26date%3D1998%26volume%3D23%26issue%3D6%26spage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00011"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00011'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="jm030354bb00011_1"><span><span class="NLM_string-ref">Scarborough, R. M.; Gretler, D. D. Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers:  Novel Parenteral and Potential Oral Antithrombotic Agents. <i>  J. Med. Chem</i>. <b>2000</b>, <i>43(19)</i>, 3453−3473.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3473&issue=19&author=R.+M.+Scarborough&author=D.+D+Gretler&title=Platelet+Glycoprotein+IIb-IIIa+Antagonists+as+Prototypical+Integrin+Blockers%3A%E2%80%89+Novel+Parenteral+and+Potential+Oral+Antithrombotic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00011_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb-IIIa%2520Antagonists%2520as%2520Prototypical%2520Integrin%2520Blockers%253A%25E2%2580%2589%2520Novel%2520Parenteral%2520and%2520Potential%2520Oral%2520Antithrombotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D19%26spage%3D3473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00012"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00012'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="jm030354bb00012_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Kleiman, N. S.; Phillips, D. R. Platelet Glycoprotein IIb/IIIa Antagonists:  What Are the Relevant Issues Concerning their Pharmacology and Clinical Use? <i>Circulation</i><b>1999</b>, <i>100</i>, 437−444.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=444&author=R.+M.+Scarborough&author=N.+S.+Kleiman&author=D.+R+Phillips&title=Platelet+Glycoprotein+IIb%2FIIIa+Antagonists%3A%E2%80%89+What+Are+the+Relevant+Issues+Concerning+their+Pharmacology+and+Clinical+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%253A%25E2%2580%2589%2520What%2520Are%2520the%2520Relevant%2520Issues%2520Concerning%2520their%2520Pharmacology%2520and%2520Clinical%2520Use%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26spage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00012_2"><span><span class="NLM_string-ref">(b) Brassard, J. A.; Curtis, B. R.; Cooper, R. A.; Ferguson, J.; Komocsar, W.; Ehardt, M.; Kupfer, S.; Maurath, C.; Swabb, E.; Cannon, C. P.; Aster, R. H. Acute Thrombocytopenia in Patients Treated with the Oral Glycoprotein IIb/IIIa Inhibitors Xemilofiban and Orbofiban:  Evidence for an Immune Etiology. <i>  Thromb. Haemost.</i><b>2002</b>, <i>88</i>, 892−897.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2002&pages=897&author=J.+A.+Brassard&author=B.+R.+Curtis&author=R.+A.+Cooper&author=J.+Ferguson&author=W.+Komocsar&author=M.+Ehardt&author=S.+Kupfer&author=C.+Maurath&author=E.+Swabb&author=C.+P.+Cannon&author=R.+H+Aster&title=Acute+Thrombocytopenia+in+Patients+Treated+with+the+Oral+Glycoprotein+IIb%2FIIIa+Inhibitors+Xemilofiban+and+Orbofiban%3A%E2%80%89+Evidence+for+an+Immune+Etiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrassard%26aufirst%3DJ.%2BA.%26atitle%3DAcute%2520Thrombocytopenia%2520in%2520Patients%2520Treated%2520with%2520the%2520Oral%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%2520Xemilofiban%2520and%2520Orbofiban%253A%25E2%2580%2589%2520Evidence%2520for%2520an%2520Immune%2520Etiology%26jtitle%3DThromb.%2520Haemost.%26date%3D2002%26volume%3D88%26spage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00012_3"><span><span class="NLM_string-ref">(c) Aster, Richard. Thrombocytopenia Induced by GPIIb/IIIa Inhibitors. <i>  Blood</i><b>2003</b>, <i>101</i>, 1.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=1&author=+Aster&title=Thrombocytopenia+Induced+by+GPIIb%2FIIIa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAster%26atitle%3DThrombocytopenia%2520Induced%2520by%2520GPIIb%252FIIIa%2520Inhibitors%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00012_4"><span><span class="NLM_string-ref">(d) Peter, K.; Schwarz, M.; Nordt, T.; Bode, C. Intrinsic Activating Properties of GP IIb/IIIa Blockers.<i> Thromb. Res.</i><b>2001</b>, <i>103 (Suppl. 1)</i>, S21−S27.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103+%28Suppl.+1&publication_year=2001&pages=S27&author=K.+Peter&author=M.+Schwarz&author=T.+Nordt&author=C+Bode&title=Intrinsic+Activating+Properties+of+GP+IIb%2FIIIa+Blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DIntrinsic%2520Activating%2520Properties%2520of%2520GP%2520IIb%252FIIIa%2520Blockers%26jtitle%3DThromb.%2520Res.%26date%3D2001%26volume%3D103%2520%2528Suppl.%25201%26spage%3DS27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00012_5"><span><span class="NLM_string-ref">(e) Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M. Bleeding Complications with Glycoprotein IIb/IIIa Inhibitors. <i>  Drugs Today</i><b>2000</b>, <i>36</i>, 503−514.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2000&pages=514&author=O.+Iqbal&author=J.+M.+Walenga&author=B.+E.+Lewis&author=M+Bakhos&title=Bleeding+Complications+with+Glycoprotein+IIb%2FIIIa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DO.%26atitle%3DBleeding%2520Complications%2520with%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%26jtitle%3DDrugs%2520Today%26date%3D2000%26volume%3D36%26spage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00012_6"><span><span class="NLM_string-ref">(f) Billheimer, J. T.; He, B.; Spitz, S. M.; Stern, A. M.; Seiffert, D. Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Activation:  Development of a Transfer Method to Mimic Peak to Trough Receptor Occupancy. <i>  Thromb. Res.</i><b>2002</b>, <i>107 (6)</i>, 303−317.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2002&pages=317&issue=6&author=J.+T.+Billheimer&author=B.+He&author=S.+M.+Spitz&author=A.+M.+Stern&author=D+Seiffert&title=Effects+of+Glycoprotein+IIb%2FIIIa+Antagonists+on+Platelet+Activation%3A%E2%80%89+Development+of+a+Transfer+Method+to+Mimic+Peak+to+Trough+Receptor+Occupancy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBillheimer%26aufirst%3DJ.%2BT.%26atitle%3DEffects%2520of%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%2520on%2520Platelet%2520Activation%253A%25E2%2580%2589%2520Development%2520of%2520a%2520Transfer%2520Method%2520to%2520Mimic%2520Peak%2520to%2520Trough%2520Receptor%2520Occupancy%26jtitle%3DThromb.%2520Res.%26date%3D2002%26volume%3D107%26issue%3D6%26spage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00013"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00013'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="jm030354bb00013_1"><span><span class="NLM_string-ref">(a) Salam, A. M.; Al Suwaidi, J. Platelet Glycoprotein IIb/IIIa Antagonists in Clinical Trials for the Treatment of Coronary Artery Disease. <i>  Exp. Opin. </i><i>Invest. Drugs </i><b>2002</b>, <i>11</i>, 1645−1658.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1658&author=A.+M.+Salam&author=J+Al+Suwaidi&title=Platelet+Glycoprotein+IIb%2FIIIa+Antagonists+in+Clinical+Trials+for+the+Treatment+of+Coronary+Artery+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00013_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalam%26aufirst%3DA.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%2520in%2520Clinical%2520Trials%2520for%2520the%2520Treatment%2520of%2520Coronary%2520Artery%2520Disease%26jtitle%3DExp.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00013_2"><span><span class="NLM_string-ref">(b) Peter, K.; Straub, A.; Kohler, B.; Volkmann, M.; Schwarz, M.; Kubler, W.; Bode, C. Platelet Activation as a Potential Mechanism of GP IIb/IIIa Inhibitor-Induced Thrombocytopenia. <i>  Am. J. Cardiol</i>. <b>1999</b>, <i>84</i>, 519−524.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1999&pages=524&author=K.+Peter&author=A.+Straub&author=B.+Kohler&author=M.+Volkmann&author=M.+Schwarz&author=W.+Kubler&author=C+Bode&title=Platelet+Activation+as+a+Potential+Mechanism+of+GP+IIb%2FIIIa+Inhibitor-Induced+Thrombocytopenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00013_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DPlatelet%2520Activation%2520as%2520a%2520Potential%2520Mechanism%2520of%2520GP%2520IIb%252FIIIa%2520Inhibitor-Induced%2520Thrombocytopenia%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1999%26volume%3D84%26spage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00014"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00014'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="jm030354bb00014_1"><span><span class="NLM_string-ref">(a) Hosking, M. P.; Carroll, R. C. Roxifiban, DuPont. <i>  Curr. Opin. Cardiovasc. </i><i>Pulm. Renal Invest. Drugs </i><b>2000</b>, <i>2</i>, 165−171.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28a%29+Hosking%2C+M.+P.%3B+Carroll%2C+R.+C.+Roxifiban%2C+DuPont.+Curr.+Opin.+Cardiovasc.+Pulm.+Renal+Invest.+Drugs+2000%2C+2%2C+165%E2%88%92171.+%28a%29+Hosking%2C+M.+P.%3B+Carroll%2C+R.+C.+Roxifiban%2C+DuPont.+Curr.+Opin.+Cardiovasc.+Pulm.+Renal+Invest.+Drugs+2000%2C+2%2C+165%E2%88%92171."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHosking%26aufirst%3DM.%2BP.%26jtitle%3DCurr.%2520Opin.%2520Cardiovasc.%2520Pulm.%2520Renal%2520Invest.%2520Drugs%26date%3D2000%26volume%3D2%26spage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00014_2"><span><span class="NLM_string-ref">(b) Mousa, S. A.; Bozarth, J. M.; Naik, U. P.; Slee, A. Platelet GPIIb/IIIa Binding Characteristics of Small Molecule RGD Mimetic:  Distinct Binding Profile for Roxifiban. <i>  Br. </i><i>J. Pharmacol.</i><b>2001</b>, <i>133</i>, 331−336.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Mousa%2C+S.+A.%3B+Bozarth%2C+J.+M.%3B+Naik%2C+U.+P.%3B+Slee%2C+A.+Platelet+GPIIb%2FIIIa+Binding+Characteristics+of+Small+Molecule+RGD+Mimetic%3A%E2%80%89+Distinct+Binding+Profile+for+Roxifiban.+Br.+J.+Pharmacol.+2001%2C+133%2C+331%E2%88%92336.+%28b%29+Mousa%2C+S.+A.%3B+Bozarth%2C+J.+M.%3B+Naik%2C+U.+P.%3B+Slee%2C+A.+Platelet+GPIIb%2FIIIa+Binding+Characteristics+of+Small+Molecule+RGD+Mimetic%3A%E2%80%89+Distinct+Binding+Profile+for+Roxifiban.+Br.+J.+Pharmacol.2001%2C+133%2C+331%E2%88%92336."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D133%26spage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00014_3"><span><span class="NLM_string-ref">(c) Mousa, S. A.; Kapil, R.; Mu, D. Intravenous and Oral Antithrombotic Efficacy of the Novel Platelet GPIIb/IIIa Antagonist Roxifiban (DMP754) and its Free Acid Form, XV459. <i>  Arterioscler. Thromb. Vasc. Biol. </i><b>1999</b>, <i>19</i>, 2535−2541.  2060  (d) Gurbel, P. A.; McKenzie, M. E.; Serebruany, V. L. Initial Platelet Activity may Predict Efficacy after Chronic Oral Glycoprotein IIb/IIIa Blockade:  Should We Still Consider Uniform Treatment Regimens? <i>Thromb. Res.</i><b>2000</b>, <i>99</i>, 105−107.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2541&author=S.+A.+Mousa&author=R.+Kapil&author=D+Mu&title=Intravenous+and+Oral+Antithrombotic+Efficacy+of+the+Novel+Platelet+GPIIb%2FIIIa+Antagonist+Roxifiban+%28DMP754%29+and+its+Free+Acid+Form%2C+XV459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DIntravenous%2520and%2520Oral%2520Antithrombotic%2520Efficacy%2520of%2520the%2520Novel%2520Platelet%2520GPIIb%252FIIIa%2520Antagonist%2520Roxifiban%2520%2528DMP754%2529%2520and%2520its%2520Free%2520Acid%2520Form%252C%2520XV459%26jtitle%3DArterioscler.%2520Thromb.%2520Vasc.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00014_4"><span><span class="NLM_string-ref">(e) Fossler, M. J.; Ebling, W. F.; Ma, S.; Kornhauser, D.; Mondick, J.; Barrett, J. S.; Garner, D.; Quon, C. Y.; Pieniaszek, H. J., Jr. Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers. <i>  J. Clin. </i><i>Pharmacol.</i><b>2002</b>,<i> 42</i>, 1326−1334.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28e%29+Fossler%2C+M.+J.%3B+Ebling%2C+W.+F.%3B+Ma%2C+S.%3B+Kornhauser%2C+D.%3B+Mondick%2C+J.%3B+Barrett%2C+J.+S.%3B+Garner%2C+D.%3B+Quon%2C+C.+Y.%3B+Pieniaszek%2C+H.+J.%2C+Jr.+Integrated+Pharmacokinetic%2FPharmacodynamic+Model+of+XV459%2C+a+Potent+and+Specific+GPIIb%2FIIIa+Inhibitor%2C+in+Healthy+Male+Volunteers.+J.+Clin.+Pharmacol.+2002%2C+42%2C+1326%E2%88%921334.+%28e%29+Fossler%2C+M.+J.%3B+Ebling%2C+W.+F.%3B+Ma%2C+S.%3B+Kornhauser%2C+D.%3B+Mondick%2C+J.%3B+Barrett%2C+J.+S.%3B+Garner%2C+D.%3B+Quon%2C+C.+Y.%3B+Pieniaszek%2C+H.+J.%2C+Jr.+Integrated+Pharmacokinetic%2FPharmacodynamic+Model+of+XV459%2C+a+Potent+and+Specific+GPIIb%2FIIIa+Inhibitor%2C+in+Healthy+Male+Volunteers.+J.+Clin.+Pharmacol.2002%2C+42%2C+1326%E2%88%921334."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFossler%26aufirst%3DM.%2BJ.%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D42%26spage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00015"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00015'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="jm030354bb00015_1"><span><span class="NLM_string-ref">(a) Smyth, M. S.; Rose, J.; Mehrotra, M. M.; Heath, J.; Ruhter, G.; Schotten, T.; Seroogy, J.; Volkots, D.; Pandey, A.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 1:  Design of Potent and Specific 3,9-Diazaspiro[5.5]undecanes. <i>  Bioorg. Med. Chem. Lett.</i><b>2001</b>, <i>11</i>, 1289−1292.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1292&author=M.+S.+Smyth&author=J.+Rose&author=M.+M.+Mehrotra&author=J.+Heath&author=G.+Ruhter&author=T.+Schotten&author=J.+Seroogy&author=D.+Volkots&author=A.+Pandey&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+1%3A%E2%80%89+Design+of+Potent+and+Specific+3%2C9-Diazaspiro%5B5.5%5Dundecanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25201%253A%25E2%2580%2589%2520Design%2520of%2520Potent%2520and%2520Specific%25203%252C9-Diazaspiro%255B5.5%255Dundecanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00015_2"><span><span class="NLM_string-ref">(b) Pandey, A.; Seroogy, J.; Volkots, D.; Smyth, M. S.; Rose, J.; Mehrotra, M. M.; Heath, J.; Ruhter, G.; Schotten, T.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 2:  Design of Potent Antagonists Containing the 3-Azaspiro[5.5]undec-9-yl Template. <i>  Bioorg. Med. Chem. Lett.</i><b>2001</b>, <i>11</i>, 1293−1296.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1296&author=A.+Pandey&author=J.+Seroogy&author=D.+Volkots&author=M.+S.+Smyth&author=J.+Rose&author=M.+M.+Mehrotra&author=J.+Heath&author=G.+Ruhter&author=T.+Schotten&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+2%3A%E2%80%89+Design+of+Potent+Antagonists+Containing+the+3-Azaspiro%5B5.5%5Dundec-9-yl+Template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25202%253A%25E2%2580%2589%2520Design%2520of%2520Potent%2520Antagonists%2520Containing%2520the%25203-Azaspiro%255B5.5%255Dundec-9-yl%2520Template%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00015_3"><span><span class="NLM_string-ref">(c) Mehrotra, M. M.; Heath, J.; Rose, J.; Smyth, M. S.; Seroogy, J.; Volkots, D.; Ruhter, G.; Schotten, T.; Alaimo, L.; Park, G.; Pandey, A.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3:  Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes. <i>  Bioorg. Med. Chem. Lett.</i><b>2002</b>, <i>12</i>, 1103−1107.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1107&author=M.+M.+Mehrotra&author=J.+Heath&author=J.+Rose&author=M.+S.+Smyth&author=J.+Seroogy&author=D.+Volkots&author=G.+Ruhter&author=T.+Schotten&author=L.+Alaimo&author=G.+Park&author=A.+Pandey&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+3%3A%E2%80%89+Synthesis+and+SAR+of+Potent+and+Specific+2%2C8-Diazaspiro%5B4.5%5Ddecanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMehrotra%26aufirst%3DM.%2BM.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25203%253A%25E2%2580%2589%2520Synthesis%2520and%2520SAR%2520of%2520Potent%2520and%2520Specific%25202%252C8-Diazaspiro%255B4.5%255Ddecanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00015_4"><span><span class="NLM_string-ref">(d) Fisher, M. J.; Jakubowski, J. A.; Masters, J. J.; Mullaney, J. T.; Ruterbories, K. J.; Paal, M.; Ruhter, G.; Scarborough, R. M.; Schotten, T.; Stenzel, W. Spiro Compounds as Inhibitors of Fibrinogen-Dependent Platelet Aggregation. U.S. Patent 6291469, 2001.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+J.+Fisher&author=J.+A.+Jakubowski&author=J.+J.+Masters&author=J.+T.+Mullaney&author=K.+J.+Ruterbories&author=M.+Paal&author=G.+Ruhter&author=R.+M.+Scarborough&author=T.+Schotten&author=W.+Stenzel&title=Spiro+Compounds+as+Inhibitors+of+Fibrinogen-Dependent+Platelet+Aggregation.+U.S.+Patent+6291469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26btitle%3DSpiro%2520Compounds%2520as%2520Inhibitors%2520of%2520Fibrinogen-Dependent%2520Platelet%2520Aggregation.%2520U.S.%2520Patent%25206291469%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00016"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00016'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="jm030354bb00016_1"><span><span class="NLM_string-ref">(a) Wagner, G.; Voigt, B.; Vieweg, H. Synthesis of N-α-(Arylsulfonylglycyl) amidinophenylalaninamides as Highly Active Inhibitors of Thrombin. <i>  Pharmazie</i><b>1984</b>, <i>39</i>, 226−230.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1984&pages=230&author=G.+Wagner&author=B.+Voigt&author=H+Vieweg&title=Synthesis+of+N-%CE%B1-%28Arylsulfonylglycyl%29+amidinophenylalaninamides+as+Highly+Active+Inhibitors+of+Thrombin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00016_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520N-%25CE%25B1-%2528Arylsulfonylglycyl%2529%2520amidinophenylalaninamides%2520as%2520Highly%2520Active%2520Inhibitors%2520of%2520Thrombin%26jtitle%3DPharmazie%26date%3D1984%26volume%3D39%26spage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00016_2"><span><span class="NLM_string-ref">(b) Judkins, B. D.; Allen, D. G.; Cook, T. A.; Evans, B.; Sardharwala, T. E. A Versatile Synthesis of Amidines from Nitriles Via Amidoximes. <i>  Synth. Commun.</i><b>1996</b>, <i>26(23)</i>, 4351−4367.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=4367&issue=23&author=B.+D.+Judkins&author=D.+G.+Allen&author=T.+A.+Cook&author=B.+Evans&author=T.+E+Sardharwala&title=A+Versatile+Synthesis+of+Amidines+from+Nitriles+Via+Amidoximes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00016_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJudkins%26aufirst%3DB.%2BD.%26atitle%3DA%2520Versatile%2520Synthesis%2520of%2520Amidines%2520from%2520Nitriles%2520Via%2520Amidoximes%26jtitle%3DSynth.%2520Commun.%26date%3D1996%26volume%3D26%26issue%3D23%26spage%3D4367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00017"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00017'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="jm030354bb00017_1"><span><span class="NLM_string-ref">(a) Rawal, V. H.; Jones, R. J.; Cava, M. P. Photocyclization Strategy for the Synthesis of Antitumor Agent CC-1065:  Synthesis of Dideoxy PDE-I and PDE-II. Synthesis of Thiopene and Furan Analogues of Dideoxy PDE-I and PDE-II. <i>  J. Org. Chem.</i><b>1987</b>, <i>52</i>, 19−28.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1987&pages=28&author=V.+H.+Rawal&author=R.+J.+Jones&author=M.+P+Cava&title=Photocyclization+Strategy+for+the+Synthesis+of+Antitumor+Agent+CC-1065%3A%E2%80%89+Synthesis+of+Dideoxy+PDE-I+and+PDE-II.+Synthesis+of+Thiopene+and+Furan+Analogues+of+Dideoxy+PDE-I+and+PDE-II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00017_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRawal%26aufirst%3DV.%2BH.%26atitle%3DPhotocyclization%2520Strategy%2520for%2520the%2520Synthesis%2520of%2520Antitumor%2520Agent%2520CC-1065%253A%25E2%2580%2589%2520Synthesis%2520of%2520Dideoxy%2520PDE-I%2520and%2520PDE-II.%2520Synthesis%2520of%2520Thiopene%2520and%2520Furan%2520Analogues%2520of%2520Dideoxy%2520PDE-I%2520and%2520PDE-II%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1987%26volume%3D52%26spage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00017_2"><span><span class="NLM_string-ref">(b) Reinecke, M. G.; Daubert, R. G. Periphral Synthesis of Secondary Medium-Ring Nitrogen Heterocycles. <i>  J. Org. Chem.</i><b>1973</b>, <i>38</i>, 3281−3287.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1973&pages=3287&author=M.+G.+Reinecke&author=R.+G+Daubert&title=Periphral+Synthesis+of+Secondary+Medium-Ring+Nitrogen+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00017_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%2BG.%26atitle%3DPeriphral%2520Synthesis%2520of%2520Secondary%2520Medium-Ring%2520Nitrogen%2520Heterocycles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1973%26volume%3D38%26spage%3D3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00018"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00018'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="jm030354bb00018_1"><span><span class="NLM_string-ref">Dong, Q.; Anderson, C. E.; Ciufolini, M. A. Reductive Cleavage of TROC Groups under Neutral Conditions with Cadmium−Lead Couple. <i>  Tetrahedron Lett</i>. <b>1995</b>, 5681−5682.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5681&publication_year=1995&pages=5682&author=Q.+Dong&author=C.+E.+Anderson&author=M.+A+Ciufolini&title=Reductive+Cleavage+of+TROC+Groups+under+Neutral+Conditions+with+Cadmium%E2%88%92Lead+Couple"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00018_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DQ.%26atitle%3DReductive%2520Cleavage%2520of%2520TROC%2520Groups%2520under%2520Neutral%2520Conditions%2520with%2520Cadmium%25E2%2588%2592Lead%2520Couple%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D5681%26spage%3D5682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00019"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00019'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="jm030354bb00019_1"><span><span class="NLM_string-ref">(a) Carrera, G. M., Jr.; Garvey, D. S. Synthesis of Novel Substituted Spirohydantoins. <i>  J. Heterocycl. Chem.</i><b>1992</b>, <i>29</i>, 847−850.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1992&pages=850&author=G.+M.+Carrera&author=+Jr&title=Synthesis+of+Novel+Substituted+Spirohydantoins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00019_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520Novel%2520Substituted%2520Spirohydantoins%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1992%26volume%3D29%26spage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00019_2"><span><span class="NLM_string-ref">(b) Suess, R. Substituierte 2,8-Diazaspiro-decan-1,3-dione. <i>  Helv. Chim. </i><i>Acta</i><b>1977</b>, <i>60(5)</i>, 1650−1656; & Jucker, E.; Sue, R. <i>Arch. Pharm</i>. <b>1961</b>, <i>294</i>, 210−220.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Suess%2C+R.+Substituierte+2%2C8-Diazaspiro-decan-1%2C3-dione.+Helv.+Chim.+Acta+1977%2C+60%285%29%2C+1650%E2%88%921656%3B+%26+Jucker%2C+E.%3B+Sue%2C+R.+Arch.+Pharm.+1961%2C+294%2C+210%E2%88%92220.+%28b%29+Suess%2C+R.+Substituierte+2%2C8-Diazaspiro-decan-1%2C3-dione.+Helv.+Chim.+Acta1977%2C+60%285%29%2C+1650%E2%88%921656%3B+%26+Jucker%2C+E.%3B+Sue%2C+R.+Arch.+Pharm.+1961%2C+294%2C+210%E2%88%92220."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00019_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuess%26aufirst%3DR.%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1977%26volume%3D60%26issue%3D5%26spage%3D1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00020"><div class="reference"><div class="NLM_citation" id="jm030354bb00020_1"><span><span class="NLM_string-ref">Fisher, M. J.; Gunn, B.; Harms, C. S.; Kline, A. D.; Mullaney, J. T.; Nunes, A.; Scarborough, R. M.; Arfsten, A. E.; Skelton, M. A.; Um, S. L.; Utterback, B. G.; Jakubowski, J. A. Non-Peptide RGD Surrogates which Mimic a Gly-Asp β-Turn:  Potent Antagonists of Platelet Glycoprotein IIb-IIIa. <i>  J. </i><i>Med. Chem</i>. <b>1997</b>, <i>40</i>, 2085−2101.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2101&author=M.+J.+Fisher&author=B.+Gunn&author=C.+S.+Harms&author=A.+D.+Kline&author=J.+T.+Mullaney&author=A.+Nunes&author=R.+M.+Scarborough&author=A.+E.+Arfsten&author=M.+A.+Skelton&author=S.+L.+Um&author=B.+G.+Utterback&author=J.+A+Jakubowski&title=Non-Peptide+RGD+Surrogates+which+Mimic+a+Gly-Asp+%CE%B2-Turn%3A%E2%80%89+Potent+Antagonists+of+Platelet+Glycoprotein+IIb-IIIa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00020_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26atitle%3DNon-Peptide%2520RGD%2520Surrogates%2520which%2520Mimic%2520a%2520Gly-Asp%2520%25CE%25B2-Turn%253A%25E2%2580%2589%2520Potent%2520Antagonists%2520of%2520Platelet%2520Glycoprotein%2520IIb-IIIa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00021"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00021'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="jm030354bb00021_1"><span><span class="NLM_string-ref">Su, T.; Naughton, M. A.; Smyth, M. S.; Rose, J. W.; Arfsten, A. E.; McCowan, J. R.; Jakubowski, J. A.; Wyss, V. L.; Ruterbories, K. J.; Sall, D. J.; Scarborough, R. M. Fibrinogen Receptor (GPIIb/IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-α-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors. <i>  J. Med. Chem.</i><b>1997</b>, <i>40</i>, 4308−4318.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Su%2C+T.%3B+Naughton%2C+M.+A.%3B+Smyth%2C+M.+S.%3B+Rose%2C+J.+W.%3B+Arfsten%2C+A.+E.%3B+McCowan%2C+J.+R.%3B+Jakubowski%2C+J.+A.%3B+Wyss%2C+V.+L.%3B+Ruterbories%2C+K.+J.%3B+Sall%2C+D.+J.%3B+Scarborough%2C+R.+M.+Fibrinogen+Receptor+%28GPIIb%2FIIIa%29+Antagonists+Derived+from+5%2C6-Bicyclic+Templates.+Amidinoindoles%2C+Amidinoindazoles%2C+and+Amidinobenzofurans+Containing+the+N-%CE%B1-Sulfonamide+Carboxylic+Acid+Function+as+Potent+Platelet+Aggregation+Inhibitors.+J.+Med.+Chem.+1997%2C+40%2C+4308%E2%88%924318.+Su%2C+T.%3B+Naughton%2C+M.+A.%3B+Smyth%2C+M.+S.%3B+Rose%2C+J.+W.%3B+Arfsten%2C+A.+E.%3B+McCowan%2C+J.+R.%3B+Jakubowski%2C+J.+A.%3B+Wyss%2C+V.+L.%3B+Ruterbories%2C+K.+J.%3B+Sall%2C+D.+J.%3B+Scarborough%2C+R.+M.+Fibrinogen+Receptor+%28GPIIb%2FIIIa%29+Antagonists+Derived+from+5%2C6-Bicyclic+Templates.+Amidinoindoles%2C+Amidinoindazoles%2C+and+Amidinobenzofurans+Containing+the+N-%CE%B1-Sulfonamide+Carboxylic+Acid+Function+as+Potent+Platelet+Aggregation+Inhibitors.+J.+Med.+Chem.1997%2C+40%2C+4308%E2%88%924318."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00021_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00022"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00022'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="jm030354bb00022_1"><span><span class="NLM_string-ref">(a) Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. <i>  J. Med. Chem.</i><b>1992</b>, <i>35</i>, 4640−4642.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4642&author=G.+D.+Hartman&author=M.+S.+Egbertson&author=W.+Halczenko&author=W.+L.+Laswell&author=M.+E.+Duggan&author=R.+L.+Smith&author=A.+M.+Naylor&author=P.+D.+Manno&author=R.+J.+Lynch&author=G.+Zhang&author=C.+T.-C.+Chang&author=R.+J+Gould&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+1.+Discovery+and+Design+of+Exosite+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25201.%2520Discovery%2520and%2520Design%2520of%2520Exosite%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00022_2"><span><span class="NLM_string-ref">(b) Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, Jr. J. J.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp. <i>  J. Med. Chem.</i><b>1994</b>, <i>37</i>, 2537−2551.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2551&author=M.+S.+Egbertson&author=C.+T.-C.+Chang&author=M.+E.+Duggan&author=R.+J.+Gould&author=W.+Halczenko&author=G.+D.+Hartman&author=W.+L.+Laswell&author=Jr.+J.+J.+Lynch&author=R.+J.+Lynch&author=P.+D.+Manno&author=A.+M.+Naylor&author=J.+D.+Prugh&author=D.+R.+Ramjit&author=G.+R.+Sitko&author=R.+S.+Smith&author=L.+M.+Turchi&author=G+Zhang&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+2.+Optimization+of+a+Tyrosine+Template+as+a+Mimic+for+Arg-Gly-Asp"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25202.%2520Optimization%2520of%2520a%2520Tyrosine%2520Template%2520as%2520a%2520Mimic%2520for%2520Arg-Gly-Asp%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00022_3"><span><span class="NLM_string-ref">(c) Xue, C.-B.; Roderick, J.; Jackson, S.; Rafalski, M.; Rockwell, A.; Mousa, S.; Olson. R. E.; DeGrado, W. F. Design, Synthesis, and in Vitro Activities of Benzamide-Core Glycoprotein IIb-IIIa Antagonists:  2,3-Diaminopropionic Acid Derivatives as Surrogates of Aspartic Acid. <i>  Bioorg. Med. Chem. </i><b>1997</b>, <i>5</i>, 693−705.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28c%29+Xue%2C+C.-B.%3B+Roderick%2C+J.%3B+Jackson%2C+S.%3B+Rafalski%2C+M.%3B+Rockwell%2C+A.%3B+Mousa%2C+S.%3B+Olson.+R.+E.%3B+DeGrado%2C+W.+F.+Design%2C+Synthesis%2C+and+in+Vitro+Activities+of+Benzamide-Core+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+2%2C3-Diaminopropionic+Acid+Derivatives+as+Surrogates+of+Aspartic+Acid.+Bioorg.+Med.+Chem.+1997%2C+5%2C+693%E2%88%92705.+%28c%29+Xue%2C+C.-B.%3B+Roderick%2C+J.%3B+Jackson%2C+S.%3B+Rafalski%2C+M.%3B+Rockwell%2C+A.%3B+Mousa%2C+S.%3B+Olson.+R.+E.%3B+DeGrado%2C+W.+F.+Design%2C+Synthesis%2C+and+in+Vitro+Activities+of+Benzamide-Core+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+2%2C3-Diaminopropionic+Acid+Derivatives+as+Surrogates+of+Aspartic+Acid.+Bioorg.+Med.+Chem.+1997%2C+5%2C+693%E2%88%92705."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.-B.%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26spage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00023"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00023'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="jm030354bb00023_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Rose, J. W.; Naughton, M. A.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Characterization of the Integrin Specificities of Disintegrins Isolated from American Pit Vipor Venoms. <i>  J. </i><i>Biol. Chem</i>. <b>1993</b>, <i>268</i>, 1058−1065.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=1065&author=R.+M.+Scarborough&author=J.+W.+Rose&author=M.+A.+Naughton&author=D.+R.+Phillips&author=L.+Nannizzi&author=A.+Arfsten&author=A.+M.+Campbell&author=I.+F+Charo&title=Characterization+of+the+Integrin+Specificities+of+Disintegrins+Isolated+from+American+Pit+Vipor+Venoms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00023_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520Integrin%2520Specificities%2520of%2520Disintegrins%2520Isolated%2520from%2520American%2520Pit%2520Vipor%2520Venoms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00023_2"><span><span class="NLM_string-ref">(b) Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. <i>  J. Med. Chem.</i><b>1995</b>, <i>38</i>, 3332−3341.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3341&author=M.+E.+Duggan&author=A.+M.+Naylor-Olsen&author=J.+J.+Perkins&author=P.+S.+Anderson&author=C.+T.-C.+Chang&author=J.+J.+Cook&author=R.+J.+Gould&author=N.+C.+Ihle&author=G.+D.+Hartman&author=J.+J.+Lynch&author=R.+J.+Lynch&author=P.+D.+Manno&author=L.+W.+Schaffer&author=R.+L+Smith&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+7.+Design+and+Synthesis+of+a+Potent%2C+Orally+Active+Fibrinogen+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00023_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25207.%2520Design%2520and%2520Synthesis%2520of%2520a%2520Potent%252C%2520Orally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00024"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00024'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="jm030354bb00024_1"><span><span class="NLM_string-ref">Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in vitro and in vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. <i>  J. Med. </i><i>Chem</i>. <b>1995</b>, <i>38</i>, 2378−2394.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=2394&author=J.+A.+Zablocki&author=J.+G.+Rico&author=R.+B.+Garland&author=T.+E.+Rogers&author=K.+Williams&author=L.+A.+Schretzman&author=S.+A.+Rao&author=P.+R.+Bovy&author=F.+S.+Tjoeng&author=R.+J.+Lindmark&author=M.+V.+Toth&author=M.+E.+Zupec&author=D.+E.+McMackins&author=S.+P.+Adams&author=M.+Miyano&author=C.+S.+Markos&author=M.+N.+Milton&author=S.+Paulson&author=M.+Herin&author=P.+Jacqmin&author=N.+S.+Nicholson&author=S.+G.+Panzer-Knodle&author=N.+F.+Haas&author=J.+D.+Page&author=J.+A.+Szalony&author=B.+B.+Taite&author=A.+K.+Salyers&author=L.+W.+King&author=J.+G.+Campion&author=L.+P+Feigen&title=Potent+in+vitro+and+in+vivo+Inhibitors+of+Platelet+Aggregation+Based+upon+the+Arg-Gly-Asp+Sequence+of+Fibrinogen.+%28Aminobenzamidino%29succinyl+%28ABAS%29+Series+of+Orally+Active+Fibrinogen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00024_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZablocki%26aufirst%3DJ.%2BA.%26atitle%3DPotent%2520in%2520vitro%2520and%2520in%2520vivo%2520Inhibitors%2520of%2520Platelet%2520Aggregation%2520Based%2520upon%2520the%2520Arg-Gly-Asp%2520Sequence%2520of%2520Fibrinogen.%2520%2528Aminobenzamidino%2529succinyl%2520%2528ABAS%2529%2520Series%2520of%2520Orally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D2394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00025"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00025'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="jm030354bb00025_1"><span><span class="NLM_string-ref">Mills, S. D. Heterocyclic Compounds. U.S. Patent 5,753,659, 1998.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=S.+D.+Mills&author=U.S.+Heterocyclic+Compounds&title=Patent+5%2C753%2C659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00025_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DS.%2BD.%26btitle%3DPatent%25205%252C753%252C659%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00026"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00026'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="jm030354bb00026_1"><span><span class="NLM_string-ref">Samanen, J. M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.; Burgess, J. L.; Callahen, J. F.; Calvo, R. R.; Chen, W.; Chen, L.; Erhard, K.; Feuarstein, G.; Heys, R.; Hwang, S.-M.; Jckas, D. R.; Keenan, R. M.; Ku, T. W.; Kwon, C.; Lee, C.-P.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzsinskas, I.; Vensalavsky, J. W.; Yuan, C.-K.; Huffman, W. F. Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb-IIIa Integrin Antagonists. <i>  J. Med. Chem.</i><b>1996</b>, <i>39</i>, 4867−4870.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Samanen%2C+J.+M.%3B+Ali%2C+F.+E.%3B+Barton%2C+L.+S.%3B+Bondinell%2C+W.+E.%3B+Burgess%2C+J.+L.%3B+Callahen%2C+J.+F.%3B+Calvo%2C+R.+R.%3B+Chen%2C+W.%3B+Chen%2C+L.%3B+Erhard%2C+K.%3B+Feuarstein%2C+G.%3B+Heys%2C+R.%3B+Hwang%2C+S.-M.%3B+Jckas%2C+D.+R.%3B+Keenan%2C+R.+M.%3B+Ku%2C+T.+W.%3B+Kwon%2C+C.%3B+Lee%2C+C.-P.%3B+Miller%2C+W.+H.%3B+Newlander%2C+K.+A.%3B+Nichols%2C+A.%3B+Parker%2C+M.%3B+Peishoff%2C+C.+E.%3B+Rhodes%2C+G.%3B+Ross%2C+S.%3B+Shu%2C+A.%3B+Simpson%2C+R.%3B+Takata%2C+D.%3B+Yellin%2C+T.+O.%3B+Uzsinskas%2C+I.%3B+Vensalavsky%2C+J.+W.%3B+Yuan%2C+C.-K.%3B+Huffman%2C+W.+F.+Potent%2C+Selective%2C+Orally+Active+3-Oxo-1%2C4-benzodiazepine+GPIIb-IIIa+Integrin+Antagonists.+J.+Med.+Chem.+1996%2C+39%2C+4867%E2%88%924870.+Samanen%2C+J.+M.%3B+Ali%2C+F.+E.%3B+Barton%2C+L.+S.%3B+Bondinell%2C+W.+E.%3B+Burgess%2C+J.+L.%3B+Callahen%2C+J.+F.%3B+Calvo%2C+R.+R.%3B+Chen%2C+W.%3B+Chen%2C+L.%3B+Erhard%2C+K.%3B+Feuarstein%2C+G.%3B+Heys%2C+R.%3B+Hwang%2C+S.-M.%3B+Jckas%2C+D.+R.%3B+Keenan%2C+R.+M.%3B+Ku%2C+T.+W.%3B+Kwon%2C+C.%3B+Lee%2C+C.-P.%3B+Miller%2C+W.+H.%3B+Newlander%2C+K.+A.%3B+Nichols%2C+A.%3B+Parker%2C+M.%3B+Peishoff%2C+C.+E.%3B+Rhodes%2C+G.%3B+Ross%2C+S.%3B+Shu%2C+A.%3B+Simpson%2C+R.%3B+Takata%2C+D.%3B+Yellin%2C+T.+O.%3B+Uzsinskas%2C+I.%3B+Vensalavsky%2C+J.+W.%3B+Yuan%2C+C.-K.%3B+Huffman%2C+W.+F.+Potent%2C+Selective%2C+Orally+Active+3-Oxo-1%2C4-benzodiazepine+GPIIb-IIIa+Integrin+Antagonists.+J.+Med.+Chem.1996%2C+39%2C+4867%E2%88%924870."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00026_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamanen%26aufirst%3DJ.%2BM.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D4870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00027"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00027'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="jm030354bb00027_1"><span><span class="NLM_string-ref">Damiano, B. P.; Mitchell, J. A.; Giardino, E.; Corcoran, T.; Haertlein, B. J.; De Garavilla, L.; Kauffman, J. A.; Hoekstra, W. J.; Maryanoff, B. E.; Andrade-Gordon, P. Antiplatelet and Antithrombotic Activity of RWJ-53308, a Novel Orally Active Glycoprotein IIb/IIIa Antagonist. <i>  Thromb. Res.</i><b>2001</b>,<i> 104</i>, 113−126.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=126&author=B.+P.+Damiano&author=J.+A.+Mitchell&author=E.+Giardino&author=T.+Corcoran&author=B.+J.+Haertlein&author=L.+De+Garavilla&author=J.+A.+Kauffman&author=W.+J.+Hoekstra&author=B.+E.+Maryanoff&author=P+Andrade-Gordon&title=Antiplatelet+and+Antithrombotic+Activity+of+RWJ-53308%2C+a+Novel+Orally+Active+Glycoprotein+IIb%2FIIIa+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00027_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26atitle%3DAntiplatelet%2520and%2520Antithrombotic%2520Activity%2520of%2520RWJ-53308%252C%2520a%2520Novel%2520Orally%2520Active%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonist%26jtitle%3DThromb.%2520Res.%26date%3D2001%26volume%3D104%26spage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00028"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00028'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="jm030354bb00028_1"><span><span class="NLM_string-ref">(a) Hayashi, Y.; Katada, J.; Harada, T.; Tachki, A.; Iijima, K.; Takiguchi, Y.; Muramatsu, M.; Miyazaki, H.; Asari, T.; Okazaki, T.; Sato, Y.; Yasuda, E.; Yano, M.; Uno, I.; Ojima, I. GPIIb-IIIa Integrin Antagonists with the New Conformational Restriction Unit, Trisubstituted β-Amino Acid Derivatives, and a Substituted Benzamidine Structure. <i>  J. Med. Chem.</i><b>1998</b>, <i>41</i>, 2345−2360.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2360&author=Y.+Hayashi&author=J.+Katada&author=T.+Harada&author=A.+Tachki&author=K.+Iijima&author=Y.+Takiguchi&author=M.+Muramatsu&author=H.+Miyazaki&author=T.+Asari&author=T.+Okazaki&author=Y.+Sato&author=E.+Yasuda&author=M.+Yano&author=I.+Uno&author=I+Ojima&title=GPIIb-IIIa+Integrin+Antagonists+with+the+New+Conformational+Restriction+Unit%2C+Trisubstituted+%CE%B2-Amino+Acid+Derivatives%2C+and+a+Substituted+Benzamidine+Structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DGPIIb-IIIa%2520Integrin%2520Antagonists%2520with%2520the%2520New%2520Conformational%2520Restriction%2520Unit%252C%2520Trisubstituted%2520%25CE%25B2-Amino%2520Acid%2520Derivatives%252C%2520and%2520a%2520Substituted%2520Benzamidine%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00028_2"><span><span class="NLM_string-ref">(b) Okumura, K.; Shimazaki, T.; Aoki, Y.; Yamashita, H.; Tanaka, E.; Banba, S.; Yazawa, K.; Kibayashi, K.; Banno, H. New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists:  Orally Active Series of N−Alkylated Amidines with a 6,6-Bicyclic Template.<i> J. Med. </i><i>Chem.</i><b>1998</b>, <i>41</i>, 4036−4052.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4052&author=K.+Okumura&author=T.+Shimazaki&author=Y.+Aoki&author=H.+Yamashita&author=E.+Tanaka&author=S.+Banba&author=K.+Yazawa&author=K.+Kibayashi&author=H+Banno&title=New+Platelet+Fibrinogen+Receptor+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+Orally+Active+Series+of+N%E2%88%92Alkylated+Amidines+with+a+6%2C6-Bicyclic+Template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DK.%26atitle%3DNew%2520Platelet%2520Fibrinogen%2520Receptor%2520Glycoprotein%2520IIb-IIIa%2520Antagonists%253A%25E2%2580%2589%2520Orally%2520Active%2520Series%2520of%2520N%25E2%2588%2592Alkylated%2520Amidines%2520with%2520a%25206%252C6-Bicyclic%2520Template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00028_3"><span><span class="NLM_string-ref">(c) Yamashita, H.; Okumura, K.; Shimazaki, T.; Kanematsu, A.; Aoki, Y.; Nakajima, Y.; Yazawa, K.; Kibayashi, K. Amidine Derivatives and Platelet Aggregation Inhibitor Containing the Same. European Patent 0760364A2, 1997.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=H.+Yamashita&author=K.+Okumura&author=T.+Shimazaki&author=A.+Kanematsu&author=Y.+Aoki&author=Y.+Nakajima&author=K.+Yazawa&author=K.+Kibayashi&title=Amidine+Derivatives+and+Platelet+Aggregation+Inhibitor+Containing+the+Same.+European+Patent+0760364A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DH.%26btitle%3DAmidine%2520Derivatives%2520and%2520Platelet%2520Aggregation%2520Inhibitor%2520Containing%2520the%2520Same.%2520European%2520Patent%25200760364A2%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00029"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00029'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="jm030354bb00029_1"><span><span class="NLM_string-ref">Muller, T. H.; Schurer, H.; Waldmann, L.; Bauer, E.; Himmelsbach, F.; Binder, K. Oral Activity of BIBU 104, a Prodrug of the Non-Peptide Fibrinogen Receptor Antagonist BIBU 52, in Mice and Monkeys. <i>  Thromb. </i><i>Haemostasis</i><b>1993</b>, <i>69</i>, 975, Abstract 1557.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1993&pages=1557&author=T.+H.+Muller&author=H.+Schurer&author=L.+Waldmann&author=E.+Bauer&author=F.+Himmelsbach&author=K+Binder&title=Oral+Activity+of+BIBU+104%2C+a+Prodrug+of+the+Non-Peptide+Fibrinogen+Receptor+Antagonist+BIBU+52%2C+in+Mice+and+Monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00029_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DT.%2BH.%26atitle%3DOral%2520Activity%2520of%2520BIBU%2520104%252C%2520a%2520Prodrug%2520of%2520the%2520Non-Peptide%2520Fibrinogen%2520Receptor%2520Antagonist%2520BIBU%252052%252C%2520in%2520Mice%2520and%2520Monkeys%26jtitle%3DThromb.%2520Haemostasis%26date%3D1993%26volume%3D69%26spage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00030"><div class="reference"><div class="NLM_citation" id="jm030354bb00030_1"><span><span class="NLM_string-ref">(a) Merlos, M.; Graul, A.; Castaner, J. Sibrafiban <i>Drugs Future</i><b>1998</b>, <i>23</i>, 1297−1303.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=M.+Merlos&author=A.+Graul&author=J.+Castaner&title=Sibrafiban+Drugs+Future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00030_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26btitle%3DSibrafiban%2520Drugs%2520Future%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00030_2"><span><span class="NLM_string-ref">(b) Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines.<i> J. Med. Chem</i>. <b>1996</b>, <i>39</i>, 3139−3147.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3147&author=T.+Weller&author=L.+Alig&author=M.+Beresini&author=B.+Blackburn&author=S.+Bunting&author=P.+Hadvary&author=M.+H.+Muller&author=D.+Knopp&author=B.+Levet-Trafit&author=M.+T.+Lipari&author=N.+B.+Modi&author=M.+Muller&author=C.+J.+Refino&author=M.+Schmitt&author=P.+Schonholzer&author=S.+Weiss&author=B+Steiner&title=Orally+Active+Fibrinogen+Receptor+Antagonists.+2.+Amidoximes+as+Prodrugs+of+Amidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00030_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DOrally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonists.%25202.%2520Amidoximes%2520as%2520Prodrugs%2520of%2520Amidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00031"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00031'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="jm030354bb00031_1"><span><span class="NLM_string-ref">Gante, J.; Juraszyk, H.; Raddatz, P.; Wurziger, H.; Bernotat-Danielowski, S.; Melzer, G.; Rippmann, F. New Antithrombotic RGD-Mimetics with High Bioavailability. <i>  Bioorg. Med. Chem. Lett.</i><b>1996</b>, <i>6 </i>(20), 2425−2430.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2430&issue=20&author=J.+Gante&author=H.+Juraszyk&author=P.+Raddatz&author=H.+Wurziger&author=S.+Bernotat-Danielowski&author=G.+Melzer&author=F+Rippmann&title=New+Antithrombotic+RGD-Mimetics+with+High+Bioavailability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00031_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGante%26aufirst%3DJ.%26atitle%3DNew%2520Antithrombotic%2520RGD-Mimetics%2520with%2520High%2520Bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26issue%3D20%26spage%3D2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00032"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00032'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="jm030354bb00032_1"><span><span class="NLM_string-ref">Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties that Influence the Oral Bioavailability of Drug Candidates. <i>  J. Med. Chem.</i><b>2002</b>, <i>45</i>, 2615−2623.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2623&author=D.+F.+Veber&author=S.+R.+Johnson&author=H.-Y.+Cheng&author=B.+R.+Smith&author=K.+W.+Ward&author=K.+D+Kopple&title=Molecular+Properties+that+Influence+the+Oral+Bioavailability+of+Drug+Candidates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00032_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26atitle%3DMolecular%2520Properties%2520that%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00033"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00033'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="jm030354bb00033_1"><span><span class="NLM_string-ref">(a) Hauptmann, J.; Paintz, M.; Kaiser, B.; Richter, M. Reduction of a Benzamidoxime Derivative to the Corresponding Benzamidine in Vivo and in Vitro. <i>  Pharmazie </i><b>1988</b>, <i>43</i>, 559−560.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1988&pages=560&author=J.+Hauptmann&author=M.+Paintz&author=B.+Kaiser&author=M+Richter&title=Reduction+of+a+Benzamidoxime+Derivative+to+the+Corresponding+Benzamidine+in+Vivo+and+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHauptmann%26aufirst%3DJ.%26atitle%3DReduction%2520of%2520a%2520Benzamidoxime%2520Derivative%2520to%2520the%2520Corresponding%2520Benzamidine%2520in%2520Vivo%2520and%2520in%2520Vitro%26jtitle%3DPharmazie%26date%3D1988%26volume%3D43%26spage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00033_2"><span><span class="NLM_string-ref">(b) Clement, B.; Zimmermann, M.; Schmitt, S. Biotransformation des Benzamidins und des Benzamidoxims durch mikrosomale Enzyme vom Kaninchen. (Biotransformation of Benzamidine and Benzamidoxime by Microsomal Enzymes of the Rabbit.) <i>Arch. Pharm. (Weinheim, Ger.) </i><b>1989</b>, <i>322</i>, 431−435.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=B.+Clement&author=M.+Zimmermann&author=S.+Schmitt&title=Ger.%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DBiotransformation%2520des%2520Benzamidins%2520und%2520des%2520Benzamidoxims%2520durch%2520mikrosomale%2520Enzyme%2520vom%2520Kaninchen.%2520%2528Biotransformation%2520of%2520Benzamidine%2520and%2520Benzamidoxime%2520by%2520Microsomal%2520Enzymes%2520of%2520the%2520Rabbit.%2529%2520Arch.%2520Pharm.%2520%2528Weinheim%26btitle%3DGer.%2529%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00033_3"><span><span class="NLM_string-ref">(c) Clement, B.; Immel, M.; Terlinden, R.; Wingen, F.-J. Reduction of Amidoxime Derivatives to Pentamidine in vivo. <i>  Arch. Pharm. </i><i>(Weinheim, Ger.) </i><b>1992</b>, <i>325</i>, 61−62.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1992&pages=62&author=B.+Clement&author=M.+Immel&author=R.+Terlinden&author=F.-J+Wingen&title=Reduction+of+Amidoxime+Derivatives+to+Pentamidine+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DReduction%2520of%2520Amidoxime%2520Derivatives%2520to%2520Pentamidine%2520in%2520vivo%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D1992%26volume%3D325%26spage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="jm030354bb00033_4"><span><span class="NLM_string-ref">(d) Clement, B.; Jung, F. N−Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P-450 2C3 or Human Liver Microsomes, Microsomal Retroreduction, and Further Oxidative Transformation of the Formed Amidoximes. <i>  Drug Metab. Dispos. </i><b>1994</b>, <i>22</i>, 486-497. 2061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=486-497&author=B.+Clement&author=F+Jung&title=N%E2%88%92Hydroxylation+of+the+Antiprotozoal+Drug+Pentamidine+Catalyzed+by+Rabbit+Liver+Cytochrome+P-450+2C3+or+Human+Liver+Microsomes%2C+Microsomal+Retroreduction%2C+and+Further+Oxidative+Transformation+of+the+Formed+Amidoximes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DN%25E2%2588%2592Hydroxylation%2520of%2520the%2520Antiprotozoal%2520Drug%2520Pentamidine%2520Catalyzed%2520by%2520Rabbit%2520Liver%2520Cytochrome%2520P-450%25202C3%2520or%2520Human%2520Liver%2520Microsomes%252C%2520Microsomal%2520Retroreduction%252C%2520and%2520Further%2520Oxidative%2520Transformation%2520of%2520the%2520Formed%2520Amidoximes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D486%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00034"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00034'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="jm030354bb00034_1"><span><span class="NLM_string-ref">Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and its Application to the Prediction of Drug Transport Properties. <i>  J. Med. Chem</i>. <b>2000</b>, <i>43</i>, 3714−3717.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3717&author=P.+Ertl&author=B.+Rohde&author=P+Selzer&title=Fast+Calculation+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-Based+Contributions+and+its+Application+to+the+Prediction+of+Drug+Transport+Properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00034_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DFast%2520Calculation%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-Based%2520Contributions%2520and%2520its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="jm030354bb00035"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'jm030354bb00035'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="jm030354bb00035_1"><span><span class="NLM_string-ref">We have recently reported that when <b>22</b> (CT51464/ML464) was administered to mice by oral gavage at a dose of 100 mg/kg, platelet aggregation, measured by platelet-rich plasma aggregometry, was inhibited within 30 min and remained disrupted for up to 10 h. During this time, the concentration of active metabolite <b>23</b> (CT50728/ML728) was 37.5 μM at its peak 30 min after oral gavage and 5 μM 8 h after oral gavage of <b>22</b>. Bakewell, S. J.; Nester, P.; Prasad, S.; Tomasson, M. H.; Dowland, N.; Mehrotra, M.; Scarborough, R.; Kanter, J.; Abe, K.; Phillips, D.; Weilbaecher, K. N. Platelet and Osteoclast β<sub>3</sub> Integrins are Critical for Bone Metastasis. <i>  Proc. Natl. Acad. Sci. U.S.A.</i><b>2003</b>, <i>100 </i>(24), 14205−14210.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=+We&title=S.+J."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00035_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWe%26atitle%3Dplatelet%2520aggregation%252C%2520measured%2520by%2520platelet-rich%2520plasma%2520aggregometry%252C%2520was%2520inhibited%2520within%252030%2520min%2520and%2520remained%2520disrupted%2520for%2520up%2520to%252010%2520h.%2520During%2520this%2520time%252C%2520the%2520concentration%2520of%2520active%2520metabolite%252023%2520%2528CT50728%252FML728%2529%2520was%252037.5%2520%25CE%25BCM%2520at%2520its%2520peak%252030%2520min%2520after%2520oral%2520gavage%2520and%25205%2520%25CE%25BCM%25208%2520h%2520after%2520oral%2520gavage%2520of%252022.%2520Bakewell%26btitle%3DS.%2520J.%26pub%3DU.S.A%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'jm030354bb00001':['jm030354bb00001_1','jm030354bb00001_2','jm030354bb00001_3','jm030354bb00001_4','jm030354bb00001_5','jm030354bb00001_6','jm030354bb00001_7'],'jm030354bb00002':['jm030354bb00002_1'],'jm030354bb00003':['jm030354bb00003_1','jm030354bb00003_2','jm030354bb00003_3','jm030354bb00003_4'],'jm030354bb00004':['jm030354bb00004_1','jm030354bb00004_2'],'jm030354bb00005':['jm030354bb00005_1'],'jm030354bb00006':['jm030354bb00006_1','jm030354bb00006_2','jm030354bb00006_3','jm030354bb00006_4','jm030354bb00006_5'],'jm030354bb00007':['jm030354bb00007_1'],'jm030354bb00008':['jm030354bb00008_1'],'jm030354bb00009':['jm030354bb00009_1','jm030354bb00009_2'],'jm030354bb00010':['jm030354bb00010_1'],'jm030354bb00011':['jm030354bb00011_1'],'jm030354bb00012':['jm030354bb00012_1','jm030354bb00012_2','jm030354bb00012_3','jm030354bb00012_4','jm030354bb00012_5','jm030354bb00012_6'],'jm030354bb00013':['jm030354bb00013_1','jm030354bb00013_2'],'jm030354bb00014':['jm030354bb00014_1','jm030354bb00014_2','jm030354bb00014_3','jm030354bb00014_4'],'jm030354bb00015':['jm030354bb00015_1','jm030354bb00015_2','jm030354bb00015_3','jm030354bb00015_4'],'jm030354bb00016':['jm030354bb00016_1','jm030354bb00016_2'],'jm030354bb00017':['jm030354bb00017_1','jm030354bb00017_2'],'jm030354bb00018':['jm030354bb00018_1'],'jm030354bb00019':['jm030354bb00019_1','jm030354bb00019_2'],'jm030354bb00020':['jm030354bb00020_1'],'jm030354bb00021':['jm030354bb00021_1'],'jm030354bb00022':['jm030354bb00022_1','jm030354bb00022_2','jm030354bb00022_3'],'jm030354bb00023':['jm030354bb00023_1','jm030354bb00023_2'],'jm030354bb00024':['jm030354bb00024_1'],'jm030354bb00025':['jm030354bb00025_1'],'jm030354bb00026':['jm030354bb00026_1'],'jm030354bb00027':['jm030354bb00027_1'],'jm030354bb00028':['jm030354bb00028_1','jm030354bb00028_2','jm030354bb00028_3'],'jm030354bb00029':['jm030354bb00029_1'],'jm030354bb00030':['jm030354bb00030_1','jm030354bb00030_2'],'jm030354bb00031':['jm030354bb00031_1'],'jm030354bb00032':['jm030354bb00032_1'],'jm030354bb00033':['jm030354bb00033_1','jm030354bb00033_2','jm030354bb00033_3','jm030354bb00033_4'],'jm030354bb00034':['jm030354bb00034_1'],'jm030354bb00035':['jm030354bb00035_1']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laure  Konnert</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lamaty</span>, <span class="hlFld-ContribAuthor ">Jean  Martinez</span>, and <span class="hlFld-ContribAuthor ">Evelina  Colacino</span>  . </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Synthesis of Hydantoins: The State of the Art of a Valuable Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (23)
                                     , 13757-13809. <a href="https://doi.org/10.1021/acs.chemrev.7b00067" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Bof%252BHydantoins%25253A%252BThe%252BState%252Bof%252Bthe%252BArt%252Bof%252Ba%252BValuable%252BScaffold%26aulast%3DKonnert%26aufirst%3DLaure%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D30012017%26date%3D23062017%26date%3D13122017%26volume%3D117%26issue%3D23%26spage%3D13757%26epage%3D13809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Polishchuk</span>, <span class="hlFld-ContribAuthor ">Oleg  Tinkov</span>, <span class="hlFld-ContribAuthor ">Tatiana  Khristova</span>, <span class="hlFld-ContribAuthor ">Ludmila  Ognichenko</span>, <span class="hlFld-ContribAuthor ">Anna  Kosinskaya</span>, <span class="hlFld-ContribAuthor ">Alexandre  Varnek</span>, and <span class="hlFld-ContribAuthor ">Victor  Kuz’min</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural and Physico-Chemical Interpretation (SPCI) of QSAR Models and Its Comparison with Matched Molecular Pair Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (8)
                                     , 1455-1469. <a href="https://doi.org/10.1021/acs.jcim.6b00371" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00371%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructural%252Band%252BPhysico-Chemical%252BInterpretation%252B%252528SPCI%252529%252Bof%252BQSAR%252BModels%252Band%252BIts%252BComparison%252Bwith%252BMatched%252BMolecular%252BPair%252BAnalysis%26aulast%3DPolishchuk%26aufirst%3DPavel%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21062016%26date%3D29072016%26date%3D22082016%26date%3D15072016%26volume%3D56%26issue%3D8%26spage%3D1455%26epage%3D1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel G.  Polishchuk</span>, <span class="hlFld-ContribAuthor ">Georgiy V.  Samoylenko</span>, <span class="hlFld-ContribAuthor ">Tetiana M.  Khristova</span>, <span class="hlFld-ContribAuthor ">Olga L.  Krysko</span>, <span class="hlFld-ContribAuthor ">Tatyana A.  Kabanova</span>, <span class="hlFld-ContribAuthor ">Vladimir M.  Kabanov</span>, <span class="hlFld-ContribAuthor ">Alexander Yu.  Kornylov</span>, <span class="hlFld-ContribAuthor ">Olga  Klimchuk</span>, <span class="hlFld-ContribAuthor ">Thierry  Langer</span>, <span class="hlFld-ContribAuthor ">Sergei A.  Andronati</span>, <span class="hlFld-ContribAuthor ">Victor E.  Kuz’min</span>, <span class="hlFld-ContribAuthor ">Andrei A.  Krysko</span>, and <span class="hlFld-ContribAuthor ">Alexandre  Varnek</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (19)
                                     , 7681-7694. <a href="https://doi.org/10.1021/acs.jmedchem.5b00865" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00865%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BVirtual%252BScreening%25252C%252Band%252BSynthesis%252Bof%252BAntagonists%252Bof%252B%2525CE%2525B1IIb%2525CE%2525B23%252Bas%252BAntiplatelet%252BAgents%26aulast%3DPolishchuk%26aufirst%3DPavel%2BG.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D03042015%26date%3D25092015%26date%3D08102015%26date%3D14092015%26volume%3D58%26issue%3D19%26spage%3D7681%26epage%3D7694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuehong  Wen</span>, <span class="hlFld-ContribAuthor ">Baoguo  Zhao</span> and <span class="hlFld-ContribAuthor ">Yian  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Cu(I)-Catalyzed Diamination of Disubstituted Terminal Olefins: An Approach to Potent NK1 Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2009,</strong> <em>11 </em>
                                    (11)
                                     , 2365-2368. <a href="https://doi.org/10.1021/ol900808z" title="DOI URL">https://doi.org/10.1021/ol900808z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol900808z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol900808z%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCu%252528I%252529-Catalyzed%252BDiamination%252Bof%252BDisubstituted%252BTerminal%252BOlefins%25253A%252BAn%252BApproach%252Bto%252BPotent%252BNK1%252BAntagonist%26aulast%3DWen%26aufirst%3DYuehong%26date%3D2009%26date%3D2009%26date%3D2009%26date%3D13%252004%25202009%26date%3D01052009%26date%3D04062009%26volume%3D11%26issue%3D11%26spage%3D2365%26epage%3D2368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Spiropiperidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 194-236. <a href="https://doi.org/10.1002/9781118686263.ch6" title="DOI URL">https://doi.org/10.1002/9781118686263.ch6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch6%26sid%3Dliteratum%253Aachs%26atitle%3DSpiropiperidines%26date%3D2018%26date%3D2018%26spage%3D194%26epage%3D236%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guilhem  Coussanes</span>, <span class="hlFld-ContribAuthor ">Katharina  Gaus</span>, <span class="hlFld-ContribAuthor ">Anthony C.  O'Sullivan</span>. </span><span class="cited-content_cbyCitation_article-title">The Synthesis of Ketone-Derived Enamides by Elimination of HCN from Cyanoamides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>2016 </em>
                                    (24)
                                     , 4176-4188. <a href="https://doi.org/10.1002/ejoc.201600638" title="DOI URL">https://doi.org/10.1002/ejoc.201600638</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201600638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201600638%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252BSynthesis%252Bof%252BKetone-Derived%252BEnamides%252Bby%252BElimination%252Bof%252BHCN%252Bfrom%252BCyanoamides%26aulast%3DCoussanes%26aufirst%3DGuilhem%26date%3D2016%26date%3D2016%26volume%3D2016%26issue%3D24%26spage%3D4176%26epage%3D4188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uwe  Jakob</span>, <span class="hlFld-ContribAuthor ">Stephan  Mundinger</span>, <span class="hlFld-ContribAuthor ">Willi  Bannwarth</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Transfer of Chelating Amides into Different Types of Esters and Lactones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2014,</strong> <em>2014 </em>
                                    (31)
                                     , 6963-6974. <a href="https://doi.org/10.1002/ejoc.201402843" title="DOI URL">https://doi.org/10.1002/ejoc.201402843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201402843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201402843%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DEfficient%252BTransfer%252Bof%252BChelating%252BAmides%252Binto%252BDifferent%252BTypes%252Bof%252BEsters%252Band%252BLactones%26aulast%3DJakob%26aufirst%3DUwe%26date%3D2014%26date%3D2014%26volume%3D2014%26issue%3D31%26spage%3D6963%26epage%3D6974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamil  Weinberg</span>, <span class="hlFld-ContribAuthor ">Axel  Stoit</span>, <span class="hlFld-ContribAuthor ">Chris G.  Kruse</span>, <span class="hlFld-ContribAuthor ">Mairi F.  Haddow</span>, <span class="hlFld-ContribAuthor ">Timothy  Gallagher</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2013,</strong> <em>69 </em>
                                    (23)
                                     , 4694-4707. <a href="https://doi.org/10.1016/j.tet.2013.03.064" title="DOI URL">https://doi.org/10.1016/j.tet.2013.03.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2013.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2013.03.064%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Band%252Bdifferential%252Bfunctionalisation%252Bof%252Bpyrrolidine%252Band%252Bpiperidine%252Bbased%252Bspirodiamine%252Bscaffolds%26aulast%3DWeinberg%26aufirst%3DKamil%26date%3D2013%26volume%3D69%26issue%3D23%26spage%3D4694%26epage%3D4707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander M.  Szabo</span>, <span class="hlFld-ContribAuthor ">Nicholas R.  Howell</span>, <span class="hlFld-ContribAuthor ">Paul  Pellegrini</span>, <span class="hlFld-ContribAuthor ">Ivan  Greguric</span>, <span class="hlFld-ContribAuthor ">Andrew  Katsifis</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrin. </span><span class="cited-content_cbyCitation_journal-name">Analytical Biochemistry</span><span> <strong>2012,</strong> <em>423 </em>
                                    (1)
                                     , 70-77. <a href="https://doi.org/10.1016/j.ab.2011.12.046" title="DOI URL">https://doi.org/10.1016/j.ab.2011.12.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ab.2011.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ab.2011.12.046%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Biochemistry%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252Bcompetition%252Bbinding%252Bassays%252Bfor%252Baffinity%252Bto%252Bthe%252Bextracellular%252Bmatrix%252Breceptors%25252C%252B%2525CE%2525B1v%2525CE%2525B23%252Band%252B%2525CE%2525B1IIb%2525CE%2525B23%252Bintegrin%26aulast%3DSzabo%26aufirst%3DAlexander%2BM.%26date%3D2012%26volume%3D423%26issue%3D1%26spage%3D70%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antje  Havemeyer</span>, <span class="hlFld-ContribAuthor ">Juliane  Lang</span>, <span class="hlFld-ContribAuthor ">Bernd  Clement</span>. </span><span class="cited-content_cbyCitation_article-title">The fourth mammalian molybdenum enzyme mARC: current state of research. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2011,</strong> <em>43 </em>
                                    (4)
                                     , 524-539. <a href="https://doi.org/10.3109/03602532.2011.608682" title="DOI URL">https://doi.org/10.3109/03602532.2011.608682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/03602532.2011.608682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F03602532.2011.608682%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DThe%252Bfourth%252Bmammalian%252Bmolybdenum%252Benzyme%252BmARC%25253A%252Bcurrent%252Bstate%252Bof%252Bresearch%26aulast%3DHavemeyer%26aufirst%3DAntje%26date%3D2011%26date%3D2011%26volume%3D43%26issue%3D4%26spage%3D524%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evgeny  Prusov</span>, <span class="hlFld-ContribAuthor ">Martin E.  Maier</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of nitrogen-containing spirocyclic scaffolds via aminoallylation/RCM sequence. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2007,</strong> <em>63 </em>
                                    (42)
                                     , 10486-10496. <a href="https://doi.org/10.1016/j.tet.2007.07.083" title="DOI URL">https://doi.org/10.1016/j.tet.2007.07.083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2007.07.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2007.07.083%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Bof%252Bnitrogen-containing%252Bspirocyclic%252Bscaffolds%252Bvia%252Baminoallylation%25252FRCM%252Bsequence%26aulast%3DPrusov%26aufirst%3DEvgeny%26date%3D2007%26volume%3D63%26issue%3D42%26spage%3D10486%26epage%3D10496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Fryszkowska</span>, <span class="hlFld-ContribAuthor ">Marta  Komar</span>, <span class="hlFld-ContribAuthor ">Dominik  Koszelewski</span>, <span class="hlFld-ContribAuthor ">Ryszard  Ostaszewski</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on enzymatic synthesis of chiral non-racemic 3-arylglutaric acid monoesters. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron: Asymmetry</span><span> <strong>2006,</strong> <em>17 </em>
                                    (6)
                                     , 961-966. <a href="https://doi.org/10.1016/j.tetasy.2006.03.002" title="DOI URL">https://doi.org/10.1016/j.tetasy.2006.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetasy.2006.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetasy.2006.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%253A%2520Asymmetry%26atitle%3DStudies%252Bon%252Benzymatic%252Bsynthesis%252Bof%252Bchiral%252Bnon-racemic%252B3-arylglutaric%252Bacid%252Bmonoesters%26aulast%3DFryszkowska%26aufirst%3DAnna%26date%3D2006%26volume%3D17%26issue%3D6%26spage%3D961%26epage%3D966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ching-Yuh  Chern</span>, <span class="hlFld-ContribAuthor ">Shinn-Jyh  Chen</span>, <span class="hlFld-ContribAuthor ">Wai-Ming  Kan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of 3-Aryl-5-Alicylic-[1,2,4]-oxadiazoles as Novel Platelet Aggregation Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2005,</strong> <em>52 </em>
                                    (2)
                                     , 331-338. <a href="https://doi.org/10.1002/jccs.200500050" title="DOI URL">https://doi.org/10.1002/jccs.200500050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.200500050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.200500050%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252B3-Aryl-5-Alicylic-%25255B1%25252C2%25252C4%25255D-oxadiazoles%252Bas%252BNovel%252BPlatelet%252BAggregation%252BInhibitors%26aulast%3DChern%26aufirst%3DChing-Yuh%26date%3D2005%26date%3D2013%26volume%3D52%26issue%3D2%26spage%3D331%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jefferson W.  Tilley</span>. </span><span class="cited-content_cbyCitation_article-title">Prodrugs of Benzamidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>,</strong>,, 889-922. <a href="https://doi.org/10.1007/978-0-387-49785-3_24" title="DOI URL">https://doi.org/10.1007/978-0-387-49785-3_24</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-0-387-49785-3_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-0-387-49785-3_24%26sid%3Dliteratum%253Aachs%26atitle%3DProdrugs%252Bof%252BBenzamidines%26aulast%3DTilley%26aufirst%3DJefferson%2BW.%26spage%3D889%26epage%3D922%26pub%3DSpringer%2520New%2520York%26atitle%3DProdrugs%26aulast%3DStella%26aufirst%3DValentino%2BJ.%26date%3D2007%26volume%3DV" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bn00001.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bn00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00001" data-index="1" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00001.jpeg" id="rightTab-_i5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 1 Oral GPIIb/IIIa antagonists that have been studied in advanced stage clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00001"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00001" data-index="2" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00001.jpeg" id="rightTab-_i8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 1 <i><sup>a</sup></i><sup></sup> Synthesis of the γ-Spirolactam Scaffolds:  4-(1-Oxo-2,8-Diazaspiro [4.5]dec-2-yl)benzonitrile <b>11</b>, 4-(3-Oxo-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile <b>12</b>, and Spiroimide Scaffold<b> 76</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) ethyl cyanoacetate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å sieves; (b) KCN, EtOH/H<sub>2</sub>O, Δ; (c) concd HCl, Δ; (d) DCC, DMF; (e) 4-cyanoaniline, TEA, DMF, rt; (f) Ac<sub>2</sub>O, NaOAc, Δ; (g) NaBH<sub>4</sub>, MeOH; (h) NaBH<sub>4</sub>, TFA; (i) 2,2,2-trichloroethyl chloroformate, CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>; separate isomers by flash chromatography; (j) 10% Cd−Pb, THF/NH<sub>4</sub>OAc, pH = 5.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00001"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00002" data-index="3" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00002.jpeg" id="rightTab-_i10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 2 <i><sup>a</sup></i><sup></sup> Synthesis of the Hydantoin and the Urea Scaffolds:  4-(1-Methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (and its 1-H analog) <b>19b</b>,<b>a</b> and 4-(1-Methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-yl)benzonitrile (and its 1-H analog) <b>18b</b>,<b>a</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) KCN, RNH<sub>2</sub>.HCl, EtOH/H<sub>2</sub>O; (b) 4-cyanophenyl isocyanate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (c) 1 N HCl, Δ; (d) NaBH<sub>4</sub>, MeOH; (e) NaBH<sub>4</sub>, TFA; (f) 2,2,2-trichloroethyl chloroformate, CH<sub>3</sub>CN/CHCl<sub>3</sub>; (g) 10% Cd−Pb, THF/NH<sub>4</sub>OAc, pH = 5.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00002"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00003" data-index="4" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00003.jpeg" id="rightTab-_i12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 3 <i><sup>a</sup></i><sup></sup> Synthesis of <b>23</b> (CT50728) and Its Double Prodrug <b>22</b> (CT51464) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt.; (b) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (c) 1 M LiOH, THF, rt; or 3 N HCl, rt; (d) NH<sub>2</sub>OH.HCl, Et<sub>3</sub>N, EtOH, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00003"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00004" data-index="5" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00004.jpeg" id="rightTab-_i13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 4 <i><sup>a</sup></i><sup></sup> Synthesis of <b>28</b> (CT50614) and Its Double Prodrug <b>27</b> (CT51269) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DMF, DIEA, rt.;(b) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (c) 3 N HCl, rt.; (d) NH<sub>2</sub>OH.HCl, Et<sub>3</sub>N, EtOH, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00004"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00005" data-index="6" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00005.jpeg" id="rightTab-_i15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 5 <i><sup>a</sup></i><sup></sup> Synthesis of <b>33</b> (CT51907) and Its Double Prodrug <b>36</b> (CT52108) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) CH<sub>2</sub>Cl<sub>2</sub>, rt.; (b) Pearlman's catalyst, EtOAc, 40 psi H<sub>2</sub>; (c) <b>11</b>, HBTU, DIEA, DMF; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH;(e) TFA;(f) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (g) 3 N HCl.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00005"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00006" data-index="7" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00006.jpeg" id="rightTab-_i17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 6 <i><sup>a</sup></i><sup></sup> Synthesis of the Substituted Amidine Analogues <b>39b</b> and <b>40b</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) (i) H<sub>2</sub>S, pyridine/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (b) morpholine, AcOH, MeOH, rt.; (c) EtNH<sub>2</sub>, AcOH, MeOH, rt.; (d) 3 N HCl, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00006"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00007" data-index="8" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00007.jpeg" id="rightTab-_i19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 7 <i><sup>a</sup></i><sup></sup> Synthesis of <b>44</b> and <b>45</b>, the 3-(<i>S</i>)- and 3-(<i>R</i>)-Methyl Analogues of <b>28</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DCC, <i>t</i>-BuOH, CH<sub>2</sub>Cl<sub>2</sub>; (b) 1 M LiOH, THF; then AcOH; (c)<b> 11</b>, HBTU, DIEA, DMF → <b>43</b>; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (e) TFA; (f) <b>11</b>, EDC·HCl, HOBt, DMF.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00007"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00008" data-index="9" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00008.jpeg" id="rightTab-_i21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 8 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-Phenylpentanedioic Acid Monoethyl Ester <b>46</b> and Its Use in the Synthesis of<b> 48</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) Ac<sub>2</sub>O, Δ; (b) EtOH, Et<sub>3</sub>N, Δ ; (c) <b>11</b>, EDC·HCl, HOBt, DMF; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (e) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00008"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00009" data-index="10" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00009.jpeg" id="rightTab-_i23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 9 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-(4-Nitrophenoxycarbonyl-amino)butyric Acid Ethyl Ester<b> 51</b> and Its Use in the Synthesis of<b> 53</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a)20% Pd(OH)<sub>2</sub>/C, EtOAc, 50 psi H<sub>2</sub>; (b) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (c) <b>11</b>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone (iii) NH<sub>4</sub>OAc, MeOH; (e) 3 N HCl.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00009"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00010" data-index="11" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00010.jpeg" id="rightTab-_i25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 10 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-(4-Nitrophenoxycarbon-ylamino)-3-phenylpropionic Acid Ethyl Ester <b>54 </b>and Its Use in the Synthesis of<b> 56</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>19b</b>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (c) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (d) 1 N LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00010"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00011" data-index="12" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00011.jpeg" id="rightTab-_i27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 11 <i><sup>a</sup></i><sup></sup> Synthesis of the 2-(2-Carboxyethyl)-2-(3,5-dimethylisoxazole-4-sulfonylamino)-3,3-dimethylbutyric Acid<b> 57 </b>and its Use in the Synthesis of <b>59 </b>(CT50787) </p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) (i) 1 N NaOH, Na<sub>2</sub>CO<sub>3</sub>, 0 °C; (ii) 2 N HCl to pH = 3; (b) <b>11</b>, EDC·HCl, DMF; (c) TFA; (d) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00011"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00012" data-index="13" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00012.jpeg" id="rightTab-_i29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 12 <i><sup>a</sup></i><sup></sup> Synthesis of the 3-Amino-2-(toluene-4-sul-fonylamino)propionic Acid Ethyl Ester <b>61 </b>and its Use in the Synthesis of<b> 63</b></p><p class="last"><p class="last"><sup>a</sup> Reagents and conditions:  (a) DIEA, DCM; (b) TFA; (c) <b>11</b>, triphosgene, CH<sub>2</sub>Cl<sub>2</sub>; (d) (i) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (ii) Ac<sub>2</sub>O, AcOH; (iii) 10% Pd/C, H<sub>2</sub>, 40 psi; (e) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00012"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00013" data-index="14" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00013.jpeg" id="rightTab-_i31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 13 <i><sup>a</sup></i><sup></sup> Synthesis of the 2-Butoxycarbonylaminopentanedioic Acid 1-Ethyl Ester<b> 67</b> and Its Use in the Synthesis of<b> 69</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) EDC·HCl, HOBt, EtOH, DMF; (b) 20% Pd(OH)<sub>2</sub>/C, 1 atm H<sub>2</sub>, EtOH; (c) <i>n</i>-butyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (d) TFA; (e) <b>11</b>, HBTU, DIEA, DMF; (f) (i) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (ii) Ac<sub>2</sub>O, AcOH; (iii) 10% Pd/C, 1 atm H<sub>2</sub>; (g) 1 M LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00013"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00014" data-index="15" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00014.jpeg" id="rightTab-_i33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 14 <i><sup>a</sup></i><sup></sup> Synthesis of the 5-Azaspiro-1-ylpentanoic Acid Analogue <b>72</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) DIEA, DMF, rt.; (b) NH<sub>2</sub>OH·HCl, Et<sub>3</sub>N, EtOH; (c) (i) Ac<sub>2</sub>O, AcOH; (ii) 10% Pd/C; H<sub>2</sub>, 40 psi; (d) 1 N LiOH, THF/H<sub>2</sub>O, rt.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00014"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bh00015" data-index="16" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bh00015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00015.jpeg" id="rightTab-_i35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first"> Scheme 15 <i><sup>a</sup></i><sup></sup> Synthesis of the 2,2-Dimethylpropionic Acid Analogue<b> 75</b></p><p class="last"><p class="last"><i><sup>a</sup></i><sup></sup> Reagents and conditions:  (a) 4-nitrophenyl chloroformate, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>12</b>, DIEA, DMF; (c) (i) H<sub>2</sub>S, Pyr/Et<sub>3</sub>N; (ii) CH<sub>3</sub>I, acetone; (iii) NH<sub>4</sub>OAc, MeOH; (d) 1 N LiOH, THF/H<sub>2</sub>O.</p></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bh00015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bh00015"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00002" data-index="17" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00002.jpeg" id="rightTab-_i44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 2 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.1 mg/kg) and po administration of <b>22</b> (1.0 mg/kg) versus time, as determined by LC/MS/MS in rats (<i>n</i> = 6). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00002"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00003" data-index="18" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00003.jpeg" id="rightTab-_i45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 3 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.1 mg/kg) and po administration of <b>22</b> (1.0 mg/kg) versus time, as determined by LC/MS/MS in dogs (<i>n</i> = 4). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00003"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00004" data-index="19" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00004.jpeg" id="rightTab-_i47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 4 Plasma levels of <b>23</b> after iv administration of <b>23</b> (0.2 mg/kg) and po administration of <b>22</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>24</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00004"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00005" data-index="20" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00005.jpeg" id="rightTab-_i48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 5 Plasma levels of <b>28</b> after iv administration of <b>28</b> (0.2 mg/kg) and po administration of <b>27</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>29</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00005"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="jm030354bf00006" data-index="21" class="article__inlineFigure"><h2 class="fig-label"></h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/medium/jm030354bf00006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00006.jpeg" id="rightTab-_i49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last"> Figure 6 Plasma levels of <b>33</b> after iv administration of <b>33</b> (0.2 mg/kg) and po administration of <b>36</b> (2.0 mg/kg) versus time, as determined by LC/MS/MS in cynomolgus monkeys (<i>n</i> = 4). <b>37</b> is the corresponding amidoxime acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-8/jm030354b/production/images/large/jm030354bf00006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm030354b&amp;id=jm030354bf00006"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-jm030354bb00001"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00001" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00001_1"><span><span class="NLM_string-ref">(a) Fuster, V.; Badimon, L.; Badimon, J. J.; Chesebro, J. H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes (Part I). <i>  N. Engl. J. </i><i>Med.</i><b>1992</b>, <i>326</i>, 242−250.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=250&author=V.+Fuster&author=L.+Badimon&author=J.+J.+Badimon&author=J.+H+Chesebro&title=The+Pathogenesis+of+Coronary+Artery+Disease+and+the+Acute+Coronary+Syndromes+%28Part+I%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuster%26aufirst%3DV.%26atitle%3DThe%2520Pathogenesis%2520of%2520Coronary%2520Artery%2520Disease%2520and%2520the%2520Acute%2520Coronary%2520Syndromes%2520%2528Part%2520I%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_2"><span><span class="NLM_string-ref">(b) Fuster, V.; Badiman, L.; Badimon, J. J.; Chesebro, J. H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes (Part II). <i>  N. Engl. J. Med.</i><b>1992</b>, <i>326</i>, 310−318.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=318&author=V.+Fuster&author=L.+Badiman&author=J.+J.+Badimon&author=J.+H+Chesebro&title=The+Pathogenesis+of+Coronary+Artery+Disease+and+the+Acute+Coronary+Syndromes+%28Part+II%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuster%26aufirst%3DV.%26atitle%3DThe%2520Pathogenesis%2520of%2520Coronary%2520Artery%2520Disease%2520and%2520the%2520Acute%2520Coronary%2520Syndromes%2520%2528Part%2520II%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_3"><span><span class="NLM_string-ref">(c) Hynes, R. O. Integrins:  Versatility, Modulation, and Signaling in Cell Adhesion. <i>  Cell</i><b>1992</b>, <i>69</i>, 11−25.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28c%29+Hynes%2C+R.+O.+Integrins%3A%E2%80%89+Versatility%2C+Modulation%2C+and+Signaling+in+Cell+Adhesion.+Cell+1992%2C+69%2C+11%E2%88%9225.+%28c%29+Hynes%2C+R.+O.+Integrins%3A%E2%80%89+Versatility%2C+Modulation%2C+and+Signaling+in+Cell+Adhesion.+Cell1992%2C+69%2C+11%E2%88%9225."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DR.%2BO.%26jtitle%3DCell%26date%3D1992%26volume%3D69%26spage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_4"><span><span class="NLM_string-ref">(d) Humphries, M. J. Integrin Cell Adhesion Receptors and the Concept of Agonism. <i>  Trends Pharmacol. Sci</i>. <b>2000</b>, <i>21</i>, 29−32.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=32&author=M.+J+Humphries&title=Integrin+Cell+Adhesion+Receptors+and+the+Concept+of+Agonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DM.%2BJ%26atitle%3DIntegrin%2520Cell%2520Adhesion%2520Receptors%2520and%2520the%2520Concept%2520of%2520Agonism%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_5"><span><span class="NLM_string-ref">(e) Aota, S.; Yamada, K. M. Integrin Functions and Signal Transduction. <i>  Adv. </i><i>Exp. Med. Biol.</i><b>1997</b>, <i>400B</i>, 669−682.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400B&publication_year=1997&pages=682&author=S.+Aota&author=K.+M+Yamada&title=Integrin+Functions+and+Signal+Transduction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DS.%26atitle%3DIntegrin%2520Functions%2520and%2520Signal%2520Transduction%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1997%26volume%3D400B%26spage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_6"><span><span class="NLM_string-ref">(f) Coller, B. S. Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy. <i>  Circulation</i><b>1995</b>, <i>92</i>, 2373−80.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=80&author=B.+S+Coller&title=Blockade+of+Platelet+GPIIb%2FIIIa+Receptors+as+an+Antithrombotic+Strategy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColler%26aufirst%3DB.%2BS%26atitle%3DBlockade%2520of%2520Platelet%2520GPIIb%252FIIIa%2520Receptors%2520as%2520an%2520Antithrombotic%2520Strategy%26jtitle%3DCirculation%26date%3D1995%26volume%3D92%26spage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00001_7"><span><span class="NLM_string-ref">(g) Ruef, J.; Katus, H. A. New Antithrombotic Drugs on the Horizon. <i>  Expert Opin. Invest. Drugs</i><b>2003</b>, <i>12(5)</i>, 781−797.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=797&issue=5&author=J.+Ruef&author=H.+A+Katus&title=New+Antithrombotic+Drugs+on+the+Horizon"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00001_7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuef%26aufirst%3DJ.%26atitle%3DNew%2520Antithrombotic%2520Drugs%2520on%2520the%2520Horizon%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D12%26issue%3D5%26spage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00002"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00002" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00002_1"><span><span class="NLM_string-ref">Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. <i>  Blood </i><b>1988</b><i>,</i><i>71</i>, 831−843.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1988&pages=843&author=D.+R.+Phillips&author=I.+F.+Charo&author=L.+V.+Parise&author=L.+A+Fitzgerald&title=The+Platelet+Membrane+Glycoprotein+IIb-IIIa+Complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00002_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26atitle%3DThe%2520Platelet%2520Membrane%2520Glycoprotein%2520IIb-IIIa%2520Complex%26jtitle%3DBlood%26date%3D1988%26volume%3D71%26spage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00003"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00003" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00003_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Design of Potent and Specific Integrin Antagonists. <i>  J. Biol. Chem.</i><b>1993</b>, <i>268</i>, 1066−1073.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=1073&author=R.+M.+Scarborough&author=M.+A.+Naughton&author=W.+Teng&author=J.+W.+Rose&author=D.+R.+Phillips&author=L.+Nannizzi&author=A.+Arfsten&author=A.+M.+Campbell&author=I.+F+Charo&title=Design+of+Potent+and+Specific+Integrin+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Specific%2520Integrin%2520Antagonists%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00003_2"><span><span class="NLM_string-ref">(b) Charo, I. F.; Nannizzi, L.; Phillips, D. R.; Hsu, M. A.; Scarborough, R. M. Inhibition of Fibrinogen Binding to GP IIb-IIIa by a GP IIIa Peptide. <i>  J. </i><i>Biol. Chem.</i><b>1991</b>, <i>266</i>, 1415−1421.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1991&pages=1421&author=I.+F.+Charo&author=L.+Nannizzi&author=D.+R.+Phillips&author=M.+A.+Hsu&author=R.+M+Scarborough&title=Inhibition+of+Fibrinogen+Binding+to+GP+IIb-IIIa+by+a+GP+IIIa+Peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DInhibition%2520of%2520Fibrinogen%2520Binding%2520to%2520GP%2520IIb-IIIa%2520by%2520a%2520GP%2520IIIa%2520Peptide%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1991%26volume%3D266%26spage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00003_3"><span><span class="NLM_string-ref">(c) Alig, L.; Edenhofer, A.; Hadvary, P.; Hurzeler, M.; Knopp, D.; Muller, M.; Steiner, B.; Trzeciak, A.; Weller, T. Low Molecular Weight, Non-Peptide Fibrinogen Receptor Antagonists. <i>  J. Med. Chem.</i><b>1992</b>, <i>35</i>, 4393−4407.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4407&author=L.+Alig&author=A.+Edenhofer&author=P.+Hadvary&author=M.+Hurzeler&author=D.+Knopp&author=M.+Muller&author=B.+Steiner&author=A.+Trzeciak&author=T+Weller&title=Low+Molecular+Weight%2C+Non-Peptide+Fibrinogen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlig%26aufirst%3DL.%26atitle%3DLow%2520Molecular%2520Weight%252C%2520Non-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00003_4"><span><span class="NLM_string-ref">(d) Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzman, L. A.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen:  A Proposal on the Nature of the Binding Interaction between the Arg-guanidine of RGDX Mimetics and the Platelet GP IIb-IIIa Receptor. <i>  J. Med. Chem.</i><b>1993</b>, <i>36</i>, 1811−1819.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1819&author=J.+A.+Zablocki&author=M.+Miyano&author=R.+B.+Garland&author=D.+Pireh&author=L.+A.+Schretzman&author=S.+N.+Rao&author=R.+J.+Lindmark&author=S.+G.+Panzer-Knodle&author=N.+S.+Nicholson&author=B.+B.+Taite&author=A.+K.+Salyers&author=L.+W.+King&author=J.+G.+Campion&author=L.+P+Feigen&title=Potent+in+Vitro+and+in+Vivo+Inhibitors+of+Platelet+Aggregation+Based+upon+the+Arg-Gly-Asp-Phe+Sequence+of+Fibrinogen%3A%E2%80%89+A+Proposal+on+the+Nature+of+the+Binding+Interaction+between+the+Arg-guanidine+of+RGDX+Mimetics+and+the+Platelet+GP+IIb-IIIa+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00003_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZablocki%26aufirst%3DJ.%2BA.%26atitle%3DPotent%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Inhibitors%2520of%2520Platelet%2520Aggregation%2520Based%2520upon%2520the%2520Arg-Gly-Asp-Phe%2520Sequence%2520of%2520Fibrinogen%253A%25E2%2580%2589%2520A%2520Proposal%2520on%2520the%2520Nature%2520of%2520the%2520Binding%2520Interaction%2520between%2520the%2520Arg-guanidine%2520of%2520RGDX%2520Mimetics%2520and%2520the%2520Platelet%2520GP%2520IIb-IIIa%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00004"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00004" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00004_1"><span><span class="NLM_string-ref">(a) Lincoff, A. M.; Topol, E. J. Overview of the Glycoprotein IIb/IIIa Interventional Trials. In <i>Platelet Glycoprotein IIb/IIIa Inhibitors in </i><i>Cardiovascular Disease, </i>2nd ed.; Lincoff, A., Michael, Eds.; Humana Press Inc.:  Totowa, N. J., 2003; pp 167−199.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=199&author=A.+M.+Lincoff&author=E.+J.+Topol&title=Platelet+Glycoprotein+IIb%2FIIIa+Inhibitors+in+Cardiovascular+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00004_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26atitle%3DOverview%2520of%2520the%2520Glycoprotein%2520IIb%252FIIIa%2520Interventional%2520Trials%26btitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%2520in%2520Cardiovascular%2520Disease%26pub%3DHumana%2520Press%2520Inc%26date%3D2003%26spage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00004_2"><span><span class="NLM_string-ref">(b) Agah, R.; Plow, E. F.; Topol, E. J. GPIIb-IIIa Antagonists. In <i>Platelets</i>; Michelson, A. D., Eds.; Academic Press:  California, 2002; pp 769−785.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=785&author=R.+Agah&author=E.+F.+Plow&author=E.+J.+Topol&title=Platelets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00004_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAgah%26aufirst%3DR.%26atitle%3DGPIIb-IIIa%2520Antagonists%26btitle%3DPlatelets%26pub%3DAcademic%2520Press%26date%3D2002%26spage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00005"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00005" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00005_1"><span><span class="NLM_string-ref">Lincoff, A. M.; Califf, R. M.; Topol, E. J. Platelet Glycoprotein IIb-IIIa, Receptor Blocade in Coronary Artery Disease. <i>  J. Am. Coll. Cardiol.</i><b>2000</b>, <i>35</i>, 1103−1115.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=1115&author=A.+M.+Lincoff&author=R.+M.+Califf&author=E.+J+Topol&title=Platelet+Glycoprotein+IIb-IIIa%2C+Receptor+Blocade+in+Coronary+Artery+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00005_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb-IIIa%252C%2520Receptor%2520Blocade%2520in%2520Coronary%2520Artery%2520Disease%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2000%26volume%3D35%26spage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00006"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00006" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00006_1"><span><span class="NLM_string-ref">(a) Coller, B. S. Anti-GPIIb/IIIa Drugs:  Current Strategies and Future Directions. <i>  Thromb. Haemost.</i><b>2001</b>, <i>86</i>, 427−443.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28a%29+Coller%2C+B.+S.+Anti-GPIIb%2FIIIa+Drugs%3A%E2%80%89+Current+Strategies+and+Future+Directions.+Thromb.+Haemost.+2001%2C+86%2C+427%E2%88%92443.+%28a%29+Coller%2C+B.+S.+Anti-GPIIb%2FIIIa+Drugs%3A%E2%80%89+Current+Strategies+and+Future+Directions.+Thromb.+Haemost.2001%2C+86%2C+427%E2%88%92443."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColler%26aufirst%3DB.%2BS.%26jtitle%3DThromb.%2520Haemost.%26date%3D2001%26volume%3D86%26spage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00006_2"><span><span class="NLM_string-ref">(b) Konstantopoulos, K.; Mousa, S. A. Antiplatelet Therapies:  Platelet GPIIb/IIIa Antagonists and Beyond. <i>  Curr. Opin. Invest. Drugs</i><b>2001</b>, <i>2</i>, 1086−1092.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Konstantopoulos%2C+K.%3B+Mousa%2C+S.+A.+Antiplatelet+Therapies%3A%E2%80%89+Platelet+GPIIb%2FIIIa+Antagonists+and+Beyond.+Curr.+Opin.+Invest.+Drugs+2001%2C+2%2C+1086%E2%88%921092.+%28b%29+Konstantopoulos%2C+K.%3B+Mousa%2C+S.+A.+Antiplatelet+Therapies%3A%E2%80%89+Platelet+GPIIb%2FIIIa+Antagonists+and+Beyond.+Curr.+Opin.+Invest.+Drugs2001%2C+2%2C+1086%E2%88%921092."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantopoulos%26aufirst%3DK.%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00006_3"><span><span class="NLM_string-ref">(c) Dogne, J.; De Leval, X.; Benoit, P.; Delarge, J.; Masereel, B.; David, J. Recent advances in antiplatelet agents. <i>  Curr. Med. Chem.</i><b>2002</b>, <i>9</i>, 577−589.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=589&author=J.+Dogne&author=X.+De+Leval&author=P.+Benoit&author=J.+Delarge&author=B.+Masereel&author=J+David&title=Recent+advances+in+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDogne%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520antiplatelet%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00006_4"><span><span class="NLM_string-ref">(d) Ojima, I.; Chakravarty, S.; Dong, Q. Antithrombotic Agents:  From RGD to Peptide Mimetics. <i>  Bioorg. Med. Chem.</i><b>1995</b>, <i>3</i>, 337−360.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28d%29+Ojima%2C+I.%3B+Chakravarty%2C+S.%3B+Dong%2C+Q.+Antithrombotic+Agents%3A%E2%80%89+From+RGD+to+Peptide+Mimetics.+Bioorg.+Med.+Chem.+1995%2C+3%2C+337%E2%88%92360.+%28d%29+Ojima%2C+I.%3B+Chakravarty%2C+S.%3B+Dong%2C+Q.+Antithrombotic+Agents%3A%E2%80%89+From+RGD+to+Peptide+Mimetics.+Bioorg.+Med.+Chem.1995%2C+3%2C+337%E2%88%92360."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1995%26volume%3D3%26spage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00006_5"><span><span class="NLM_string-ref">(e) Scarborough, R. M. Structure−Activity Relationships of β-Amino Acid-Containing Integrin Anagonists. <i>  Curr. Med. Chem.</i><b>1999</b>, <i>6</i>, 971−981.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=981&author=R.+M+Scarborough&title=Structure%E2%88%92Activity+Relationships+of+%CE%B2-Amino+Acid-Containing+Integrin+Anagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00006_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM%26atitle%3DStructure%25E2%2588%2592Activity%2520Relationships%2520of%2520%25CE%25B2-Amino%2520Acid-Containing%2520Integrin%2520Anagonists%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D1999%26volume%3D6%26spage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00007"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00007" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00007_1"><span><span class="NLM_string-ref">Mousa, S. A.; Iqbal, O.; Fareed, J. Antithrombotics and Thrombolytics in Stroke. <i>  Curr. Opin. Invest. Drugs</i><b>2002</b>,<i> 3</i>, 878−885.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=885&author=S.+A.+Mousa&author=O.+Iqbal&author=J+Fareed&title=Antithrombotics+and+Thrombolytics+in+Stroke"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00007_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DAntithrombotics%2520and%2520Thrombolytics%2520in%2520Stroke%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00008"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00008" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00008_1"><span><span class="NLM_string-ref">Wang, W.; Borchardt, R. T.; Wang, B. Orally Active Peptidomimetic RGD Analogues that are Glycoprotein IIb/IIIa Antagonists. <i>  Curr. Med. Chem.</i><b>2000</b>, <i>7</i>, 437−453.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=453&author=W.+Wang&author=R.+T.+Borchardt&author=B+Wang&title=Orally+Active+Peptidomimetic+RGD+Analogues+that+are+Glycoprotein+IIb%2FIIIa+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00008_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26atitle%3DOrally%2520Active%2520Peptidomimetic%2520RGD%2520Analogues%2520that%2520are%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2000%26volume%3D7%26spage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00009"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00009" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00009_1"><span><span class="NLM_string-ref">(a) Cannon, C. P. The Evolving Story of Oral Platelet Glycoprotein IIb-IIIa Receptor Inhibitors. <i>  Curr. Opin. Cardiovascular, Pulmonary & Renal </i><i>Invest. Drugs </i><b>2000</b>, <i>2</i>, 114−123.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=123&author=C.+P+Cannon&title=The+Evolving+Story+of+Oral+Platelet+Glycoprotein+IIb-IIIa+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00009_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP%26atitle%3DThe%2520Evolving%2520Story%2520of%2520Oral%2520Platelet%2520Glycoprotein%2520IIb-IIIa%2520Receptor%2520Inhibitors%26jtitle%3DCurr.%2520Opin.%2520Cardiovascular%252C%2520Pulmonary%2520%2526%2520Renal%2520Invest.%2520Drugs%26date%3D2000%26volume%3D2%26spage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00009_2"><span><span class="NLM_string-ref">(b) Quinn, M. J.; Plow, E. F.; Topol, E. J. Platelet Glycoprotein IIb/IIIa Inhibitors:  Recognition of a Two-Edged Sword? <i>Circulation</i><b>2002</b>, <i>106</i>, 379−385.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=385&author=M.+J.+Quinn&author=E.+F.+Plow&author=E.+J+Topol&title=Platelet+Glycoprotein+IIb%2FIIIa+Inhibitors%3A%E2%80%89+Recognition+of+a+Two-Edged+Sword"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00009_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DM.%2BJ.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%253A%25E2%2580%2589%2520Recognition%2520of%2520a%2520Two-Edged%2520Sword%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00010"><div class="reference"><div class="NLM_citation" id="rightTab-jm030354bb00010_1"><span><span class="NLM_string-ref">Scarborough, R. M. Eptifibatide. <i>  Drugs Future</i><b>1998</b>, <i>23(6)</i>, 585−590.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scarborough%2C+R.+M.+Eptifibatide.+Drugs+Future+1998%2C+23%286%29%2C+585%E2%88%92590.+Scarborough%2C+R.+M.+Eptifibatide.+Drugs+Future1998%2C+23%286%29%2C+585%E2%88%92590."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00010_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26jtitle%3DDrugs%2520Future%26date%3D1998%26volume%3D23%26issue%3D6%26spage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00011"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00011" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00011_1"><span><span class="NLM_string-ref">Scarborough, R. M.; Gretler, D. D. Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers:  Novel Parenteral and Potential Oral Antithrombotic Agents. <i>  J. Med. Chem</i>. <b>2000</b>, <i>43(19)</i>, 3453−3473.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3473&issue=19&author=R.+M.+Scarborough&author=D.+D+Gretler&title=Platelet+Glycoprotein+IIb-IIIa+Antagonists+as+Prototypical+Integrin+Blockers%3A%E2%80%89+Novel+Parenteral+and+Potential+Oral+Antithrombotic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00011_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb-IIIa%2520Antagonists%2520as%2520Prototypical%2520Integrin%2520Blockers%253A%25E2%2580%2589%2520Novel%2520Parenteral%2520and%2520Potential%2520Oral%2520Antithrombotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D19%26spage%3D3473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00012"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00012" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00012_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Kleiman, N. S.; Phillips, D. R. Platelet Glycoprotein IIb/IIIa Antagonists:  What Are the Relevant Issues Concerning their Pharmacology and Clinical Use? <i>Circulation</i><b>1999</b>, <i>100</i>, 437−444.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=444&author=R.+M.+Scarborough&author=N.+S.+Kleiman&author=D.+R+Phillips&title=Platelet+Glycoprotein+IIb%2FIIIa+Antagonists%3A%E2%80%89+What+Are+the+Relevant+Issues+Concerning+their+Pharmacology+and+Clinical+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%253A%25E2%2580%2589%2520What%2520Are%2520the%2520Relevant%2520Issues%2520Concerning%2520their%2520Pharmacology%2520and%2520Clinical%2520Use%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26spage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00012_2"><span><span class="NLM_string-ref">(b) Brassard, J. A.; Curtis, B. R.; Cooper, R. A.; Ferguson, J.; Komocsar, W.; Ehardt, M.; Kupfer, S.; Maurath, C.; Swabb, E.; Cannon, C. P.; Aster, R. H. Acute Thrombocytopenia in Patients Treated with the Oral Glycoprotein IIb/IIIa Inhibitors Xemilofiban and Orbofiban:  Evidence for an Immune Etiology. <i>  Thromb. Haemost.</i><b>2002</b>, <i>88</i>, 892−897.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2002&pages=897&author=J.+A.+Brassard&author=B.+R.+Curtis&author=R.+A.+Cooper&author=J.+Ferguson&author=W.+Komocsar&author=M.+Ehardt&author=S.+Kupfer&author=C.+Maurath&author=E.+Swabb&author=C.+P.+Cannon&author=R.+H+Aster&title=Acute+Thrombocytopenia+in+Patients+Treated+with+the+Oral+Glycoprotein+IIb%2FIIIa+Inhibitors+Xemilofiban+and+Orbofiban%3A%E2%80%89+Evidence+for+an+Immune+Etiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrassard%26aufirst%3DJ.%2BA.%26atitle%3DAcute%2520Thrombocytopenia%2520in%2520Patients%2520Treated%2520with%2520the%2520Oral%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%2520Xemilofiban%2520and%2520Orbofiban%253A%25E2%2580%2589%2520Evidence%2520for%2520an%2520Immune%2520Etiology%26jtitle%3DThromb.%2520Haemost.%26date%3D2002%26volume%3D88%26spage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00012_3"><span><span class="NLM_string-ref">(c) Aster, Richard. Thrombocytopenia Induced by GPIIb/IIIa Inhibitors. <i>  Blood</i><b>2003</b>, <i>101</i>, 1.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=1&author=+Aster&title=Thrombocytopenia+Induced+by+GPIIb%2FIIIa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAster%26atitle%3DThrombocytopenia%2520Induced%2520by%2520GPIIb%252FIIIa%2520Inhibitors%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00012_4"><span><span class="NLM_string-ref">(d) Peter, K.; Schwarz, M.; Nordt, T.; Bode, C. Intrinsic Activating Properties of GP IIb/IIIa Blockers.<i> Thromb. Res.</i><b>2001</b>, <i>103 (Suppl. 1)</i>, S21−S27.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103+%28Suppl.+1&publication_year=2001&pages=S27&author=K.+Peter&author=M.+Schwarz&author=T.+Nordt&author=C+Bode&title=Intrinsic+Activating+Properties+of+GP+IIb%2FIIIa+Blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DIntrinsic%2520Activating%2520Properties%2520of%2520GP%2520IIb%252FIIIa%2520Blockers%26jtitle%3DThromb.%2520Res.%26date%3D2001%26volume%3D103%2520%2528Suppl.%25201%26spage%3DS27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00012_5"><span><span class="NLM_string-ref">(e) Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M. Bleeding Complications with Glycoprotein IIb/IIIa Inhibitors. <i>  Drugs Today</i><b>2000</b>, <i>36</i>, 503−514.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2000&pages=514&author=O.+Iqbal&author=J.+M.+Walenga&author=B.+E.+Lewis&author=M+Bakhos&title=Bleeding+Complications+with+Glycoprotein+IIb%2FIIIa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DO.%26atitle%3DBleeding%2520Complications%2520with%2520Glycoprotein%2520IIb%252FIIIa%2520Inhibitors%26jtitle%3DDrugs%2520Today%26date%3D2000%26volume%3D36%26spage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00012_6"><span><span class="NLM_string-ref">(f) Billheimer, J. T.; He, B.; Spitz, S. M.; Stern, A. M.; Seiffert, D. Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Activation:  Development of a Transfer Method to Mimic Peak to Trough Receptor Occupancy. <i>  Thromb. Res.</i><b>2002</b>, <i>107 (6)</i>, 303−317.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2002&pages=317&issue=6&author=J.+T.+Billheimer&author=B.+He&author=S.+M.+Spitz&author=A.+M.+Stern&author=D+Seiffert&title=Effects+of+Glycoprotein+IIb%2FIIIa+Antagonists+on+Platelet+Activation%3A%E2%80%89+Development+of+a+Transfer+Method+to+Mimic+Peak+to+Trough+Receptor+Occupancy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00012_6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBillheimer%26aufirst%3DJ.%2BT.%26atitle%3DEffects%2520of%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%2520on%2520Platelet%2520Activation%253A%25E2%2580%2589%2520Development%2520of%2520a%2520Transfer%2520Method%2520to%2520Mimic%2520Peak%2520to%2520Trough%2520Receptor%2520Occupancy%26jtitle%3DThromb.%2520Res.%26date%3D2002%26volume%3D107%26issue%3D6%26spage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00013"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00013" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00013_1"><span><span class="NLM_string-ref">(a) Salam, A. M.; Al Suwaidi, J. Platelet Glycoprotein IIb/IIIa Antagonists in Clinical Trials for the Treatment of Coronary Artery Disease. <i>  Exp. Opin. </i><i>Invest. Drugs </i><b>2002</b>, <i>11</i>, 1645−1658.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1658&author=A.+M.+Salam&author=J+Al+Suwaidi&title=Platelet+Glycoprotein+IIb%2FIIIa+Antagonists+in+Clinical+Trials+for+the+Treatment+of+Coronary+Artery+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00013_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalam%26aufirst%3DA.%2BM.%26atitle%3DPlatelet%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonists%2520in%2520Clinical%2520Trials%2520for%2520the%2520Treatment%2520of%2520Coronary%2520Artery%2520Disease%26jtitle%3DExp.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00013_2"><span><span class="NLM_string-ref">(b) Peter, K.; Straub, A.; Kohler, B.; Volkmann, M.; Schwarz, M.; Kubler, W.; Bode, C. Platelet Activation as a Potential Mechanism of GP IIb/IIIa Inhibitor-Induced Thrombocytopenia. <i>  Am. J. Cardiol</i>. <b>1999</b>, <i>84</i>, 519−524.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1999&pages=524&author=K.+Peter&author=A.+Straub&author=B.+Kohler&author=M.+Volkmann&author=M.+Schwarz&author=W.+Kubler&author=C+Bode&title=Platelet+Activation+as+a+Potential+Mechanism+of+GP+IIb%2FIIIa+Inhibitor-Induced+Thrombocytopenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00013_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DPlatelet%2520Activation%2520as%2520a%2520Potential%2520Mechanism%2520of%2520GP%2520IIb%252FIIIa%2520Inhibitor-Induced%2520Thrombocytopenia%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1999%26volume%3D84%26spage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00014"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00014" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00014_1"><span><span class="NLM_string-ref">(a) Hosking, M. P.; Carroll, R. C. Roxifiban, DuPont. <i>  Curr. Opin. Cardiovasc. </i><i>Pulm. Renal Invest. Drugs </i><b>2000</b>, <i>2</i>, 165−171.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28a%29+Hosking%2C+M.+P.%3B+Carroll%2C+R.+C.+Roxifiban%2C+DuPont.+Curr.+Opin.+Cardiovasc.+Pulm.+Renal+Invest.+Drugs+2000%2C+2%2C+165%E2%88%92171.+%28a%29+Hosking%2C+M.+P.%3B+Carroll%2C+R.+C.+Roxifiban%2C+DuPont.+Curr.+Opin.+Cardiovasc.+Pulm.+Renal+Invest.+Drugs+2000%2C+2%2C+165%E2%88%92171."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHosking%26aufirst%3DM.%2BP.%26jtitle%3DCurr.%2520Opin.%2520Cardiovasc.%2520Pulm.%2520Renal%2520Invest.%2520Drugs%26date%3D2000%26volume%3D2%26spage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00014_2"><span><span class="NLM_string-ref">(b) Mousa, S. A.; Bozarth, J. M.; Naik, U. P.; Slee, A. Platelet GPIIb/IIIa Binding Characteristics of Small Molecule RGD Mimetic:  Distinct Binding Profile for Roxifiban. <i>  Br. </i><i>J. Pharmacol.</i><b>2001</b>, <i>133</i>, 331−336.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Mousa%2C+S.+A.%3B+Bozarth%2C+J.+M.%3B+Naik%2C+U.+P.%3B+Slee%2C+A.+Platelet+GPIIb%2FIIIa+Binding+Characteristics+of+Small+Molecule+RGD+Mimetic%3A%E2%80%89+Distinct+Binding+Profile+for+Roxifiban.+Br.+J.+Pharmacol.+2001%2C+133%2C+331%E2%88%92336.+%28b%29+Mousa%2C+S.+A.%3B+Bozarth%2C+J.+M.%3B+Naik%2C+U.+P.%3B+Slee%2C+A.+Platelet+GPIIb%2FIIIa+Binding+Characteristics+of+Small+Molecule+RGD+Mimetic%3A%E2%80%89+Distinct+Binding+Profile+for+Roxifiban.+Br.+J.+Pharmacol.2001%2C+133%2C+331%E2%88%92336."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D133%26spage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00014_3"><span><span class="NLM_string-ref">(c) Mousa, S. A.; Kapil, R.; Mu, D. Intravenous and Oral Antithrombotic Efficacy of the Novel Platelet GPIIb/IIIa Antagonist Roxifiban (DMP754) and its Free Acid Form, XV459. <i>  Arterioscler. Thromb. Vasc. Biol. </i><b>1999</b>, <i>19</i>, 2535−2541.  2060  (d) Gurbel, P. A.; McKenzie, M. E.; Serebruany, V. L. Initial Platelet Activity may Predict Efficacy after Chronic Oral Glycoprotein IIb/IIIa Blockade:  Should We Still Consider Uniform Treatment Regimens? <i>Thromb. Res.</i><b>2000</b>, <i>99</i>, 105−107.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2541&author=S.+A.+Mousa&author=R.+Kapil&author=D+Mu&title=Intravenous+and+Oral+Antithrombotic+Efficacy+of+the+Novel+Platelet+GPIIb%2FIIIa+Antagonist+Roxifiban+%28DMP754%29+and+its+Free+Acid+Form%2C+XV459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DIntravenous%2520and%2520Oral%2520Antithrombotic%2520Efficacy%2520of%2520the%2520Novel%2520Platelet%2520GPIIb%252FIIIa%2520Antagonist%2520Roxifiban%2520%2528DMP754%2529%2520and%2520its%2520Free%2520Acid%2520Form%252C%2520XV459%26jtitle%3DArterioscler.%2520Thromb.%2520Vasc.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00014_4"><span><span class="NLM_string-ref">(e) Fossler, M. J.; Ebling, W. F.; Ma, S.; Kornhauser, D.; Mondick, J.; Barrett, J. S.; Garner, D.; Quon, C. Y.; Pieniaszek, H. J., Jr. Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers. <i>  J. Clin. </i><i>Pharmacol.</i><b>2002</b>,<i> 42</i>, 1326−1334.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28e%29+Fossler%2C+M.+J.%3B+Ebling%2C+W.+F.%3B+Ma%2C+S.%3B+Kornhauser%2C+D.%3B+Mondick%2C+J.%3B+Barrett%2C+J.+S.%3B+Garner%2C+D.%3B+Quon%2C+C.+Y.%3B+Pieniaszek%2C+H.+J.%2C+Jr.+Integrated+Pharmacokinetic%2FPharmacodynamic+Model+of+XV459%2C+a+Potent+and+Specific+GPIIb%2FIIIa+Inhibitor%2C+in+Healthy+Male+Volunteers.+J.+Clin.+Pharmacol.+2002%2C+42%2C+1326%E2%88%921334.+%28e%29+Fossler%2C+M.+J.%3B+Ebling%2C+W.+F.%3B+Ma%2C+S.%3B+Kornhauser%2C+D.%3B+Mondick%2C+J.%3B+Barrett%2C+J.+S.%3B+Garner%2C+D.%3B+Quon%2C+C.+Y.%3B+Pieniaszek%2C+H.+J.%2C+Jr.+Integrated+Pharmacokinetic%2FPharmacodynamic+Model+of+XV459%2C+a+Potent+and+Specific+GPIIb%2FIIIa+Inhibitor%2C+in+Healthy+Male+Volunteers.+J.+Clin.+Pharmacol.2002%2C+42%2C+1326%E2%88%921334."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00014_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFossler%26aufirst%3DM.%2BJ.%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D42%26spage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00015"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00015" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00015_1"><span><span class="NLM_string-ref">(a) Smyth, M. S.; Rose, J.; Mehrotra, M. M.; Heath, J.; Ruhter, G.; Schotten, T.; Seroogy, J.; Volkots, D.; Pandey, A.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 1:  Design of Potent and Specific 3,9-Diazaspiro[5.5]undecanes. <i>  Bioorg. Med. Chem. Lett.</i><b>2001</b>, <i>11</i>, 1289−1292.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1292&author=M.+S.+Smyth&author=J.+Rose&author=M.+M.+Mehrotra&author=J.+Heath&author=G.+Ruhter&author=T.+Schotten&author=J.+Seroogy&author=D.+Volkots&author=A.+Pandey&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+1%3A%E2%80%89+Design+of+Potent+and+Specific+3%2C9-Diazaspiro%5B5.5%5Dundecanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25201%253A%25E2%2580%2589%2520Design%2520of%2520Potent%2520and%2520Specific%25203%252C9-Diazaspiro%255B5.5%255Dundecanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00015_2"><span><span class="NLM_string-ref">(b) Pandey, A.; Seroogy, J.; Volkots, D.; Smyth, M. S.; Rose, J.; Mehrotra, M. M.; Heath, J.; Ruhter, G.; Schotten, T.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 2:  Design of Potent Antagonists Containing the 3-Azaspiro[5.5]undec-9-yl Template. <i>  Bioorg. Med. Chem. Lett.</i><b>2001</b>, <i>11</i>, 1293−1296.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1296&author=A.+Pandey&author=J.+Seroogy&author=D.+Volkots&author=M.+S.+Smyth&author=J.+Rose&author=M.+M.+Mehrotra&author=J.+Heath&author=G.+Ruhter&author=T.+Schotten&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+2%3A%E2%80%89+Design+of+Potent+Antagonists+Containing+the+3-Azaspiro%5B5.5%5Dundec-9-yl+Template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25202%253A%25E2%2580%2589%2520Design%2520of%2520Potent%2520Antagonists%2520Containing%2520the%25203-Azaspiro%255B5.5%255Dundec-9-yl%2520Template%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00015_3"><span><span class="NLM_string-ref">(c) Mehrotra, M. M.; Heath, J.; Rose, J.; Smyth, M. S.; Seroogy, J.; Volkots, D.; Ruhter, G.; Schotten, T.; Alaimo, L.; Park, G.; Pandey, A.; Scarborough, R. M. Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3:  Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes. <i>  Bioorg. Med. Chem. Lett.</i><b>2002</b>, <i>12</i>, 1103−1107.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1107&author=M.+M.+Mehrotra&author=J.+Heath&author=J.+Rose&author=M.+S.+Smyth&author=J.+Seroogy&author=D.+Volkots&author=G.+Ruhter&author=T.+Schotten&author=L.+Alaimo&author=G.+Park&author=A.+Pandey&author=R.+M+Scarborough&title=Spirocyclic+Nonpeptide+Glycoprotein+IIb-IIIa+Antagonists.+Part+3%3A%E2%80%89+Synthesis+and+SAR+of+Potent+and+Specific+2%2C8-Diazaspiro%5B4.5%5Ddecanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMehrotra%26aufirst%3DM.%2BM.%26atitle%3DSpirocyclic%2520Nonpeptide%2520Glycoprotein%2520IIb-IIIa%2520Antagonists.%2520Part%25203%253A%25E2%2580%2589%2520Synthesis%2520and%2520SAR%2520of%2520Potent%2520and%2520Specific%25202%252C8-Diazaspiro%255B4.5%255Ddecanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00015_4"><span><span class="NLM_string-ref">(d) Fisher, M. J.; Jakubowski, J. A.; Masters, J. J.; Mullaney, J. T.; Ruterbories, K. J.; Paal, M.; Ruhter, G.; Scarborough, R. M.; Schotten, T.; Stenzel, W. Spiro Compounds as Inhibitors of Fibrinogen-Dependent Platelet Aggregation. U.S. Patent 6291469, 2001.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+J.+Fisher&author=J.+A.+Jakubowski&author=J.+J.+Masters&author=J.+T.+Mullaney&author=K.+J.+Ruterbories&author=M.+Paal&author=G.+Ruhter&author=R.+M.+Scarborough&author=T.+Schotten&author=W.+Stenzel&title=Spiro+Compounds+as+Inhibitors+of+Fibrinogen-Dependent+Platelet+Aggregation.+U.S.+Patent+6291469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00015_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26btitle%3DSpiro%2520Compounds%2520as%2520Inhibitors%2520of%2520Fibrinogen-Dependent%2520Platelet%2520Aggregation.%2520U.S.%2520Patent%25206291469%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00016"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00016" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00016_1"><span><span class="NLM_string-ref">(a) Wagner, G.; Voigt, B.; Vieweg, H. Synthesis of N-α-(Arylsulfonylglycyl) amidinophenylalaninamides as Highly Active Inhibitors of Thrombin. <i>  Pharmazie</i><b>1984</b>, <i>39</i>, 226−230.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1984&pages=230&author=G.+Wagner&author=B.+Voigt&author=H+Vieweg&title=Synthesis+of+N-%CE%B1-%28Arylsulfonylglycyl%29+amidinophenylalaninamides+as+Highly+Active+Inhibitors+of+Thrombin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00016_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520N-%25CE%25B1-%2528Arylsulfonylglycyl%2529%2520amidinophenylalaninamides%2520as%2520Highly%2520Active%2520Inhibitors%2520of%2520Thrombin%26jtitle%3DPharmazie%26date%3D1984%26volume%3D39%26spage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00016_2"><span><span class="NLM_string-ref">(b) Judkins, B. D.; Allen, D. G.; Cook, T. A.; Evans, B.; Sardharwala, T. E. A Versatile Synthesis of Amidines from Nitriles Via Amidoximes. <i>  Synth. Commun.</i><b>1996</b>, <i>26(23)</i>, 4351−4367.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=4367&issue=23&author=B.+D.+Judkins&author=D.+G.+Allen&author=T.+A.+Cook&author=B.+Evans&author=T.+E+Sardharwala&title=A+Versatile+Synthesis+of+Amidines+from+Nitriles+Via+Amidoximes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00016_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJudkins%26aufirst%3DB.%2BD.%26atitle%3DA%2520Versatile%2520Synthesis%2520of%2520Amidines%2520from%2520Nitriles%2520Via%2520Amidoximes%26jtitle%3DSynth.%2520Commun.%26date%3D1996%26volume%3D26%26issue%3D23%26spage%3D4367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00017"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00017" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00017_1"><span><span class="NLM_string-ref">(a) Rawal, V. H.; Jones, R. J.; Cava, M. P. Photocyclization Strategy for the Synthesis of Antitumor Agent CC-1065:  Synthesis of Dideoxy PDE-I and PDE-II. Synthesis of Thiopene and Furan Analogues of Dideoxy PDE-I and PDE-II. <i>  J. Org. Chem.</i><b>1987</b>, <i>52</i>, 19−28.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1987&pages=28&author=V.+H.+Rawal&author=R.+J.+Jones&author=M.+P+Cava&title=Photocyclization+Strategy+for+the+Synthesis+of+Antitumor+Agent+CC-1065%3A%E2%80%89+Synthesis+of+Dideoxy+PDE-I+and+PDE-II.+Synthesis+of+Thiopene+and+Furan+Analogues+of+Dideoxy+PDE-I+and+PDE-II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00017_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRawal%26aufirst%3DV.%2BH.%26atitle%3DPhotocyclization%2520Strategy%2520for%2520the%2520Synthesis%2520of%2520Antitumor%2520Agent%2520CC-1065%253A%25E2%2580%2589%2520Synthesis%2520of%2520Dideoxy%2520PDE-I%2520and%2520PDE-II.%2520Synthesis%2520of%2520Thiopene%2520and%2520Furan%2520Analogues%2520of%2520Dideoxy%2520PDE-I%2520and%2520PDE-II%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1987%26volume%3D52%26spage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00017_2"><span><span class="NLM_string-ref">(b) Reinecke, M. G.; Daubert, R. G. Periphral Synthesis of Secondary Medium-Ring Nitrogen Heterocycles. <i>  J. Org. Chem.</i><b>1973</b>, <i>38</i>, 3281−3287.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1973&pages=3287&author=M.+G.+Reinecke&author=R.+G+Daubert&title=Periphral+Synthesis+of+Secondary+Medium-Ring+Nitrogen+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00017_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%2BG.%26atitle%3DPeriphral%2520Synthesis%2520of%2520Secondary%2520Medium-Ring%2520Nitrogen%2520Heterocycles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1973%26volume%3D38%26spage%3D3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00018"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00018" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00018_1"><span><span class="NLM_string-ref">Dong, Q.; Anderson, C. E.; Ciufolini, M. A. Reductive Cleavage of TROC Groups under Neutral Conditions with Cadmium−Lead Couple. <i>  Tetrahedron Lett</i>. <b>1995</b>, 5681−5682.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5681&publication_year=1995&pages=5682&author=Q.+Dong&author=C.+E.+Anderson&author=M.+A+Ciufolini&title=Reductive+Cleavage+of+TROC+Groups+under+Neutral+Conditions+with+Cadmium%E2%88%92Lead+Couple"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00018_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DQ.%26atitle%3DReductive%2520Cleavage%2520of%2520TROC%2520Groups%2520under%2520Neutral%2520Conditions%2520with%2520Cadmium%25E2%2588%2592Lead%2520Couple%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D5681%26spage%3D5682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00019"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00019" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00019_1"><span><span class="NLM_string-ref">(a) Carrera, G. M., Jr.; Garvey, D. S. Synthesis of Novel Substituted Spirohydantoins. <i>  J. Heterocycl. Chem.</i><b>1992</b>, <i>29</i>, 847−850.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1992&pages=850&author=G.+M.+Carrera&author=+Jr&title=Synthesis+of+Novel+Substituted+Spirohydantoins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00019_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520Novel%2520Substituted%2520Spirohydantoins%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1992%26volume%3D29%26spage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00019_2"><span><span class="NLM_string-ref">(b) Suess, R. Substituierte 2,8-Diazaspiro-decan-1,3-dione. <i>  Helv. Chim. </i><i>Acta</i><b>1977</b>, <i>60(5)</i>, 1650−1656; & Jucker, E.; Sue, R. <i>Arch. Pharm</i>. <b>1961</b>, <i>294</i>, 210−220.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28b%29+Suess%2C+R.+Substituierte+2%2C8-Diazaspiro-decan-1%2C3-dione.+Helv.+Chim.+Acta+1977%2C+60%285%29%2C+1650%E2%88%921656%3B+%26+Jucker%2C+E.%3B+Sue%2C+R.+Arch.+Pharm.+1961%2C+294%2C+210%E2%88%92220.+%28b%29+Suess%2C+R.+Substituierte+2%2C8-Diazaspiro-decan-1%2C3-dione.+Helv.+Chim.+Acta1977%2C+60%285%29%2C+1650%E2%88%921656%3B+%26+Jucker%2C+E.%3B+Sue%2C+R.+Arch.+Pharm.+1961%2C+294%2C+210%E2%88%92220."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00019_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuess%26aufirst%3DR.%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1977%26volume%3D60%26issue%3D5%26spage%3D1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00020"><div class="reference"><div class="NLM_citation" id="rightTab-jm030354bb00020_1"><span><span class="NLM_string-ref">Fisher, M. J.; Gunn, B.; Harms, C. S.; Kline, A. D.; Mullaney, J. T.; Nunes, A.; Scarborough, R. M.; Arfsten, A. E.; Skelton, M. A.; Um, S. L.; Utterback, B. G.; Jakubowski, J. A. Non-Peptide RGD Surrogates which Mimic a Gly-Asp β-Turn:  Potent Antagonists of Platelet Glycoprotein IIb-IIIa. <i>  J. </i><i>Med. Chem</i>. <b>1997</b>, <i>40</i>, 2085−2101.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2101&author=M.+J.+Fisher&author=B.+Gunn&author=C.+S.+Harms&author=A.+D.+Kline&author=J.+T.+Mullaney&author=A.+Nunes&author=R.+M.+Scarborough&author=A.+E.+Arfsten&author=M.+A.+Skelton&author=S.+L.+Um&author=B.+G.+Utterback&author=J.+A+Jakubowski&title=Non-Peptide+RGD+Surrogates+which+Mimic+a+Gly-Asp+%CE%B2-Turn%3A%E2%80%89+Potent+Antagonists+of+Platelet+Glycoprotein+IIb-IIIa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00020_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26atitle%3DNon-Peptide%2520RGD%2520Surrogates%2520which%2520Mimic%2520a%2520Gly-Asp%2520%25CE%25B2-Turn%253A%25E2%2580%2589%2520Potent%2520Antagonists%2520of%2520Platelet%2520Glycoprotein%2520IIb-IIIa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00021"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00021" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00021_1"><span><span class="NLM_string-ref">Su, T.; Naughton, M. A.; Smyth, M. S.; Rose, J. W.; Arfsten, A. E.; McCowan, J. R.; Jakubowski, J. A.; Wyss, V. L.; Ruterbories, K. J.; Sall, D. J.; Scarborough, R. M. Fibrinogen Receptor (GPIIb/IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-α-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors. <i>  J. Med. Chem.</i><b>1997</b>, <i>40</i>, 4308−4318.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Su%2C+T.%3B+Naughton%2C+M.+A.%3B+Smyth%2C+M.+S.%3B+Rose%2C+J.+W.%3B+Arfsten%2C+A.+E.%3B+McCowan%2C+J.+R.%3B+Jakubowski%2C+J.+A.%3B+Wyss%2C+V.+L.%3B+Ruterbories%2C+K.+J.%3B+Sall%2C+D.+J.%3B+Scarborough%2C+R.+M.+Fibrinogen+Receptor+%28GPIIb%2FIIIa%29+Antagonists+Derived+from+5%2C6-Bicyclic+Templates.+Amidinoindoles%2C+Amidinoindazoles%2C+and+Amidinobenzofurans+Containing+the+N-%CE%B1-Sulfonamide+Carboxylic+Acid+Function+as+Potent+Platelet+Aggregation+Inhibitors.+J.+Med.+Chem.+1997%2C+40%2C+4308%E2%88%924318.+Su%2C+T.%3B+Naughton%2C+M.+A.%3B+Smyth%2C+M.+S.%3B+Rose%2C+J.+W.%3B+Arfsten%2C+A.+E.%3B+McCowan%2C+J.+R.%3B+Jakubowski%2C+J.+A.%3B+Wyss%2C+V.+L.%3B+Ruterbories%2C+K.+J.%3B+Sall%2C+D.+J.%3B+Scarborough%2C+R.+M.+Fibrinogen+Receptor+%28GPIIb%2FIIIa%29+Antagonists+Derived+from+5%2C6-Bicyclic+Templates.+Amidinoindoles%2C+Amidinoindazoles%2C+and+Amidinobenzofurans+Containing+the+N-%CE%B1-Sulfonamide+Carboxylic+Acid+Function+as+Potent+Platelet+Aggregation+Inhibitors.+J.+Med.+Chem.1997%2C+40%2C+4308%E2%88%924318."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00021_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00022"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00022" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00022_1"><span><span class="NLM_string-ref">(a) Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. <i>  J. Med. Chem.</i><b>1992</b>, <i>35</i>, 4640−4642.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4642&author=G.+D.+Hartman&author=M.+S.+Egbertson&author=W.+Halczenko&author=W.+L.+Laswell&author=M.+E.+Duggan&author=R.+L.+Smith&author=A.+M.+Naylor&author=P.+D.+Manno&author=R.+J.+Lynch&author=G.+Zhang&author=C.+T.-C.+Chang&author=R.+J+Gould&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+1.+Discovery+and+Design+of+Exosite+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25201.%2520Discovery%2520and%2520Design%2520of%2520Exosite%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00022_2"><span><span class="NLM_string-ref">(b) Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, Jr. J. J.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp. <i>  J. Med. Chem.</i><b>1994</b>, <i>37</i>, 2537−2551.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2551&author=M.+S.+Egbertson&author=C.+T.-C.+Chang&author=M.+E.+Duggan&author=R.+J.+Gould&author=W.+Halczenko&author=G.+D.+Hartman&author=W.+L.+Laswell&author=Jr.+J.+J.+Lynch&author=R.+J.+Lynch&author=P.+D.+Manno&author=A.+M.+Naylor&author=J.+D.+Prugh&author=D.+R.+Ramjit&author=G.+R.+Sitko&author=R.+S.+Smith&author=L.+M.+Turchi&author=G+Zhang&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+2.+Optimization+of+a+Tyrosine+Template+as+a+Mimic+for+Arg-Gly-Asp"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25202.%2520Optimization%2520of%2520a%2520Tyrosine%2520Template%2520as%2520a%2520Mimic%2520for%2520Arg-Gly-Asp%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00022_3"><span><span class="NLM_string-ref">(c) Xue, C.-B.; Roderick, J.; Jackson, S.; Rafalski, M.; Rockwell, A.; Mousa, S.; Olson. R. E.; DeGrado, W. F. Design, Synthesis, and in Vitro Activities of Benzamide-Core Glycoprotein IIb-IIIa Antagonists:  2,3-Diaminopropionic Acid Derivatives as Surrogates of Aspartic Acid. <i>  Bioorg. Med. Chem. </i><b>1997</b>, <i>5</i>, 693−705.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%28c%29+Xue%2C+C.-B.%3B+Roderick%2C+J.%3B+Jackson%2C+S.%3B+Rafalski%2C+M.%3B+Rockwell%2C+A.%3B+Mousa%2C+S.%3B+Olson.+R.+E.%3B+DeGrado%2C+W.+F.+Design%2C+Synthesis%2C+and+in+Vitro+Activities+of+Benzamide-Core+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+2%2C3-Diaminopropionic+Acid+Derivatives+as+Surrogates+of+Aspartic+Acid.+Bioorg.+Med.+Chem.+1997%2C+5%2C+693%E2%88%92705.+%28c%29+Xue%2C+C.-B.%3B+Roderick%2C+J.%3B+Jackson%2C+S.%3B+Rafalski%2C+M.%3B+Rockwell%2C+A.%3B+Mousa%2C+S.%3B+Olson.+R.+E.%3B+DeGrado%2C+W.+F.+Design%2C+Synthesis%2C+and+in+Vitro+Activities+of+Benzamide-Core+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+2%2C3-Diaminopropionic+Acid+Derivatives+as+Surrogates+of+Aspartic+Acid.+Bioorg.+Med.+Chem.+1997%2C+5%2C+693%E2%88%92705."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00022_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.-B.%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26spage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00023"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00023" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00023_1"><span><span class="NLM_string-ref">(a) Scarborough, R. M.; Rose, J. W.; Naughton, M. A.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Characterization of the Integrin Specificities of Disintegrins Isolated from American Pit Vipor Venoms. <i>  J. </i><i>Biol. Chem</i>. <b>1993</b>, <i>268</i>, 1058−1065.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=1065&author=R.+M.+Scarborough&author=J.+W.+Rose&author=M.+A.+Naughton&author=D.+R.+Phillips&author=L.+Nannizzi&author=A.+Arfsten&author=A.+M.+Campbell&author=I.+F+Charo&title=Characterization+of+the+Integrin+Specificities+of+Disintegrins+Isolated+from+American+Pit+Vipor+Venoms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00023_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520Integrin%2520Specificities%2520of%2520Disintegrins%2520Isolated%2520from%2520American%2520Pit%2520Vipor%2520Venoms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00023_2"><span><span class="NLM_string-ref">(b) Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. <i>  J. Med. Chem.</i><b>1995</b>, <i>38</i>, 3332−3341.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3341&author=M.+E.+Duggan&author=A.+M.+Naylor-Olsen&author=J.+J.+Perkins&author=P.+S.+Anderson&author=C.+T.-C.+Chang&author=J.+J.+Cook&author=R.+J.+Gould&author=N.+C.+Ihle&author=G.+D.+Hartman&author=J.+J.+Lynch&author=R.+J.+Lynch&author=P.+D.+Manno&author=L.+W.+Schaffer&author=R.+L+Smith&title=Non-Peptide+Fibrinogen+Receptor+Antagonists.+7.+Design+and+Synthesis+of+a+Potent%2C+Orally+Active+Fibrinogen+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00023_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DNon-Peptide%2520Fibrinogen%2520Receptor%2520Antagonists.%25207.%2520Design%2520and%2520Synthesis%2520of%2520a%2520Potent%252C%2520Orally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00024"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00024" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00024_1"><span><span class="NLM_string-ref">Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in vitro and in vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. <i>  J. Med. </i><i>Chem</i>. <b>1995</b>, <i>38</i>, 2378−2394.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=2394&author=J.+A.+Zablocki&author=J.+G.+Rico&author=R.+B.+Garland&author=T.+E.+Rogers&author=K.+Williams&author=L.+A.+Schretzman&author=S.+A.+Rao&author=P.+R.+Bovy&author=F.+S.+Tjoeng&author=R.+J.+Lindmark&author=M.+V.+Toth&author=M.+E.+Zupec&author=D.+E.+McMackins&author=S.+P.+Adams&author=M.+Miyano&author=C.+S.+Markos&author=M.+N.+Milton&author=S.+Paulson&author=M.+Herin&author=P.+Jacqmin&author=N.+S.+Nicholson&author=S.+G.+Panzer-Knodle&author=N.+F.+Haas&author=J.+D.+Page&author=J.+A.+Szalony&author=B.+B.+Taite&author=A.+K.+Salyers&author=L.+W.+King&author=J.+G.+Campion&author=L.+P+Feigen&title=Potent+in+vitro+and+in+vivo+Inhibitors+of+Platelet+Aggregation+Based+upon+the+Arg-Gly-Asp+Sequence+of+Fibrinogen.+%28Aminobenzamidino%29succinyl+%28ABAS%29+Series+of+Orally+Active+Fibrinogen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00024_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZablocki%26aufirst%3DJ.%2BA.%26atitle%3DPotent%2520in%2520vitro%2520and%2520in%2520vivo%2520Inhibitors%2520of%2520Platelet%2520Aggregation%2520Based%2520upon%2520the%2520Arg-Gly-Asp%2520Sequence%2520of%2520Fibrinogen.%2520%2528Aminobenzamidino%2529succinyl%2520%2528ABAS%2529%2520Series%2520of%2520Orally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D2394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00025"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00025" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00025_1"><span><span class="NLM_string-ref">Mills, S. D. Heterocyclic Compounds. U.S. Patent 5,753,659, 1998.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=S.+D.+Mills&author=U.S.+Heterocyclic+Compounds&title=Patent+5%2C753%2C659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00025_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DS.%2BD.%26btitle%3DPatent%25205%252C753%252C659%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00026"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00026" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00026_1"><span><span class="NLM_string-ref">Samanen, J. M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.; Burgess, J. L.; Callahen, J. F.; Calvo, R. R.; Chen, W.; Chen, L.; Erhard, K.; Feuarstein, G.; Heys, R.; Hwang, S.-M.; Jckas, D. R.; Keenan, R. M.; Ku, T. W.; Kwon, C.; Lee, C.-P.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzsinskas, I.; Vensalavsky, J. W.; Yuan, C.-K.; Huffman, W. F. Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb-IIIa Integrin Antagonists. <i>  J. Med. Chem.</i><b>1996</b>, <i>39</i>, 4867−4870.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Samanen%2C+J.+M.%3B+Ali%2C+F.+E.%3B+Barton%2C+L.+S.%3B+Bondinell%2C+W.+E.%3B+Burgess%2C+J.+L.%3B+Callahen%2C+J.+F.%3B+Calvo%2C+R.+R.%3B+Chen%2C+W.%3B+Chen%2C+L.%3B+Erhard%2C+K.%3B+Feuarstein%2C+G.%3B+Heys%2C+R.%3B+Hwang%2C+S.-M.%3B+Jckas%2C+D.+R.%3B+Keenan%2C+R.+M.%3B+Ku%2C+T.+W.%3B+Kwon%2C+C.%3B+Lee%2C+C.-P.%3B+Miller%2C+W.+H.%3B+Newlander%2C+K.+A.%3B+Nichols%2C+A.%3B+Parker%2C+M.%3B+Peishoff%2C+C.+E.%3B+Rhodes%2C+G.%3B+Ross%2C+S.%3B+Shu%2C+A.%3B+Simpson%2C+R.%3B+Takata%2C+D.%3B+Yellin%2C+T.+O.%3B+Uzsinskas%2C+I.%3B+Vensalavsky%2C+J.+W.%3B+Yuan%2C+C.-K.%3B+Huffman%2C+W.+F.+Potent%2C+Selective%2C+Orally+Active+3-Oxo-1%2C4-benzodiazepine+GPIIb-IIIa+Integrin+Antagonists.+J.+Med.+Chem.+1996%2C+39%2C+4867%E2%88%924870.+Samanen%2C+J.+M.%3B+Ali%2C+F.+E.%3B+Barton%2C+L.+S.%3B+Bondinell%2C+W.+E.%3B+Burgess%2C+J.+L.%3B+Callahen%2C+J.+F.%3B+Calvo%2C+R.+R.%3B+Chen%2C+W.%3B+Chen%2C+L.%3B+Erhard%2C+K.%3B+Feuarstein%2C+G.%3B+Heys%2C+R.%3B+Hwang%2C+S.-M.%3B+Jckas%2C+D.+R.%3B+Keenan%2C+R.+M.%3B+Ku%2C+T.+W.%3B+Kwon%2C+C.%3B+Lee%2C+C.-P.%3B+Miller%2C+W.+H.%3B+Newlander%2C+K.+A.%3B+Nichols%2C+A.%3B+Parker%2C+M.%3B+Peishoff%2C+C.+E.%3B+Rhodes%2C+G.%3B+Ross%2C+S.%3B+Shu%2C+A.%3B+Simpson%2C+R.%3B+Takata%2C+D.%3B+Yellin%2C+T.+O.%3B+Uzsinskas%2C+I.%3B+Vensalavsky%2C+J.+W.%3B+Yuan%2C+C.-K.%3B+Huffman%2C+W.+F.+Potent%2C+Selective%2C+Orally+Active+3-Oxo-1%2C4-benzodiazepine+GPIIb-IIIa+Integrin+Antagonists.+J.+Med.+Chem.1996%2C+39%2C+4867%E2%88%924870."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00026_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamanen%26aufirst%3DJ.%2BM.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D4870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00027"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00027" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00027_1"><span><span class="NLM_string-ref">Damiano, B. P.; Mitchell, J. A.; Giardino, E.; Corcoran, T.; Haertlein, B. J.; De Garavilla, L.; Kauffman, J. A.; Hoekstra, W. J.; Maryanoff, B. E.; Andrade-Gordon, P. Antiplatelet and Antithrombotic Activity of RWJ-53308, a Novel Orally Active Glycoprotein IIb/IIIa Antagonist. <i>  Thromb. Res.</i><b>2001</b>,<i> 104</i>, 113−126.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=126&author=B.+P.+Damiano&author=J.+A.+Mitchell&author=E.+Giardino&author=T.+Corcoran&author=B.+J.+Haertlein&author=L.+De+Garavilla&author=J.+A.+Kauffman&author=W.+J.+Hoekstra&author=B.+E.+Maryanoff&author=P+Andrade-Gordon&title=Antiplatelet+and+Antithrombotic+Activity+of+RWJ-53308%2C+a+Novel+Orally+Active+Glycoprotein+IIb%2FIIIa+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00027_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26atitle%3DAntiplatelet%2520and%2520Antithrombotic%2520Activity%2520of%2520RWJ-53308%252C%2520a%2520Novel%2520Orally%2520Active%2520Glycoprotein%2520IIb%252FIIIa%2520Antagonist%26jtitle%3DThromb.%2520Res.%26date%3D2001%26volume%3D104%26spage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00028"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00028" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00028_1"><span><span class="NLM_string-ref">(a) Hayashi, Y.; Katada, J.; Harada, T.; Tachki, A.; Iijima, K.; Takiguchi, Y.; Muramatsu, M.; Miyazaki, H.; Asari, T.; Okazaki, T.; Sato, Y.; Yasuda, E.; Yano, M.; Uno, I.; Ojima, I. GPIIb-IIIa Integrin Antagonists with the New Conformational Restriction Unit, Trisubstituted β-Amino Acid Derivatives, and a Substituted Benzamidine Structure. <i>  J. Med. Chem.</i><b>1998</b>, <i>41</i>, 2345−2360.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2360&author=Y.+Hayashi&author=J.+Katada&author=T.+Harada&author=A.+Tachki&author=K.+Iijima&author=Y.+Takiguchi&author=M.+Muramatsu&author=H.+Miyazaki&author=T.+Asari&author=T.+Okazaki&author=Y.+Sato&author=E.+Yasuda&author=M.+Yano&author=I.+Uno&author=I+Ojima&title=GPIIb-IIIa+Integrin+Antagonists+with+the+New+Conformational+Restriction+Unit%2C+Trisubstituted+%CE%B2-Amino+Acid+Derivatives%2C+and+a+Substituted+Benzamidine+Structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DGPIIb-IIIa%2520Integrin%2520Antagonists%2520with%2520the%2520New%2520Conformational%2520Restriction%2520Unit%252C%2520Trisubstituted%2520%25CE%25B2-Amino%2520Acid%2520Derivatives%252C%2520and%2520a%2520Substituted%2520Benzamidine%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00028_2"><span><span class="NLM_string-ref">(b) Okumura, K.; Shimazaki, T.; Aoki, Y.; Yamashita, H.; Tanaka, E.; Banba, S.; Yazawa, K.; Kibayashi, K.; Banno, H. New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists:  Orally Active Series of N−Alkylated Amidines with a 6,6-Bicyclic Template.<i> J. Med. </i><i>Chem.</i><b>1998</b>, <i>41</i>, 4036−4052.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4052&author=K.+Okumura&author=T.+Shimazaki&author=Y.+Aoki&author=H.+Yamashita&author=E.+Tanaka&author=S.+Banba&author=K.+Yazawa&author=K.+Kibayashi&author=H+Banno&title=New+Platelet+Fibrinogen+Receptor+Glycoprotein+IIb-IIIa+Antagonists%3A%E2%80%89+Orally+Active+Series+of+N%E2%88%92Alkylated+Amidines+with+a+6%2C6-Bicyclic+Template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DK.%26atitle%3DNew%2520Platelet%2520Fibrinogen%2520Receptor%2520Glycoprotein%2520IIb-IIIa%2520Antagonists%253A%25E2%2580%2589%2520Orally%2520Active%2520Series%2520of%2520N%25E2%2588%2592Alkylated%2520Amidines%2520with%2520a%25206%252C6-Bicyclic%2520Template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00028_3"><span><span class="NLM_string-ref">(c) Yamashita, H.; Okumura, K.; Shimazaki, T.; Kanematsu, A.; Aoki, Y.; Nakajima, Y.; Yazawa, K.; Kibayashi, K. Amidine Derivatives and Platelet Aggregation Inhibitor Containing the Same. European Patent 0760364A2, 1997.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=H.+Yamashita&author=K.+Okumura&author=T.+Shimazaki&author=A.+Kanematsu&author=Y.+Aoki&author=Y.+Nakajima&author=K.+Yazawa&author=K.+Kibayashi&title=Amidine+Derivatives+and+Platelet+Aggregation+Inhibitor+Containing+the+Same.+European+Patent+0760364A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00028_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DH.%26btitle%3DAmidine%2520Derivatives%2520and%2520Platelet%2520Aggregation%2520Inhibitor%2520Containing%2520the%2520Same.%2520European%2520Patent%25200760364A2%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00029"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00029" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00029_1"><span><span class="NLM_string-ref">Muller, T. H.; Schurer, H.; Waldmann, L.; Bauer, E.; Himmelsbach, F.; Binder, K. Oral Activity of BIBU 104, a Prodrug of the Non-Peptide Fibrinogen Receptor Antagonist BIBU 52, in Mice and Monkeys. <i>  Thromb. </i><i>Haemostasis</i><b>1993</b>, <i>69</i>, 975, Abstract 1557.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1993&pages=1557&author=T.+H.+Muller&author=H.+Schurer&author=L.+Waldmann&author=E.+Bauer&author=F.+Himmelsbach&author=K+Binder&title=Oral+Activity+of+BIBU+104%2C+a+Prodrug+of+the+Non-Peptide+Fibrinogen+Receptor+Antagonist+BIBU+52%2C+in+Mice+and+Monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00029_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DT.%2BH.%26atitle%3DOral%2520Activity%2520of%2520BIBU%2520104%252C%2520a%2520Prodrug%2520of%2520the%2520Non-Peptide%2520Fibrinogen%2520Receptor%2520Antagonist%2520BIBU%252052%252C%2520in%2520Mice%2520and%2520Monkeys%26jtitle%3DThromb.%2520Haemostasis%26date%3D1993%26volume%3D69%26spage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00030"><div class="reference"><div class="NLM_citation" id="rightTab-jm030354bb00030_1"><span><span class="NLM_string-ref">(a) Merlos, M.; Graul, A.; Castaner, J. Sibrafiban <i>Drugs Future</i><b>1998</b>, <i>23</i>, 1297−1303.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=M.+Merlos&author=A.+Graul&author=J.+Castaner&title=Sibrafiban+Drugs+Future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00030_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26btitle%3DSibrafiban%2520Drugs%2520Future%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00030_2"><span><span class="NLM_string-ref">(b) Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines.<i> J. Med. Chem</i>. <b>1996</b>, <i>39</i>, 3139−3147.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3147&author=T.+Weller&author=L.+Alig&author=M.+Beresini&author=B.+Blackburn&author=S.+Bunting&author=P.+Hadvary&author=M.+H.+Muller&author=D.+Knopp&author=B.+Levet-Trafit&author=M.+T.+Lipari&author=N.+B.+Modi&author=M.+Muller&author=C.+J.+Refino&author=M.+Schmitt&author=P.+Schonholzer&author=S.+Weiss&author=B+Steiner&title=Orally+Active+Fibrinogen+Receptor+Antagonists.+2.+Amidoximes+as+Prodrugs+of+Amidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00030_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DOrally%2520Active%2520Fibrinogen%2520Receptor%2520Antagonists.%25202.%2520Amidoximes%2520as%2520Prodrugs%2520of%2520Amidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00031"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00031" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00031_1"><span><span class="NLM_string-ref">Gante, J.; Juraszyk, H.; Raddatz, P.; Wurziger, H.; Bernotat-Danielowski, S.; Melzer, G.; Rippmann, F. New Antithrombotic RGD-Mimetics with High Bioavailability. <i>  Bioorg. Med. Chem. Lett.</i><b>1996</b>, <i>6 </i>(20), 2425−2430.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2430&issue=20&author=J.+Gante&author=H.+Juraszyk&author=P.+Raddatz&author=H.+Wurziger&author=S.+Bernotat-Danielowski&author=G.+Melzer&author=F+Rippmann&title=New+Antithrombotic+RGD-Mimetics+with+High+Bioavailability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00031_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGante%26aufirst%3DJ.%26atitle%3DNew%2520Antithrombotic%2520RGD-Mimetics%2520with%2520High%2520Bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26issue%3D20%26spage%3D2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00032"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00032" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00032_1"><span><span class="NLM_string-ref">Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties that Influence the Oral Bioavailability of Drug Candidates. <i>  J. Med. Chem.</i><b>2002</b>, <i>45</i>, 2615−2623.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2623&author=D.+F.+Veber&author=S.+R.+Johnson&author=H.-Y.+Cheng&author=B.+R.+Smith&author=K.+W.+Ward&author=K.+D+Kopple&title=Molecular+Properties+that+Influence+the+Oral+Bioavailability+of+Drug+Candidates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00032_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26atitle%3DMolecular%2520Properties%2520that%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00033"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00033" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00033_1"><span><span class="NLM_string-ref">(a) Hauptmann, J.; Paintz, M.; Kaiser, B.; Richter, M. Reduction of a Benzamidoxime Derivative to the Corresponding Benzamidine in Vivo and in Vitro. <i>  Pharmazie </i><b>1988</b>, <i>43</i>, 559−560.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1988&pages=560&author=J.+Hauptmann&author=M.+Paintz&author=B.+Kaiser&author=M+Richter&title=Reduction+of+a+Benzamidoxime+Derivative+to+the+Corresponding+Benzamidine+in+Vivo+and+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHauptmann%26aufirst%3DJ.%26atitle%3DReduction%2520of%2520a%2520Benzamidoxime%2520Derivative%2520to%2520the%2520Corresponding%2520Benzamidine%2520in%2520Vivo%2520and%2520in%2520Vitro%26jtitle%3DPharmazie%26date%3D1988%26volume%3D43%26spage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00033_2"><span><span class="NLM_string-ref">(b) Clement, B.; Zimmermann, M.; Schmitt, S. Biotransformation des Benzamidins und des Benzamidoxims durch mikrosomale Enzyme vom Kaninchen. (Biotransformation of Benzamidine and Benzamidoxime by Microsomal Enzymes of the Rabbit.) <i>Arch. Pharm. (Weinheim, Ger.) </i><b>1989</b>, <i>322</i>, 431−435.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=B.+Clement&author=M.+Zimmermann&author=S.+Schmitt&title=Ger.%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DBiotransformation%2520des%2520Benzamidins%2520und%2520des%2520Benzamidoxims%2520durch%2520mikrosomale%2520Enzyme%2520vom%2520Kaninchen.%2520%2528Biotransformation%2520of%2520Benzamidine%2520and%2520Benzamidoxime%2520by%2520Microsomal%2520Enzymes%2520of%2520the%2520Rabbit.%2529%2520Arch.%2520Pharm.%2520%2528Weinheim%26btitle%3DGer.%2529%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00033_3"><span><span class="NLM_string-ref">(c) Clement, B.; Immel, M.; Terlinden, R.; Wingen, F.-J. Reduction of Amidoxime Derivatives to Pentamidine in vivo. <i>  Arch. Pharm. </i><i>(Weinheim, Ger.) </i><b>1992</b>, <i>325</i>, 61−62.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1992&pages=62&author=B.+Clement&author=M.+Immel&author=R.+Terlinden&author=F.-J+Wingen&title=Reduction+of+Amidoxime+Derivatives+to+Pentamidine+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DReduction%2520of%2520Amidoxime%2520Derivatives%2520to%2520Pentamidine%2520in%2520vivo%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D1992%26volume%3D325%26spage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-jm030354bb00033_4"><span><span class="NLM_string-ref">(d) Clement, B.; Jung, F. N−Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P-450 2C3 or Human Liver Microsomes, Microsomal Retroreduction, and Further Oxidative Transformation of the Formed Amidoximes. <i>  Drug Metab. Dispos. </i><b>1994</b>, <i>22</i>, 486-497. 2061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=486-497&author=B.+Clement&author=F+Jung&title=N%E2%88%92Hydroxylation+of+the+Antiprotozoal+Drug+Pentamidine+Catalyzed+by+Rabbit+Liver+Cytochrome+P-450+2C3+or+Human+Liver+Microsomes%2C+Microsomal+Retroreduction%2C+and+Further+Oxidative+Transformation+of+the+Formed+Amidoximes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00033_4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClement%26aufirst%3DB.%26atitle%3DN%25E2%2588%2592Hydroxylation%2520of%2520the%2520Antiprotozoal%2520Drug%2520Pentamidine%2520Catalyzed%2520by%2520Rabbit%2520Liver%2520Cytochrome%2520P-450%25202C3%2520or%2520Human%2520Liver%2520Microsomes%252C%2520Microsomal%2520Retroreduction%252C%2520and%2520Further%2520Oxidative%2520Transformation%2520of%2520the%2520Formed%2520Amidoximes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D486%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00034"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00034" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00034_1"><span><span class="NLM_string-ref">Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and its Application to the Prediction of Drug Transport Properties. <i>  J. Med. Chem</i>. <b>2000</b>, <i>43</i>, 3714−3717.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3717&author=P.+Ertl&author=B.+Rohde&author=P+Selzer&title=Fast+Calculation+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-Based+Contributions+and+its+Application+to+the+Prediction+of+Drug+Transport+Properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00034_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DFast%2520Calculation%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-Based%2520Contributions%2520and%2520its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-jm030354bb00035"><div class="reference"><strong class="refLabel"><a href="#jm030354bb00035" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-jm030354bb00035_1"><span><span class="NLM_string-ref">We have recently reported that when <b>22</b> (CT51464/ML464) was administered to mice by oral gavage at a dose of 100 mg/kg, platelet aggregation, measured by platelet-rich plasma aggregometry, was inhibited within 30 min and remained disrupted for up to 10 h. During this time, the concentration of active metabolite <b>23</b> (CT50728/ML728) was 37.5 μM at its peak 30 min after oral gavage and 5 μM 8 h after oral gavage of <b>22</b>. Bakewell, S. J.; Nester, P.; Prasad, S.; Tomasson, M. H.; Dowland, N.; Mehrotra, M.; Scarborough, R.; Kanter, J.; Abe, K.; Phillips, D.; Weilbaecher, K. N. Platelet and Osteoclast β<sub>3</sub> Integrins are Critical for Bone Metastasis. <i>  Proc. Natl. Acad. Sci. U.S.A.</i><b>2003</b>, <i>100 </i>(24), 14205−14210.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=+We&title=S.+J."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=jm030354bb00035_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWe%26atitle%3Dplatelet%2520aggregation%252C%2520measured%2520by%2520platelet-rich%2520plasma%2520aggregometry%252C%2520was%2520inhibited%2520within%252030%2520min%2520and%2520remained%2520disrupted%2520for%2520up%2520to%252010%2520h.%2520During%2520this%2520time%252C%2520the%2520concentration%2520of%2520active%2520metabolite%252023%2520%2528CT50728%252FML728%2529%2520was%252037.5%2520%25CE%25BCM%2520at%2520its%2520peak%252030%2520min%2520after%2520oral%2520gavage%2520and%25205%2520%25CE%25BCM%25208%2520h%2520after%2520oral%2520gavage%2520of%252022.%2520Bakewell%26btitle%3DS.%2520J.%26pub%3DU.S.A%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="NLM_notes" id="rightTab-"><div id="" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53"><a href="/doi/suppl/10.1021%2Fjm030354b">Supporting Information Available</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Analytical data, selected HRMS data, tables of <sup>1</sup>H NMR, and HPLC methods/data for final compounds. This material is available free of charge via the Internet at <a class="ext-link" href="http://pubs.acs.org" target="_blank">http://pubs.acs.org</a>. </div></div></div><div class="article_supporting-info" id=""><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm030354b/suppl_file/jm030354b_s.pdf">jm030354b_s.pdf (966.56 kb)</a></li></ul></div></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm030354b&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2004.47.issue-8%3Barticle%3Aarticle%3A10.1021%2Fjm030354b%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm030354b" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                474KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992d6fcfc23db2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
